text string | url string | crawl_date timestamp[ms] | label int64 | id string |
|---|---|---|---|---|
New nuclear unit now serving customers with clean, reliable energy 24/7
ATLANTA, July 31, 2023 /PRNewswire/ -- Georgia Power declared today that Plant Vogtle Unit 3 has entered commercial operation and is now serving customers and the State of Georgia. The new unit represents a long-term investment in the state's clean energy future and will provide reliable, emissions-free energy to customers for decades to come.
"The Plant Vogtle 3 & 4 nuclear expansion is another incredible example of how Georgia Power is building a reliable and resilient energy future for our state," said Kim Greene, chairman, president and CEO of Georgia Power. "It is important that we make these kinds of long-term investments and see them through so we can continue providing clean, safe, reliable and affordable energy to our 2.7 million customers. Today's achievement is a testament to our commitment to doing just that, and it marks the first day of the next 60 to 80 years that Vogtle Unit 3 will serve our customers with clean, reliable energy."
Vogtle Unit 3 is the first newly-constructed nuclear unit in the U.S. in over 30 years and can power an estimated 500,000 homes and businesses. Once all four units are online, the Plant Vogtle site will be the largest generator of clean energy in the nation and support continued growth in Georgia as more industries, businesses and families come to the state.
"Today is a historic day for the State of Georgia, Southern Company, and the entire energy sector, as we continue transforming the way we power the lives of millions of Americans," said Chris Womack, president and CEO of Southern Company. "With Unit 3 completed, and Unit 4 in the final stages of construction and testing, this project shows just how new nuclear can and will play a critical role in achieving a clean energy future for the United States. Bringing this unit safely into service is a credit to the hard work and dedication of our teams at Southern Company and the thousands of additional workers who have helped build that future at this site, as well as all of the partners who have helped make this day a reality."
Nuclear energy is the only zero-emission baseload energy source available today, offering high reliability, and efficient operations around the clock. Nuclear energy currently provides approximately 25% of Georgia Power's overall energy mix, including the existing units at Plant Vogtle and Georgia's other nuclear facility at Plant Hatch in Baxley, Georgia.
"The Vogtle expansion is an American energy success story and would not be possible without the support of strong public and private partners like our partners at North America's Building Trades Unions," said Tom Fanning, chairman of the Board of Directors for Southern Company. "We continue to appreciate their support and those who have stood with us at the local, state and federal levels to complete this new clean energy source to serve electric customers. Providing leadership in our industry and a commitment to safety and quality are in Southern Company's DNA. Today's milestone at the Vogtle expansion site underscores this legacy, and I couldn't be prouder of the dedication our teams have shown in seeing Unit 3 through to completion."
The final stages of construction and testing continue at Vogtle Unit 4, with the unit projected to be placed in service during the late fourth quarter 2023 or the first quarter of 2024. The unit completed hot functional testing in May, in significantly less time than Unit 3 as the team continues leveraging best practices and learnings from the earlier unit. The Vogtle site has also received nuclear fuel for Unit 4, with a total of 157 fuel assemblies necessary for the safe and reliable startup of the unit.
Also, last week, Georgia Power announced the receipt of the 103(g) finding from the Nuclear Regulatory Commission (NRC) for Vogtle Unit 4. This finding was confirmed in an official letter received by Southern Nuclear and signifies that the new unit has been constructed and will be operated in conformance with the Combined License and NRC regulations. No further NRC findings are necessary in order for Southern Nuclear to load fuel or begin the startup sequence for the new unit.
The new Vogtle units are an essential part of Georgia Power's commitment to delivering clean, safe, reliable and affordable energy to its 2.7 million customers. Southern Nuclear will operate the new units on behalf of the co-owners: Georgia Power, Oglethorpe Power, MEAG Power and Dalton Utilities.
About Georgia Power
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America's premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company's promise to 2.7 million customers in all but four of Georgia's 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), Twitter (Twitter.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).
Cautionary Note Regarding Forward-Looking Statements
Certain information contained in this release is forward-looking information based on current expectations and plans that involve risks and uncertainties. Forward-looking information includes, among other things, statements concerning the projected in-service date for Plant Vogtle Unit 4 and the future operations of Plant Vogtle Units 3 and 4. Georgia Power cautions that there are certain factors that can cause actual results to differ materially from the forward-looking information that has been provided. The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of Georgia Power; accordingly, there can be no assurance that such suggested results will be realized. The following factors, in addition to those discussed in Georgia Power's Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent securities filings, could cause actual results to differ materially from management expectations as suggested by such forward-looking information: the ability to control costs and avoid cost and schedule overruns during the development, construction, and operation of facilities or other projects, including Plant Vogtle Unit 4, which includes components based on new technology that only within the last few years began initial operation in the global nuclear industry at this scale, due to current and/or future challenges which include, but are not limited to, changes in labor costs, availability and productivity, challenges with the management of contractors or vendors, subcontractor performance, adverse weather conditions, shortages, delays, increased costs, or inconsistent quality of equipment, materials, and labor, contractor or supplier delay, the impacts of inflation, delays due to judicial or regulatory action, nonperformance under construction, operating, or other agreements, operational readiness, including specialized operator training and required site safety programs, engineering or design problems or any remediation related thereto, design and other licensing-based compliance matters, challenges with start-up activities, including major equipment failure, or system integration, and/or operational performance, continued challenges related to the COVID-19 pandemic or future pandemic health events, continued public and policymaker support for projects, environmental and geological conditions, delays or increased costs to interconnect facilities to transmission grids, and increased financing costs as a result of changes in market interest rates or as a result of project delays; the ability to overcome or mitigate the current challenges, or challenges yet to be identified, at Plant Vogtle Unit 4, that could further impact the cost and schedule for the project; legal proceedings and regulatory approvals and actions related to construction projects, such as Plant Vogtle Unit 4, including Georgia Public Service Commission approvals and U.S. Nuclear Regulatory Commission ("NRC") actions; under certain specified circumstances, a decision by holders of more than 10% of the ownership interests of Plant Vogtle Unit 3 and 4 not to proceed with construction; the notices of tender by Oglethorpe Power Corporation and the City of Dalton of a portion of their ownership interests in Plant Vogtle Units 3 and 4 to Georgia Power, including related litigation; the ability to construct facilities in accordance with the requirements of permits and licenses (including satisfaction of NRC requirements), to satisfy any environmental performance standards and the requirements of tax credits and other incentives, and to integrate facilities into the Southern Company system upon completion of construction; the inherent risks involved in operating and constructing nuclear generating facilities; the ability of counterparties of Georgia Power to make payments as and when due and to perform as required; the direct or indirect effect on Georgia Power's business resulting from cyber intrusion or physical attack and the threat of cyber and physical attacks; catastrophic events such as fires, earthquakes, explosions, floods, tornadoes, hurricanes and other storms, droughts, pandemic health events, political unrest, wars or other similar occurrences; the potential effects of the continued COVID-19 pandemic; and the direct or indirect effects on Georgia Power's business resulting from incidents affecting the U.S. electric grid or operation of generating or storage resources. Georgia Power expressly disclaim any obligation to update any forward–looking information.
View original content to download multimedia:
SOURCE Georgia Power | https://www.wagmtv.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ | 2023-07-31T11:23:18 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ |
- Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023
- Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disorders
- Brain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date
- Advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications
- Orphan drug designation (ODD) granted by the European Commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)
- Type A meeting planned with FDA regarding troriluzole program in Spinocerebellar Ataxia Type 3 (SCA3) and enrollment in Phase 3 obsessive compulsive disorder (OCD) trial expected to complete at end of 2023
NEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "In less than a year since our spin-off, the Biohaven team has driven strong and consistent progress across multiple drug development platforms. We were excited to recently report positive interim data from the ongoing EEG biomarker study of our lead Kv7 activator, BHV-7000. As expected, BHV-7000 demonstrated CNS activity consistent with what has been reported in EEG studies with other Kv7 channel activators in development that are clinically effective in treating epilepsy and with other approved anti-seizure medications. Importantly, BHV-7000 demonstrates CNS target engagement but is not associated with the typical CNS adverse events associated with other ASMs, like somnolence and fatigue. We look forward to completing the higher dose groups in this EEG study and initiating Phase 2/3 studies with our once daily, extended-release oral formulation later this year."
Dr. Coric continued, "We also shared a number of equally exciting announcements across our broader pipeline this quarter. We successfully administered the first three doses in the SAD portion of our ongoing SAD/MAD study evaluating BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor. Potential therapeutic concentrations of BHV-8000 were achieved and BHV-8000 was well tolerated with only mild adverse events reported, reinforcing our plans to start a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. In addition, we have advanced IND enabling preclinical studies and remain on track to submit an IND with our IgG degrader, BHV-1300, later this year. We also anticipate submitting an IND with our IgA degrader in 2024 as we continue to advance multiple clinical degrader candidates across a wide range of indications. We also shared key updates for our taldefgrobep alfa program (an anti-myostatin) with enrollment completion in our pivotal study in SMA and a planned Phase 2 trial initiation in obesity."
"Finally, I want to reaffirm Biohaven's commitment to the SCA3 patient community in spite of the recent disappointing regulatory decision by the FDA not to review our submitted NDA. Given the seriousness of SCA3 and consistent treatment benefits observed across multiple prespecified outcome measures, including an 80% delay in disease progression over the one-year study period with substantial risk reduction in falls, we believe that full consideration of all available data is warranted for this ultra-rare disease. Biohaven has built its foundation around our patient mission and we plan to continue to work with regulatory agencies to try to advance troriluzole for individuals suffering from SCA3."
Second Quarter 2023 and Recent Business Highlights
- Announced positive interim data from EEG biomarker study with BHV-7000 - In July 2023, the Company provided a preliminary data update from the ongoing electroencephalogram (EEG) biomarker study for the Kv7 Channel Activator platform. Preliminary Phase 1 data confirmed evidence of target engagement in the central nervous system for subjects with projected therapeutic concentrations of BHV-7000 (based on the EC50 from preclinical models), measured by changes from baseline in EEG spectral power that occurred after dosing. These pharmacodynamic (PD) effects were similar to those reported in the literature for anti-seizure medicines (ASMs), including Kv7 activators in development that are clinically effective in treating epilepsy. BHV-7000's PD effects were also differentiated from those reported for other Kv7 activators including, specifically, the absence of increases in EEG spectral power in frequency bands associated with drowsiness and somnolence. Results from the low-dose group validate the preclinical hypothesis, confirm the Phase 1 SAD/MAD clinical data, and provide strong support for Biohaven's plans to initiate pivotal studies with BHV-7000 in focal epilepsy and bipolar disorder in the second half of 2023. The preliminary data highlight BHV-7000's differentiation and potentially favorable clinical profile compared to other ASMs, and the Company expects to present the complete EEG results by the end of the year. Additionally, new pharmacokinetic data from multiple clinical formulations being studied has now confirmed a once daily extended-release oral formulation that will be used in the Phase 2/3 clinical programs.
- Successfully dosed three cohorts with single ascending doses of oral, brain penetrant, dual TYK2/JAK1 agent, BHV-8000 - In July 2023, the Company announced that it successfully dosed three cohorts in the SAD portion of an ongoing SAD/MAD Phase 1 study evaluating brain penetrant TYK2/JAK1 agent, BHV-8000 in healthy volunteers. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and PD of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported. These data provide support for further development of BHV-8000, and the Company anticipates beginning a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. The Company had previously reported initiation of dosing with BHV-8000 in the Phase 1 study at Biohaven's R&D Day in May 2023.
- Reported on continued progress observed with Biohaven's first-in-class bispecific IgG degrader, BHV-1300, as compound advances to IND filing in 2H2023 - In July 2023, the Company shared an update on BHV-1300's highly competitive safety, manufacturable and PD profile. The Company is assembling a pipeline of partially de-risked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track for submission in 2023 and an IND application for Biohaven's IgA degrader on track for submission in 2024
- Type A meeting planned to comprehensively address FDA's concerns in connection with Troriluzole program in SCA3 - In July 2023, the Company announced that the FDA informed Biohaven it would not review the recently submitted New Drug Application (NDA) for troriluzole for the treatment of spinocerebellar ataxia type 3 (SCA3), an ultra-rare, genetically-defined, neurodegenerative disease associated with progressive disability, frequent falls, loss of ambulation, speech and swallowing impairment, and premature death that is the most common SCA genotype worldwide. The FDA informed Biohaven it would not review the application given that the study's primary endpoint was not met and thus, would not permit a substantive review. Biohaven is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible given no therapy is currently approved for this ultra-rare genetic disorder. Biohaven plans to request a Type A meeting to comprehensively address FDA's concerns cited in the refusal to file letter.
- EMA orphan drug designation granted for taldefgrobep alfa for the treatment of SMA: - In July 2023, the Company announced that taldefgrobep alfa received orphan drug designation (ODD) from the European Commission for taldefgrobep for the treatment of SMA. Taldefgrobep previously received Fast-Track and ODD from the FDA. At Biohaven's R&D Day, the Company announced plans to complete randomization of approximately 180 patients in global SMA trial.
Upcoming Milestones:
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company plans to reach significant pipeline milestones in the coming periods. Biohaven expects to:
- Announce Phase 1 EEG study results by year-end 2023: The Company expects to present complete results from its ongoing EEG study with BHV-7000 in healthy volunteers by the end of the year.
- Initiate Phase 2/3 studies with BHV-7000 in the second half of 2023: Biohaven expects to initiate pivotal trials in patients with focal epilepsy and bipolar disorder in the second half of 2023.
- Submit IND with BHV-1300, the Company's lead extracellular degrader: The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023 and expects to initiate Phase 2 studies in 2024.
- Submit IND with selective Gd-IgA1 degrader: The Company expects to submit an IND with a Gd-IgA1 degrader indicated for IgA nephropathy in the first half of 2024.
- Initiate Phase 2 study with BHV-8000: The Company commenced Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor for neuroinflammatory disorders, in the first half of 2023 and expects to initiate a Phase 2 study in Parkinson's disease in 2024.
- Submit IND with BHV-2100 in chronic pain: The Company expects to submit an IND with BHV-2100, a selective TRPM3 antagonist in the Company's ion channel platform, in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023: Two Phase 3 randomized, double-blind, placebo-controlled studies of troriluzole in OCD are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in at least one Phase 3 trial by year-end 2023.
- Complete enrollment in Phase 3 clinical study of taldefgrobep alfa in SMA: The Company expects to complete enrollment in the study of taldefgrobep in SMA in the second half of 2023.
- Continue advancements across multiple neuroscience and immunoscience indications: The Company's preclinical pipeline includes a platform of bispecific degraders of extracellular proteins directed against IgG, IgA and other targets, TRPM3 and Kv7 family of ion channels, and other undisclosed targets, including those with disease-modifying potential.
Capital Position:
Cash, cash equivalents and marketable securities as of June 30, 2023 was $349.0 million, including $13.9 million of restricted cash, and excluding $40.4 million of cash payable to Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 20221.
Second Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were $79.5 million for the three months ended June 30, 2023, compared to $177.1 million for the three months ended June 30, 2022. Non-cash share-based compensation expense was $2.5 million for the three months ended June 30, 2023, a decrease of $10.3 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
General and Administrative (G&A) Expenses: General and administrative expenses were $14.5 million for the three months ended June 30, 2023, compared to $20.0 million for the three months ended June 30, 2022. The decrease of $5.5 million was primarily due to decreased non-cash share-based compensation costs. Non-cash share-based compensation expense was $2.2 million for the three months ended June 30, 2023, a decrease of $5.8 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
Other Income (Expense), Net: Other income (expense), net was a net income of $5.8 million for the three months ended June 30, 2023, compared to net expense of $0.1 million for the three months ended June 30, 2022. The increase of $5.9 million was primarily due to an increase in net investment income and an increase of $1.7 million in other income related to our transition services provided to the Former Parent, which is largely non-recurring.
Net Loss: Biohaven reported a net loss for the three months ended June 30, 2023, of $90.3 million, or $1.32 per share, compared to $203.3 million, or $5.16 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended June 30, 2023 was $85.7 million, or $1.25 per share, compared to $182.5 million, or $4.63 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under "Non-GAAP Financial Measures," exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the "Spin-Off"), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022. The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods.
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:
SOURCE Biohaven Ltd. | https://www.wkyt.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ | 2023-07-31T11:23:22 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ |
BEIJING, July 31, 2023 /PRNewswire/ -- Gravitas Education Holdings, Inc. ("GEHI" or the "Company") (NYSE: GEHI), a leading early childhood education service provider in China, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 3/F, No. 28 Building, Fangguyuan Section 1, Fangzhuang Fengtai District, Beijing 100078, People's Republic of China, at 10:00 a.m. (Beijing time) on September 11, 2023, for the purposes of considering and, if thought fit, approving the transactions contemplated in the Agreement and Plan of Merger (the "Merger Agreement"), dated April 18, 2023, by and among the Company, Bright Sunlight Limited, a Cayman Islands exempted company and a direct, wholly owned subsidiary of the Company ("Merger Sub"), Best Assistant Education Online Limited, a Cayman Islands exempted company ("Best Assistant") and a controlled subsidiary of NetDragon Websoft Holdings Limited (HKEX: 0777, "NetDragon"), a Cayman Islands exempted company, and solely for purposes of certain named sections thereof, NetDragon. It is contemplated that Best Assistant will transfer the education business of NetDragon outside of the PRC to Elmtree Inc., a Cayman Islands exempted company limited by shares ("eLMTree") and currently a wholly owned subsidiary of Best Assistant. Pursuant to the Merger Agreement, Merger Sub will merge with and into eLMTree with eLMTree continuing as the surviving company and becoming a wholly owned subsidiary of the Company (the "Merger").
Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each ordinary share of eLMTree issued and outstanding immediately prior to the Effective Time (excluding the Dissenting Shares and the Excluded Shares, each as defined in the Merger Agreement) will be cancelled in exchange for the right to receive a number of validly issued, fully paid and non-assessable ordinary shares of the Company in a transaction exempt from the registration requirements under the Securities Act of 1933.
Shareholders of the Company will also be asked to consider and vote on certain additional Merger-related proposals at the EGM, including, among others:
- that, subject to and conditional upon the Merger becoming effective, the fifth amended and restated memorandum and article of association of the Company be amended and restated by their deletion in their entirety and the substitution of in their place of the sixth amended and restated memorandum and articles of association of the Company (the "A&R MAA") effective immediately prior to the Effective Time of the Merger;
- that, subject to and conditional upon the Merger becoming effective, the name of the Company be changed from "Gravitas Education Holdings, Inc." to "Mynd.ai, Inc." effective immediately prior to the Effective Time;
- that, subject to and conditional upon the Merger becoming effective, immediately prior to the Effective Time, the authorized share capital of the Company be varied as follows: (a) the authorized share capital of the Company shall be varied to US$1,000,000 divided into 1,000,000,000 shares comprising of (i) 990,000,000 ordinary shares of a par value of US$0.001 each (each a "ListCo Ordinary Share") and (ii) 10,000,000 shares of a par value of US$0.001 each of such class or classes (however designated) as the board of directors may determine in accordance with the A&R MAA, and (b) all Class A ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class A Ordinary Shares") and all Class B ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class B Ordinary Shares") in the authorized share capital of the Company (including all issued and outstanding ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares, and all authorized but unissued ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares) shall be re-designated as ListCo Ordinary Shares.
Holders of the Company's ordinary shares whose names are on the register of members of the Company at the close of business in the Cayman Islands on August 7, 2023, are entitled to notice of, and to vote at, the EGM or any adjournment or postponement thereof in person. Holders of the Company's American depositary shares ("ADSs") at the close of business in New York City on August 7, 2023, are entitled to exercise their voting rights for the underlying ordinary shares and must act through Citibank, N.A., the depositary of the Company's ADS program.
The notice of the EGM, which contains the detailed proposals to be presented at the EGM, and the proxy statement related to the EGM, are being filed today with the U.S. Securities and Exchange Commission ("SEC") and can be obtained without charge from the SEC's website (http://www.sec.gov). These documents are also available in the "Financial Information" section of the Company's investor relations website at https://ir.geh.com.cn/. In addition, the proxy materials (including the proxy statement) will be mailed to the Company's shareholders and holders of ADSs.
SHAREHOLDERS AND ADS HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN VOTING INSTRUCTIONS AND IMPORTANT INFORMATION ABOUT THE COMPANY, ELMTREE, THE MERGER AND RELATED MATTERS.
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of eLMTree or the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Forward-Looking Statements
This press release contains certain "forward-looking statements." These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the pending transactions described herein, and the parties' perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the Merger, including the equity values, the benefits of the Merger, expected revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words "will," "expect," "believe," "estimate," "intend," "plan" and similar expressions indicate forward-looking statements.
Such forward-looking statements are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from the expectations as a result of a variety of factors. Such forward-looking statements are based upon management's current expectations and include known and unknown risks, uncertainties and other factors, many of which are hard to predict or control, that may cause the actual results, performance, or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the Merger, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iii) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of the Company or eLMTree; (iv) risks related to disruption of management time from ongoing business operations due to the Merger; (v) the risk that any announcements relating to the Merger could have adverse effects on the market price of the Company's securities; (vi) the risk that the Merger and its announcement could have an adverse effect on the ability of eLMTree to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (vii) any changes in the business or operating prospects of eLMTree or its businesses; (viii) changes in applicable laws and regulations; and (ix) risks relating to the combined company's ability to enhance its services and products, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the proxy statement that will be filed with the SEC by the Company in connection with the Merger, and other documents that the parties may file with or furnish to the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and eLMTree, the Company and their subsidiaries and affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information and Where to Find It
The Company will file with the SEC and mail to its shareholders and ADS holders a proxy statement in connection with the Merger. Investors and security holders are urged to read the proxy statement when it becomes available because it will contain voting instructions and important information regarding the proposed arrangement. You may access the proxy statement (when available) and other related documents filed by the Company with the SEC at the SEC's website at www.sec.gov. You also may obtain the proxy statement and other documents filed by the Company with the SEC relating to the proposed arrangement for free by accessing the Company's website at https://ir.geh.com.cn/ by clicking on the link for "Financial Information," and then clicking on the link for "SEC Filings."
CONTACT: Gravitas Education Holdings, Inc., Investor Relations, E-mail: ir@geh.com.cn
View original content:
SOURCE Gravitas Education Holdings Inc. | https://www.1011now.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ | 2023-07-31T11:23:22 | 0 | https://www.1011now.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ |
The Nation's Largest Network for Affordable Housing Protects Consumers from Unfair Fees and Costs
BOCA RATON, Fla., July 31, 2023 /PRNewswire/ -- AffordableHousing.com today announced it will join the White House and a compendium of government agencies and other private sector companies in large-scale efforts to end junk fees and ensure that Americans are provided with honest, transparent pricing. More than 100 million property searches per year are performed on AffordableHousing.com–the largest platform for affordable housing in the nation.
"For decades, families have relied on us to help them find affordable housing," says Richard Cupelli, CEO at AffordableHousing.com. "We take pride in advocating for these families, so it was a natural fit for us to join forces with the Administration and other socially responsible companies to help protect consumers in our industry."
On July 19, 2023, the White House published a Fact Sheet announcing its crack-down on junk fees in the rental market, highlighting private-sector commitments supporting this initiative made by the three major rental housing platforms: AffordableHousing.com, Zillow, and Apartments.com.
Late last year, the President called on federal agencies, Congress, and private companies to take action to address junk fees across the economy. The initiative aims to ensure Americans are provided with honest, transparent pricing. By February 2023, the Consumer Financial Protection Bureau (CFPB) announced proposed rules limiting credit card late fees. The Federal Communications Commission (FCC) finalized a rule requiring cable and internet providers to list fees up front. And the Department of Transportation (DOT) proposed a requirement for airlines and booking services show the full price of a plane ticket, including baggage and other fees.
In March, HUD Secretary Marcia Fudge released an open letter to housing providers and state and local governments, encouraging them to adopt policies promoting greater fairness and transparency of fees faced by renters. Substantial research shows such fees obstruct comparison shopping, impede competition, and lead to consumers paying more.
A long-standing resource for families seeking affordable housing, AffordableHousing.com has policies in place supporting this transparency and protecting its customers from unfair fees.
Renters can search available properties free on AffordableHousing.com, and property owners are required to be upfront about all refundable and non-refundable rental fees and costs. AffordableHousing.com also does not charge rental application fees.
"Our socially responsible technology platform has allowed us to establish the largest network of affordable housing in the nation," says Cupelli. "We understand the accountability that comes with our standing in the industry and the trust that our customers place in us."
As a hub for housing agencies across the nation, AffordableHousing.com also allows state and local governments to have their own customized website that serves their local community, enforces their specific regulatory requirements, centralizes all affordable housing, and simplifies the application and approval process.
"We are working with AffordableHousing.com to implement the Vermont Affordable Housing Hub, which will allow families to easily find and apply to all affordable housing in the state," says Kathleen Berk, Executive Director at Vermont State Housing Authority. "By utilizing AffordableHousing.com's custom housing hub to build our state-specific site, we can streamline compliance with state laws, which have strict application fee guidelines. We can also add safeguards to protect our families by providing the Clear and Fair Lease template for property owners to use. These leases will also comply with affordable housing programs, like Section 8."
AffordableHousing.com also rewards reputable property owners. Those with a history of good standing can qualify for a Trusted Owner Badge, which ensures their credibility to prospective renters on the site and increases consumer confidence. Trusted Owners also receive prominent listing status.
Earning and maintaining status as a Trusted Owner requires providing various levels of documentation to verify qualifications and authenticity, adhering to all relevant federal, state, and local laws, and complying with the site's reasonable fee guidelines.
Together with its research partner, Learning Collider (www.learningcollider.org), AffordableHousing.com is conducting research into the real cost of administrative fees, the impact of fee transparency in rental listings, and the effectiveness of platform features like the common application for rental and government programs—an endeavor that the company has been urging agencies to adopt for years.
"Our research partnership with AffordableHousing.com has allowed us to analyze the impacts of rental fees on low-income families in real-time," says Peter Bergman, Professor at UT Austin and Director of the Learning Collider research lab. "Together, we are advancing research to identify junk fees and establish transparent fee practices, easing the path to affordable rentals for families across the U.S."
The President announced in latest White House Fact Sheet, released on July 27, 2023, further plans to protect renters, naming AffordableHousing.com as an ally in the initiative and endorsing the site's plans to deploy additional consumer protection tools by the end of the year, including "Clear and Fair" digital leases, which will align with the principles outlined in the White House Blueprint for a Renter Bill of Rights. Property owners who use these "Clear and Fair" digital leases will be acknowledged on AffordableHousing.com.
About AffordableHousing.com: For more than 20 years, AffordableHousing.com has provided innovative technology and real solutions that help solve some of the most complex challenges impacting the availability of affordable housing in the United States. By simplifying access to available resources, AffordableHousing.com boosts participation in government programs, increasing the much-needed supply of affordable housing nationwide, and providing more homes to more families.
View original content to download multimedia:
SOURCE AffordableHousing.com | https://www.wagmtv.com/prnewswire/2023/07/31/white-house-announces-partnership-with-affordablehousingcom-end-junk-fees/ | 2023-07-31T11:23:24 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/white-house-announces-partnership-with-affordablehousingcom-end-junk-fees/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Today, Blitz Insurance, a specialty insurance carrier, partners with Ascend to modernize payment experiences for insurance brokers selling in specialty markets. With this partnership, Blitz Insurance will open new customer segments by offering both direct bill and premium financing into their payments workflow.
"When we looked into the market for a solution, Ascend was the right choice. Ascend meets our needs for a better payments experience for our partners while reducing everyone's operational expenses," said Brandon Murphy, Chief Distribution Officer of Blitz Insurance. "We will now have the ability to not only expand to direct bill and a premium finance option but also simplify the movement of money between us and our partners."
With Ascend, Blitz Insurance is now able to provide a direct bill in addition to their existing agency bill workflow - allowing brokers to decide what billing method works best for them. By utilizing Ascend, Blitz Insurance not only grows their footprint of appointed brokers but also gains administrative efficiency by automating what would otherwise have been a large operational undertaking.
Ascend automatically attributes incoming payments to policies in real time, speeding up the reconciliation process. By modernizing the payments experience and speeding up the reconciliation of incoming premiums, Blitz Insurance can offer a best-in-class experience to its brokers and agents.
"We find that across the insurance ecosystem - companies want to provide a seamless payment workflow for their customers and their teams," said Andrew Wynn, co-CEO of Ascend. "Ascend is built so brokers and carriers can offer this experience without shouldering the administrative resources and costs needed to support these operations."
About Ascend
Ascend is the first insurance payments platform that automates financial operations from collections and financing to carrier and commission payables. Founded by two-time insurtech entrepreneurs Andrew Wynn and Praveen Chekuri, Ascend helps insurance brokers, MGAs, and carriers improve their bottom lines by eliminating expensive and labor-intensive payment workflows. To learn more, please visit LinkedIn, Twitter or check out https://www.useascend.com/.
About Blitz Insurance
Blitz is a tech-driven insurer revolutionizing the $60B specialty market catering to SME segment. By leveraging industry knowledge and cutting-edge technology, we deliver a simpler, smarter, and faster coverage experience.
The company is led by a veteran team of insurance and technology experts and has been funded with $25M from its founder & CEO, a Forbes-listed serial entrepreneur in the real estate and insurance industries.
Contact:
Mike Nguyen
press@useascend.com
View original content to download multimedia:
SOURCE Ascend | https://www.wkyt.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ | 2023-07-31T11:23:29 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ |
LA ROMANA, Dominican Republic, July 31, 2023 /PRNewswire/ -- The international known company Hilton Hotels & Resorts opens its doors to its Hilton Garden Inn La Romana hotel project in the Dominican Republic, in collaboration with a group of important investors under the company Riverhome Capital S.A.S., whose main shareholder is the prominent Dominican former major league player, Edwin Encarnación; together with the vision of the lawyer Guillermo Estrella Ramia and the Minister of Tourism, David Collado.
The inauguration was led by Luis Abinader Corona, president of the Dominican Republic and who expressed that "This hotel has something very special, opening up the beach and the sector of La Caleta of La Romana, which for a long time was closed to the province and its visitors. Since private investment must always be accompanied by public infrastructure, we are working on creating them, so we are all part of this development of La Romana."
With an investment of 25 million united states dollars and the creation of more than 300 direct jobs, it is considered as a hotel option for the growing flows of tourists that the area is currently receiving. Located a short distance from other points of relevance, such as La Romana Airport 18 minutes away, Casa de Campo 12 minutes away and Central Romana just a few blocks away.
The new hotel facility has a privileged location on a 5,000 square meters property, located on the coast of the municipal district of La Caleta, La Romana province. With a capacity of 130 rooms, distributed in five of the seven floors of the building, it also counts with swimming pools, two bars, a restaurant, gym, event, meeting and multipurpose rooms, and outdoor areas, ideal for social and corporate celebrations.
The hotel responds to the interest of Edwin Encarnación to invest in the development of his province of origin, who expressed that "from the moment this project was presented to me, I knew that I had to be part and be the one to assume this. I joined the development of this hotel, with the only requirement that most of the workers came from here, from my town La Romana, and we achieved this."
View original content to download multimedia:
SOURCE Grupo De Valle | https://www.1011now.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ | 2023-07-31T11:23:29 | 0 | https://www.1011now.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ |
- Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 39.5% - Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 27.9% - Net Profit Attributable to Owners of the Company for the First Half Increased 14.6% to RMB 5,313 Million
- Diluted Earnings per Share (EPS) for the First Half Increased 20.9% to RMB1.79
- Adjusted Non-IFRS Net Profit Attributable to Owners of the Company for the First Half Increased 18.5% to RMB5,095 Million
- Adjusted Non-IFRS Diluted EPS for the First Half Increased 18.5% to RMB1.73[1]
- Free Cash Flow Achieved RMB2,926 Million for the First Half, Turned Positive and Grew Strongly
SHANGHAI, July 31, 2023 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half ending June 30, 2023 ("Reporting Period").
This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the 2023 Interim Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.
All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.
The 2023 Interim Report of the Company has not been audited.
Second Quarter 2023 Financial Highlights
Revenue grew 6.7% year-over-year to RMB9,908 million, excluding COVID-19 commercial projects, revenue grew strongly by 39.5%. This is primarily attributable to the Company's continued excellent execution of our unique Contract Research, Development and Manufacturing Organization (CRDMO) business model to achieve strong synergy and continuous growth:
- WuXi Chemistry revenue grew 2.6% year-over-year to RMB7,034 million, excluding COVID-19 commercial projects, revenue grew strongly by 51.6%. Adjusted non-IFRS gross profit grew 12.9% year-over-year to RMB3,216 million, with a gross profit margin of 45.7%.
- WuXi Testing revenue grew 23.6% year-over-year to RMB1,638 million and adjusted non-IFRS gross profit grew 36.2% year-over-year to RMB640 million, with a gross profit margin of 39.1%.
- WuXi Biology revenue grew 17.5% year-over-year to RMB656 million and adjusted non-IFRS gross profit grew 21.3% year-over-year to RMB 271 million, with a gross profit margin of 41.4%.
- WuXi ATU revenue grew 22.9% year-over-year to RMB389 million and adjusted non-IFRS gross profit was RMB(16) million, with a gross profit margin of (4.2)%
- WuXi DDSU revenue declined 17.9% year-over-year to RMB176 million and adjusted non-IFRS gross profit grew year-over-year 5.2% to RMB63 million, with a gross profit margin of 35.8%. Meanwhile, we received the first royalty income from customers in the second quarter, which is a breakthrough for DDSU.
Unit: RMB million
- IFRS gross profit increased 18.1% year-over-year to RMB4,030 million. Gross profit margin was 40.7%[2]
- Adjusted non-IFRS gross profit increased 16.4% year-over-year to RM4,177 million. Adjusted non-IFRS gross margin was 42.2%.
- Net profit attributable to owners of the Company increased 5.1% year-over-year to RMB3,145 million.
- Adjusted non-IFRS net profit attributable to owners of the Company increased 22.4% year-over-year to RMB2,753 million.
First-Half 2023 Financial Highlights
Revenue grew 6.3% year-over-year to RMB18,871 million, excluding COVID-19 commercial projects, revenue grew strongly by 27.9%. This is primarily attributable to the Company's continued excellent execution of our unique Contract Research, Development and Manufacturing Organization (CRDMO) business model to achieve strong synergy and continuous growth:
- WuXi Chemistry revenue grew 3.8% year-over-year to RMB13,467 million, excluding COVID-19 commercial projects, revenue grew strongly by 36.1%. Adjusted non-IFRS gross profit grew 14.9% year-over-year to RMB6,103 million, with a gross profit margin of 45.3%.
- WuXi Testing revenue grew 18.7% year-over-year to RMB3,091 million and adjusted non-IFRS gross profit grew 26.1% year-over-year to RMB1,168 million, with a gross profit margin of 37.8%.
- WuXi Biology revenue grew 13.0% year-over-year to RMB1,233 million and adjusted non-IFRS gross profit grew 15.1% year-over-year to RMB511 million, with a gross profit margin of 41.5%.
- WuXi ATU revenue grew 16.0% year-over-year to RMB714 million and adjusted non-IFRS gross profit was RMB(40) million, with a gross profit margin of (5.7)%.
- WuXi DDSU revenue declined 24.9% year-over-year to RMB342 million and adjusted non-IFRS gross profit declined 26.2% year-over-year to RMB103 million, with a gross profit margin of 30.1%. Meanwhile, DDSU achieved a breakthrough in receiving the first royalty income from customers.
Unit: RMB million
- IFRS gross profit increased 17.6% year-over-year to RMB7,556 million. Gross profit margin was 40.0%[3].
- Adjusted non-IFRS gross profit increased 15.7% year-over-year to RMB7,855 million. Adjusted non-IFRS gross margin was 41.6%.
- Net profit attributable to owners of the Company increased 14.6% year-over-year to RMB 5,313 million.
- Adjusted non-IFRS net profit attributable to owners of the Company increased 18.5% year-over-year to RMB5,095 million.
- Diluted EPS increased 20.9% year-over-year to RMB1.79, while adjusted diluted non-IFRS EPS increased by 18.5% year-over-year to RMB1.73.
- Free cash flow achieved RMB2,926 million, turned positive and grew strongly year-over-year.
First-Half 2023 Business Operation Highlights
- As an industry innovation enabler, we grow together with our customers. In the first half of 2023, we added over 600 new customers, and in total we served more than 6,000 active customers over the past 12 months. Backlog grew 25% year-over-year excluding COVID-19 commercial projects. We continued to optimize our cross-platform synergies to better serve our customers worldwide, strengthen our unique competitive advantage as a fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) and Contract Testing, Development and Manufacturing Organization (CTDMO) platform, and provide one-stop services for our customers from discovery to development and manufacturing. The diversified revenue streams from customers across regions ensure the stability and resilience of the Company's financial performance.
- WuXi Chemistry: Integrated CRDMO Business Model Drives Steady Growth, with Continued Expansion in New Modalities (WuXi TIDES)
- In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to customers, which grew 20% year-over-year. Through our chemistry drug discovery services, we enabled our customers to accelerate their research while generating opportunities for our downstream business units. In the past 12 months, 120 molecules have transitioned from R to D&M, representing a year-on-year growth of 21%. Through our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our global customers, supporting the sustainable growth of our CRDMO business.
- We continued executing our "long-tail" strategy. Demand from "long-tail" customers in discovery services of small molecule and new modalities continued to grow, with the number of new customers growing 17% year-over-year.
- In the first half of 2023, D&M services revenue grew 2.1% year-over-year to RMB9.67 billion. Excluding COVID-19 commercial projects, D&M services revenue grew strongly by 54.5%.
- In the first half of 2023, we added 583 molecules to our D&M pipeline. To date, our D&M pipeline consists of 2,819 molecules, including 56 commercial projects, 59 in phase III, 301 in phase II and 2,403 in phase I and pre-clinical stages, among which, 8 commercial and phase III projects were added in the first half of 2023.
- In the first half of 2023, TIDES revenue grew 37.9% year-over-year to RMB1.33 billion. As of June 30, 2023, backlog of TIDES grew strongly by 188% year-over-year. We expect revenue growth from TIDES business to exceed 70% in 2023.
- The number of TIDES D&M customers increased 25% year-over-year to 121, and the number of TIDES molecules increased 46% year-over-year to 207.
- WuXi Testing: Lab Testing Services Drive Steady Growth, Clinical Business Fully Recovered
- The Company provides a full range of laboratory testing services for our customers, including drug metabolism and pharmacokinetics (DMPK), toxicology, and bioanalysis for drug development testing, as well as medical device testing. We provide customers with high-quality services, realize "one report for global submission," and enable customers to save time, reduce costs and increase efficiency.
- H1 2023 revenue from drug safety evaluation services grew 24% year-over-year. We maintained our industry leadership position in Asia Pacific for drug safety evaluation services that meet global regulatory requirements. In the first half of 2023, new lab testing facilities in Qidong and Suzhou began operations as scheduled, ensuring the business growth to accelerate in the second half of 2023.
- Moreover, we continued to enhance capabilities related to new modalities, with comprehensive coverage such as target protein degradation, nucleic acids, conjugates, and cell and gene therapies (CGT), etc.
- SMO revenue grew strongly by 53.9% in Q2 2023 and 34.3% in H1 2023, maintaining a leadership position in China. In the first half of 2023, SMO supported 25 new drug approvals for customers.
- In the first half of 2023, clinical CRO enabled our customers to obtain 8 IND approvals and submit 3 NDA filings.
- WuXi Biology: Strong Contribution from New Modalities; Early Discovery Screening Platform Continued to Generate Downstream Opportunities
- WuXi ATU: CTDMO Business Model Drives Growth
- WuXi DDSU: the First Year to Receive New Drug Application (NDA) Approval of New Drugs Developed for Customers; Breakthrough to Receive the First Royalty Income
Our Commitment to ESG
As an industry innovation enabler, a trusted partner and a contributor to the global healthcare industry, the Company is committed to environmental protection and sustainability, and to being a good global corporate citizenship.
Our outstanding ESG performance has been recognized by major global ESG rating agencies, including MSCI, S&P Global, Sustainalytics, CDP and EcoVadis. In June 2023, we received the fourth "Silver" medal recognition from EcoVadis for our Couvet site in Switzerland.
By the first half of 2023, our carbon emission intensity, energy consumption intensity and water use intensity reduced by 20.1%, 18.4%, and 31.6%, respectively, as compared to the baseline year 2020.
As we continue to advance our sustainability strategy, we embrace our shared responsibility to be good stewards of the environment.
Management Comment
Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "We continued to achieve steady growth of revenue, net profit, and free cash flow in the first half of 2023. Our revenue increased 6.3% year-over-year to RMB18.87 billion, or 27.9% if excluding COVID-19 commercial projects. Our adjusted non-IFRS net profit attributable to owners of the Company increased 18.5% year-over-year, outpacing the revenue growth rate, and our free cash flow achieved RMB2.93 billion, as a result of the Company's pursuit of operational excellence and productivity."
"The Company's performance in the first half of 2023 demonstrated that WuXi AppTec's unique CRDMO and CTDMO business models can effectively meet the growing demands from customers worldwide and continue to drive solid growth for the Company. In 2023, we aim to deliver a 5-7% revenue growth, increase adjusted non-IFRS gross profit by 13-14%, and expand free cash flow by 750-850%. We remain committed to prioritizing our customers' needs and enhancing our capacity and capabilities as we support our customers' efforts to bring groundbreaking therapies to patients around the world. Together, we can realize our vision that 'every drug can be made and every disease can be treated'."
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com
Forward-Looking Statements
This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our customers' intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Use of Non-IFRS and Adjusted Non-IFRS Financial Measures
We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses, amortization of intangible assets acquired in business combinations, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither is required by, or presented in accordance with IFRS.
We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such adjusted non-IFRS net profit attributable to owners of the Company, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.
For more information, please contact:
Ms. Ruijia Tang (for investors)
IR Director
Email: tang_ruijia@wuxiapptec.com
Mr. Davy Wu (for media)
PR Director
Email: davy_wu@wuxiapptec.com
View original content:
SOURCE WuXi AppTec | https://www.wagmtv.com/prnewswire/2023/07/31/wuxi-apptec-announced-strong-results-second-quarter-first-half-2023-top-an-exceptionally-strong-year-2022/ | 2023-07-31T11:23:30 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/wuxi-apptec-announced-strong-results-second-quarter-first-half-2023-top-an-exceptionally-strong-year-2022/ |
STAMFORD, Conn., July 31, 2023 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, recently announced the successful sale of an 11.5 MWp PV project to the Swiss-based energy company MET Group. The project was sold at the Ready-to-Build ("RTB") stage and MET Group will complete the construction and operate the power plant. This is the first project developed to RTB stage by Emeren Germany GmbH, the Berlin-based subsidiary of Emeren Group, since its entry into the market in early 2021. Capcora, a German consulting company, acted as the exclusive sell-side M&A advisor to Emeren.
The new PV power plant will be located in Kentzlin nestled in the state of Mecklenburg-Western Pomerania and the commercial operations are expected to start in the second half of 2024.
Yumin Liu, CEO of Emeren Group, commented, "This project is an important milestone for our business in Germany and represents our commitment to developing renewable energy infrastructure in the region. We look forward to continuing to work with our local partners to build a more sustainable future."
Bernd Wollwerth-Carl, Director of Emeren Germany GmbH, added, "We are delighted to have sold our first RTB project in Germany. Starting from scratch in 2021, we managed to grow quickly in a competitive German PV market, establishing partnerships and building a pipeline of medium and large-scale ground mounted PV plants. With MET, we found a reliable and competent partner and we look forward to further expanding our cooperation."
Christian Hürlimann, Renewables CEO of MET Group, commented, "The Kentzlin project fits well into MET's strategic vision to enter the highly competitive German renewables market, as well as to further expand its renewables portfolio across Europe and particularly in Western Europe. Emeren Group's expertise in renewable energy was instrumental in achieving this milestone, and we anticipate future collaboration on additional projects."
Henning Prigge, Director at Capcora, adds: "We are delighted to have played a pivotal role in Emeren's successful project sale to MET Group, a prominent integrated European energy company. Our long-standing partnership with Emeren has allowed us to witness their growth and success, and we couldn't be happier to have been a part of this milestone. This collaboration reinforces our commitment to providing top-notch support and solutions to our valued clients."
About Emeren Group Ltd
Emeren Group Ltd (NYSE: SOL) is a leading global solar project developer, owner, and operator with a pipeline of projects and IPP assets totaling over 3 GW, as well as a storage pipeline of over 6 GWh across Europe, North America, and Asia. The Company focuses on solar power project development, construction management and project financing services with local professional teams across multiple countries. For more information, go to www.emeren.com.
About MET Group
MET Group is an integrated European energy company, headquartered in Switzerland, with activities and assets in natural gas and power markets. MET is present in 14 countries through subsidiaries, 30 national gas markets, and 22 international trading hubs. MET has extensive experience in operating green (renewable) and flexible (conventional) energy assets, thus providing the widest possible support to energy transition. In 2022, MET Group's consolidated sales revenue amounted to EUR 41.5 billion, the total traded volume of natural gas was 109 BCM including futures, total traded electricity 67 TWh including futures.
About Capcora
Capcora is an independent financial advisory boutique specializing in M&A and project finance services to accelerate the energy transition in Europe. Founded in 2015, the Frankfurt-based company helps its clients succeed in the renewable energy and infrastructure sectors by advising them on sell-side and buy-side transactions, and by raising mezzanine, unitranche or senior debt.
View original content to download multimedia:
SOURCE Emeren Group Ltd | https://www.wkyt.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ | 2023-07-31T11:23:35 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ |
- CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled
- Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population
CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threatening cardiovascular (CV) events. The study enrolled more than 1,400 patients.
Eplontersen is an investigational antisense medicine designed to inhibit the production of transthyretin and slow the progression of cardiomyopathy for people living with hereditary or wild-type ATTR-CM.
"CARDIO-TTRansform is the largest and most comprehensive ATTR-CM study ever conducted. The evaluation of eplontersen in this broad, diverse patient population will enable robust and clinically meaningful analysis of the composite endpoint of CV mortality and recurrent CV events," said Eugene Schneider, M.D., executive vice president and chief clinical development officer for Ionis. "It will also allow us to gather data from important patient subsets, including patients with or without stabilizer therapy and those with or without hereditary disease within the evolving ATTR-CM landscape. We look forward to reporting results as early as the first half of 2025."
As part of a global development and commercialization agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. The U.S. Food and Drug Administration accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.
For more information on the CARDIO-TTRansform study, please visit www.clinicaltrials.gov (NCT04136171).
About the CARDIO-TTRansform Study
CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase 3 cardiovascular outcome study in more than 1,400 patients with ATTR cardiomyopathy (ATTR-CM). It is designed to compare eplontersen to placebo in patients with both wild-type ATTRwt-CM and hereditary ATTRv-CM who are either naïve to treatment or on a currently available standard of care. The primary composite endpoint is cardiovascular (CV) mortality and recurrent CV clinical events comparing the two study arms up to week 140. Secondary endpoints include the change from baseline in the 6-minute walk test (6MWT) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at week 121, as well as the rates of CV mortality, CV clinical events and all-cause mortality at week 140.
About Eplontersen
Eplontersen is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to inhibit the production of TTR protein. Eplontersen is being developed as a monthly self-administered subcutaneous injection to treat all types of ATTR. ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.
About Transthyretin-mediated Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. It is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within three to five years from disease onset. ATTR-CM includes both the genetic and wild-type form of the disease. Worldwide, there are an estimated 300,000 – 500,0001,2 patients with ATTR-CM.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of eplontersen, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
1 Mohamed-Salem L, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018 Nov 1;270:192-196. doi: 10.1016/j.ijcard.2018.06.006.
2 Cuscaden C, et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020 May 8. doi: 10.1007/s12350-020-02152-x.
View original content to download multimedia:
SOURCE Ionis Pharmaceuticals, Inc. | https://www.1011now.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ | 2023-07-31T11:23:36 | 0 | https://www.1011now.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ |
GUANGZHOU, China, July 31, 2023 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG), a leading China-based beauty group, today announced that it has published its 2022 Environmental, Social and Governance ("ESG") report, outlining the Company's progress and performance in key ESG areas.
The report provides a comprehensive review of Yatsen's ESG initiatives and developments, including corporate governance, research and development, employee rights protection, human capital development, environmental sustainability and social responsibility, among others.
To view the report in full, please visit the ESG section on the Yatsen Investor Relations website. Alternatively, please click here for the English version and here for the Chinese version of the 2022 report.
About Yatsen Holding Limited
Yatsen Holding Limited (NYSE: YSG) is a leading China-based beauty group with the mission of creating an exciting new journey of beauty discovery for consumers around the world. Founded in 2016, the Company has launched and acquired numerous color cosmetics and skincare brands, including Perfect Diary, Little Ondine, Abby's Choice, Galénic, DR.WU (its mainland China business), Eve Lom, Pink Bear and EANTiM. The Company's flagship brand, Perfect Diary, is one of the leading color cosmetics brands in China in terms of retail sales value. The Company primarily reaches and engages with customers directly, both online and offline, with an expansive presence across all major e-commerce, social and content platforms in China.
For more information, please visit http://ir.yatsenglobal.com/.
For investor and media inquiries, please contact:
In China:
Yatsen Holding Limited
Investor Relations
E-mail: ir@yatsenglobal.com
The Piacente Group, Inc
Hui Fan
Tel: +86-10-6508-0677
E-mail: yatsen@thepiacentegroup.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: yatsen@thepiacentegroup.com
View original content:
SOURCE Yatsen Holding Limited | https://www.wagmtv.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ | 2023-07-31T11:23:37 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ |
BEIJING, July 31, 2023 /PRNewswire/ -- Gravitas Education Holdings, Inc. ("GEHI" or the "Company") (NYSE: GEHI), a leading early childhood education service provider in China, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 3/F, No. 28 Building, Fangguyuan Section 1, Fangzhuang Fengtai District, Beijing 100078, People's Republic of China, at 10:00 a.m. (Beijing time) on September 11, 2023, for the purposes of considering and, if thought fit, approving the transactions contemplated in the Agreement and Plan of Merger (the "Merger Agreement"), dated April 18, 2023, by and among the Company, Bright Sunlight Limited, a Cayman Islands exempted company and a direct, wholly owned subsidiary of the Company ("Merger Sub"), Best Assistant Education Online Limited, a Cayman Islands exempted company ("Best Assistant") and a controlled subsidiary of NetDragon Websoft Holdings Limited (HKEX: 0777, "NetDragon"), a Cayman Islands exempted company, and solely for purposes of certain named sections thereof, NetDragon. It is contemplated that Best Assistant will transfer the education business of NetDragon outside of the PRC to Elmtree Inc., a Cayman Islands exempted company limited by shares ("eLMTree") and currently a wholly owned subsidiary of Best Assistant. Pursuant to the Merger Agreement, Merger Sub will merge with and into eLMTree with eLMTree continuing as the surviving company and becoming a wholly owned subsidiary of the Company (the "Merger").
Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each ordinary share of eLMTree issued and outstanding immediately prior to the Effective Time (excluding the Dissenting Shares and the Excluded Shares, each as defined in the Merger Agreement) will be cancelled in exchange for the right to receive a number of validly issued, fully paid and non-assessable ordinary shares of the Company in a transaction exempt from the registration requirements under the Securities Act of 1933.
Shareholders of the Company will also be asked to consider and vote on certain additional Merger-related proposals at the EGM, including, among others:
- that, subject to and conditional upon the Merger becoming effective, the fifth amended and restated memorandum and article of association of the Company be amended and restated by their deletion in their entirety and the substitution of in their place of the sixth amended and restated memorandum and articles of association of the Company (the "A&R MAA") effective immediately prior to the Effective Time of the Merger;
- that, subject to and conditional upon the Merger becoming effective, the name of the Company be changed from "Gravitas Education Holdings, Inc." to "Mynd.ai, Inc." effective immediately prior to the Effective Time;
- that, subject to and conditional upon the Merger becoming effective, immediately prior to the Effective Time, the authorized share capital of the Company be varied as follows: (a) the authorized share capital of the Company shall be varied to US$1,000,000 divided into 1,000,000,000 shares comprising of (i) 990,000,000 ordinary shares of a par value of US$0.001 each (each a "ListCo Ordinary Share") and (ii) 10,000,000 shares of a par value of US$0.001 each of such class or classes (however designated) as the board of directors may determine in accordance with the A&R MAA, and (b) all Class A ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class A Ordinary Shares") and all Class B ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class B Ordinary Shares") in the authorized share capital of the Company (including all issued and outstanding ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares, and all authorized but unissued ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares) shall be re-designated as ListCo Ordinary Shares.
Holders of the Company's ordinary shares whose names are on the register of members of the Company at the close of business in the Cayman Islands on August 7, 2023, are entitled to notice of, and to vote at, the EGM or any adjournment or postponement thereof in person. Holders of the Company's American depositary shares ("ADSs") at the close of business in New York City on August 7, 2023, are entitled to exercise their voting rights for the underlying ordinary shares and must act through Citibank, N.A., the depositary of the Company's ADS program.
The notice of the EGM, which contains the detailed proposals to be presented at the EGM, and the proxy statement related to the EGM, are being filed today with the U.S. Securities and Exchange Commission ("SEC") and can be obtained without charge from the SEC's website (http://www.sec.gov). These documents are also available in the "Financial Information" section of the Company's investor relations website at https://ir.geh.com.cn/. In addition, the proxy materials (including the proxy statement) will be mailed to the Company's shareholders and holders of ADSs.
SHAREHOLDERS AND ADS HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN VOTING INSTRUCTIONS AND IMPORTANT INFORMATION ABOUT THE COMPANY, ELMTREE, THE MERGER AND RELATED MATTERS.
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of eLMTree or the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Forward-Looking Statements
This press release contains certain "forward-looking statements." These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the pending transactions described herein, and the parties' perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the Merger, including the equity values, the benefits of the Merger, expected revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words "will," "expect," "believe," "estimate," "intend," "plan" and similar expressions indicate forward-looking statements.
Such forward-looking statements are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from the expectations as a result of a variety of factors. Such forward-looking statements are based upon management's current expectations and include known and unknown risks, uncertainties and other factors, many of which are hard to predict or control, that may cause the actual results, performance, or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the Merger, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iii) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of the Company or eLMTree; (iv) risks related to disruption of management time from ongoing business operations due to the Merger; (v) the risk that any announcements relating to the Merger could have adverse effects on the market price of the Company's securities; (vi) the risk that the Merger and its announcement could have an adverse effect on the ability of eLMTree to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (vii) any changes in the business or operating prospects of eLMTree or its businesses; (viii) changes in applicable laws and regulations; and (ix) risks relating to the combined company's ability to enhance its services and products, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the proxy statement that will be filed with the SEC by the Company in connection with the Merger, and other documents that the parties may file with or furnish to the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and eLMTree, the Company and their subsidiaries and affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information and Where to Find It
The Company will file with the SEC and mail to its shareholders and ADS holders a proxy statement in connection with the Merger. Investors and security holders are urged to read the proxy statement when it becomes available because it will contain voting instructions and important information regarding the proposed arrangement. You may access the proxy statement (when available) and other related documents filed by the Company with the SEC at the SEC's website at www.sec.gov. You also may obtain the proxy statement and other documents filed by the Company with the SEC relating to the proposed arrangement for free by accessing the Company's website at https://ir.geh.com.cn/ by clicking on the link for "Financial Information," and then clicking on the link for "SEC Filings."
CONTACT: Gravitas Education Holdings, Inc., Investor Relations, E-mail: ir@geh.com.cn
View original content:
SOURCE Gravitas Education Holdings Inc. | https://www.wkyt.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ | 2023-07-31T11:23:42 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ |
Juggernaut and Mr. Highman will continue as substantial shareholders of Bobbie. The acquisition positions the combined company as the third largest fully integrated infant and toddler brand in the U.S., creating a more resilient industry for American families
WASHINGTON, July 31, 2023 /PRNewswire/ -- Juggernaut Capital Partners, a leading middle market private equity investor primarily in the consumer and healthcare sectors, is pleased to announce the sale of Nature's One, the pediatric nutrition company founded by Jay Highman which set the bar for quality and innovation in formula over decades. Joining forces with Bobbie Baby, Inc., the nation's fastest growing infant formula company, the combined business will be the first of its kind in pediatric nutrition.
"Nature's One is a true pioneer in the pediatric nutrition space. Juggernaut partnered with founder, Jay Highman, to accelerate product development and vertical integration initiatives. Over the past five years, the company completed the first FDA-approved clinical feeding study of an organic infant formula and designed and constructed the first newly built infant formula facility in the U.S. in 35 years," said John Shulman, Founder and Managing Partner at Juggernaut. "It has been a pleasure to partner with Jay and his team. We believe the combination with Bobbie cements the organization as a continued disruptor and a next-generation industry leader. We are proud to continue as a meaningful shareholder in the go-forward company."
Founded in 1997, Nature's One introduced the first organic baby formula to the U.S. market. Recognized for its dedication to purity and quality, all of the company's formulas have received the Clean Label Project's Purity Award and have tested best in class for purity and nutrition when compared to popular baby formulas sold in the U.S. Nature's One operates the only independent, FDA audited organic infant nutrition facility in the U.S.
Nature's One was advised by CG / Sawaya Partners (operating under Canaccord Genuity) and Morgan Lewis & Bockius LLP. Bobbie was advised by Perella Weinberg Partners LP and Goodwin Procter LLP.
About Juggernaut Capital Partners:
Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies, primarily in the consumer and healthcare sectors. Juggernaut is currently investing out of Juggernaut Capital Partners V, L.P. For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.
About Nature's One:
Founded in 1997, Nature's One introduced the first organic formula, Baby's Only® Organic in the United States. Nature's One has dedicated 25 years to the research, development, and sourcing of pure ingredients. Recognized as the first and highest-ranked formulas for purity and nutritional superiority by the Clean Label Project, Baby's Only Formulas are preferred by parents who want to offer their child a "Better Start…for Life™." Baby's Only Formulas are sold nationally at Whole Foods, Target, Walmart, Sam's Club, and many fine natural food retailers, as well online at www.naturesone.com.
About Bobbie:
Bobbie is the mission-driven organic pediatric nutrition company that exists to build a parenting culture of confidence, not comparison. Founded in 2018, Bobbie hit the market with its flagship European-inspired formula in 2021 as the first direct-to-consumer, subscription-based infant formula in the U.S. Today, it's proud to be the only mom-founded and led infant formula brand in the world, and the fastest-growing in the U.S. since the 1980's. Bobbie is focused on providing purposefully sourced, USDA Organic products made with simple ingredients – crafted right here in America, for American families. For more information, visit www.hibobbie.com.
View original content:
SOURCE Juggernaut Capital Partners | https://www.1011now.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ | 2023-07-31T11:23:42 | 1 | https://www.1011now.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ |
The cutting-edge platform empowers B2B SaaS start-ups to reduce churn, increase upsell, and boost NRR
WILMINGTON, Del., July 31, 2023 /PRNewswire/ -- ZapScale, a new-age customer success platform, is making waves in the industry by offering an unrivalled one-day onboarding experience along with the ability to track 150 customer data points for a comprehensive 360-degree view of customer health. This ground-breaking feature sets ZapScale apart from its competitors.
The secret behind ZapScale's lightning-fast onboarding lies in its comprehensive toolkit. With a robust framework of 40 pre-built KPI-based health frameworks, 60 pre-designed playbooks to automate CS ops, and seamless native integrations with all popular tools, ZapScale empowers businesses to gain complete visibility over customer data. With deep customer health insights, ZapScale's customers have seen an improvement in retention and increase in upsell opportunities.
Manasij Ganguli, Founder and CEO of ZapScale, shares his personal motivation for creating this game-changing platform: "ZapScale was born out of my passion to empower B2B SaaS start-ups with an efficient and effective CS platform. Having faced numerous customer success challenges in my previous start-up, which I successfully sold in 2019, I realized the critical need for a solution that could streamline, optimize, and accelerate CS operations.
For small to mid-sized businesses that have limited time and resources, implementing a CS platform has historically been a daunting task, taking weeks, if not months, to set up essential elements like customer health, playbooks, and integrations. ZapScale has addressed this challenge by offering a user-friendly and efficient implementation process, eliminating waste of time and resources. Now, businesses can seamlessly focus on their customers right from day 1."
ZapScale eliminates the traditional barriers and time-consuming processes associated with implementing CS platforms using key in-built features that facilitate custom mapping, support custom fields, and require no unique key to integrate applications, ensuring a tailored yet quick integration experience.
ZapScale is swiftly gaining traction in the market, with 30+ global companies already using the customer success platform. Starting at $249 per month, with a one-month free trial, ZapScale is helping businesses significantly improve their customer success initiatives.
For more information about ZapScale and to schedule a demo, visit www.zapscale.com.
Contact:
Nikita Kalra
Marketing Head, ZapScale
nikita@zapscale.com
Logo: https://mma.prnewswire.com/media/2097823/ZS_Logo.jpg
View original content:
SOURCE ZapScale | https://www.wagmtv.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ | 2023-07-31T11:23:43 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ |
LA ROMANA, Dominican Republic, July 31, 2023 /PRNewswire/ -- The international known company Hilton Hotels & Resorts opens its doors to its Hilton Garden Inn La Romana hotel project in the Dominican Republic, in collaboration with a group of important investors under the company Riverhome Capital S.A.S., whose main shareholder is the prominent Dominican former major league player, Edwin Encarnación; together with the vision of the lawyer Guillermo Estrella Ramia and the Minister of Tourism, David Collado.
The inauguration was led by Luis Abinader Corona, president of the Dominican Republic and who expressed that "This hotel has something very special, opening up the beach and the sector of La Caleta of La Romana, which for a long time was closed to the province and its visitors. Since private investment must always be accompanied by public infrastructure, we are working on creating them, so we are all part of this development of La Romana."
With an investment of 25 million united states dollars and the creation of more than 300 direct jobs, it is considered as a hotel option for the growing flows of tourists that the area is currently receiving. Located a short distance from other points of relevance, such as La Romana Airport 18 minutes away, Casa de Campo 12 minutes away and Central Romana just a few blocks away.
The new hotel facility has a privileged location on a 5,000 square meters property, located on the coast of the municipal district of La Caleta, La Romana province. With a capacity of 130 rooms, distributed in five of the seven floors of the building, it also counts with swimming pools, two bars, a restaurant, gym, event, meeting and multipurpose rooms, and outdoor areas, ideal for social and corporate celebrations.
The hotel responds to the interest of Edwin Encarnación to invest in the development of his province of origin, who expressed that "from the moment this project was presented to me, I knew that I had to be part and be the one to assume this. I joined the development of this hotel, with the only requirement that most of the workers came from here, from my town La Romana, and we achieved this."
View original content to download multimedia:
SOURCE Grupo De Valle | https://www.wkyt.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ | 2023-07-31T11:23:48 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ |
BURLINGTON, N.C., July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 14, 2023, in New York City, beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET.
This event will highlight Labcorp's go-forward strategy from Labcorp Chairman & CEO Adam Schechter, followed by business overviews and a longer-term financial outlook. Presentations will be followed by a Q&A session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 1:00 p.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
View original content to download multimedia:
SOURCE Labcorp | https://www.1011now.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ | 2023-07-31T11:23:49 | 1 | https://www.1011now.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ |
KETTERING, Ohio (WDTN) — On Sunday afternoon, local restaurants got a chance to show off their flavor at the 36th annual Taste of the Fraze.
“It’s like a double whammy,” said 21-year-old Luke Lawrence, owner of Hole N One Donuts. “You know, you get free advertising. We always like giving out donut holes, especially on a hot day like this, because they’re soft and it’s a good thing to go around.”
It was Lawrence’s second year at the Kettering-Moraine Chamber of Commerce “Taste” event. He said it’s good for business and he urged others to sign up in the future.
“This year we saw a lot of new businesses compared to last year. I said this is our second year. We hope to continue coming years after this as well. But I definitely think it’s a good place for new businesses or businesses that have been around for a while. All together I think it’s a pretty fun event.”
And that’s the goal of the event. Organizers said they want to bring out more businesses and give them a chance to meet members of the community — while also giving the people who come a chance to try new restaurants.
“We like to think of it as a networking event too, because for us it’s a win-win. We want to provide the restaurants, their target market, people that eat out, order catering and buy gift certificates,” said Ann-Lisa Allen, president of the Kettering-Moraine Chamber of Commerce.
“We want them to attend this event and get to know our restaurants on a little better level.” | https://www.wdtn.com/news/local-news/community-members-try-new-restaurants-at-taste-of-the-fraze/ | 2023-07-31T11:23:50 | 0 | https://www.wdtn.com/news/local-news/community-members-try-new-restaurants-at-taste-of-the-fraze/ |
The tech giant made the line of sneakers as a one-time gift for its employees in the '90s. A size 10.5 pair has found its way onto the Sotheby's website, where it's on sale for $50,000.
Copyright 2023 NPR
The tech giant made the line of sneakers as a one-time gift for its employees in the '90s. A size 10.5 pair has found its way onto the Sotheby's website, where it's on sale for $50,000.
Copyright 2023 NPR | https://www.nprillinois.org/2023-07-31/a-pair-of-white-sneakers-made-specifically-for-apple-employees-is-up-for-auction | 2023-07-31T11:23:51 | 1 | https://www.nprillinois.org/2023-07-31/a-pair-of-white-sneakers-made-specifically-for-apple-employees-is-up-for-auction |
- CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled
- Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population
CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threatening cardiovascular (CV) events. The study enrolled more than 1,400 patients.
Eplontersen is an investigational antisense medicine designed to inhibit the production of transthyretin and slow the progression of cardiomyopathy for people living with hereditary or wild-type ATTR-CM.
"CARDIO-TTRansform is the largest and most comprehensive ATTR-CM study ever conducted. The evaluation of eplontersen in this broad, diverse patient population will enable robust and clinically meaningful analysis of the composite endpoint of CV mortality and recurrent CV events," said Eugene Schneider, M.D., executive vice president and chief clinical development officer for Ionis. "It will also allow us to gather data from important patient subsets, including patients with or without stabilizer therapy and those with or without hereditary disease within the evolving ATTR-CM landscape. We look forward to reporting results as early as the first half of 2025."
As part of a global development and commercialization agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. The U.S. Food and Drug Administration accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.
For more information on the CARDIO-TTRansform study, please visit www.clinicaltrials.gov (NCT04136171).
About the CARDIO-TTRansform Study
CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase 3 cardiovascular outcome study in more than 1,400 patients with ATTR cardiomyopathy (ATTR-CM). It is designed to compare eplontersen to placebo in patients with both wild-type ATTRwt-CM and hereditary ATTRv-CM who are either naïve to treatment or on a currently available standard of care. The primary composite endpoint is cardiovascular (CV) mortality and recurrent CV clinical events comparing the two study arms up to week 140. Secondary endpoints include the change from baseline in the 6-minute walk test (6MWT) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at week 121, as well as the rates of CV mortality, CV clinical events and all-cause mortality at week 140.
About Eplontersen
Eplontersen is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to inhibit the production of TTR protein. Eplontersen is being developed as a monthly self-administered subcutaneous injection to treat all types of ATTR. ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.
About Transthyretin-mediated Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. It is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within three to five years from disease onset. ATTR-CM includes both the genetic and wild-type form of the disease. Worldwide, there are an estimated 300,000 – 500,0001,2 patients with ATTR-CM.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of eplontersen, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
1 Mohamed-Salem L, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018 Nov 1;270:192-196. doi: 10.1016/j.ijcard.2018.06.006.
2 Cuscaden C, et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020 May 8. doi: 10.1007/s12350-020-02152-x.
View original content to download multimedia:
SOURCE Ionis Pharmaceuticals, Inc. | https://www.wkyt.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ | 2023-07-31T11:23:54 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ |
Adult Males are Slightly More Likely to Live with Parents Than Their Female Counterparts
58% of Gen Z Consumers Live with Family Members
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from the 24th edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS. The Household Finances Deep Dive Edition examines the impact of household composition on consumers' ability to manage expenses and put aside savings. The series draws on insights from a survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data.
The Paycheck-to-Paycheck Landscape
In June 2023, 61% of U.S. consumers lived paycheck to paycheck, unchanged from June 2022 — as is the share of those struggling to pay bills (at 21%) — even though more middle-income consumers cited living paycheck to paycheck in June 2023 than last year. Among consumers earning $50,000 to $100,000, 65% lived paycheck to paycheck as of June 2023, compared to 60% in June 2022. Meanwhile, the shares of high-income consumers — those earning more than $100,000 annually — and low-income consumers — those earning less than $50,000 annually — living paycheck to paycheck in June 2023 sit at 45% and 77%, respectively, relatively unchanged from June 2022.
This stability in the financial situation of U.S. households indicates that consumers continue to adapt to inflationary pressures, finding ways to manage their spending and live within their means.
Household Composition Determines Financial Lifestyle
Consumers living with only a partner or spouse are likely to face less financial hardship, while those with dependents and those living with friends or housemates are more likely to live paycheck to paycheck.
The research finds that 86% of consumers live with one or more people, and one-third of paycheck-to-paycheck consumers live in households of four or more people. Consumers not living paycheck to paycheck are most likely to reside in two-person households, at 41%. Meanwhile, 49% of millennials and 55% of bridge millennials live in households of four or more people, making them the age groups most likely to reside in the largest households.
There is also a direct correlation among household size, stage of life and financial lifestyle. As household size increases, the ratio of income earners to non-earners typically falls, attributable to households with dependent children. When looking at the share of paycheck-to-paycheck consumers who live in a two-member household, the data finds that 54% do so — 7 percentage points below the sample average. Meanwhile, at 66%, consumers with children under the age of 18 are 12% more likely to live paycheck to paycheck than those without children, at 59%. Among consumers living with friends or housemates, 77% live paycheck to paycheck — the most likely to do so. This suggests that those sharing expenses with a partner or spouse fare better, that is until they have children or even parents to support.
"As household size increases, the ratio of income earners to household members typically falls, creating a higher likelihood of financial distress," said Alia Dudum, LendingClub's Money Expert. "The relationship between household income and household composition explains why many families tend to struggle financially and why millennials and bridge millennials, many of whom are in their peak child-rearing years, tend to remain financially vulnerable."
Economic Considerations Top Reason to Stay in the Family Household
Economics are the main driver for consumers to live with family longer, with 43% wanting to save money and 30% unable to afford housing independently. Besides economic reasons, consumers remain at home to maintain family ties (24%), for transitional reasons (23%), and to provide care (22%).
At one-fifth (20%), adult males are slightly more likely to live with parents than their female counterparts (18%), a phenomenon that grows significantly among those financially struggling (26% of males compared to 18% of females). At 58%, Gen Z is the generation most likely to stay with family members, with 50% citing economic reasons. Members of Gen Z living with three or more people — often familial settings — spent 22% of their income on housing, compared to 30% of those living alone or with a partner.
That said, consumers living with family members to offset expenses are not planning extended stays. For example, one-third of those consumers expect to move out in the coming year, particularly millennials and bridge millennials.
Financial Transparency Determined by Relationship Status
Financial transparency within shared households is paramount to ensure bills are paid and expenses are covered, but the transparency level depends on who consumers live with. Couples living together share financial information 87% of the time and have a joint bank account 76% of the time. Parents are also likely to discuss finances with the children residing in their household, with 45% of parents sharing financial information with their children and 34% granting them access to a shared account. Bill splitting is the most common financial interaction for consumers living with friends or housemates, at 74%. Additionally, borrowing money from other household members is a financial option many use to make ends meet, with consumers mostly engaging in this practice with parents or siblings, at 47%, and friends and housemates, at 44%.
Families and couples maintain outstanding credit card balances that are significantly higher, on average, than those of consumers who live alone. Consumers with children under the age of 18 average 50% more credit card debt than those who live alone. Families represent the lion's share of credit card spending, holding average balances of $6,300 for consumers living with a partner and $7,200 for those living with children under 18. Living with a partner or children also significantly increases a consumer's likelihood of having an auto loan or mortgage.
"With today's inflationary pressures, sharing household finances has become not only common but crucial," continued Dudum. "The increasing complexity of modern lifestyles and the rising cost of living have necessitated a shift in the way consumers approach household finances. One person solely bearing the burden of managing all financial matters has become a minority practice. Instead, couples, families, and even roommates increasingly jointly navigate their economic realities, and it's a trend that is here to stay."
To view the full report, visit: https://www.pymnts.com/study/reality-check-paycheck-to-paycheck-inflation-household-spending-shared-expenses/
Methodology
New Reality Check: The Paycheck-to-Paycheck Report — The Household Finances Deep Dive Edition is based on a census-balanced survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data. The data in this report is not intended to be a representation of LendingClub's core member base. The Paycheck-to-Paycheck series expands on existing data published by government agencies, such as the Federal Reserve System and the Bureau of Labor Statistics, to provide a deep look into the core elements of American consumers' financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 51% of respondents identified as female, 33% were college-educated and 38% declared incomes of more than $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $85 billion in loans, our advanced credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4.7 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
Contact:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.1011now.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ | 2023-07-31T11:23:55 | 0 | https://www.1011now.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ |
HONG KONG (AP) — A French man is believed to have fallen to his death from a high-rise residential building in Hong Kong last week, police said on Monday, with local media outlets identifying him as daredevil Remi Lucidi.
Police said a 30-year-old man’s body was found on a patio in the city’s upscale Mid-Levels area. He was believed to have engaged in extreme sports, police said, without identifying him.
Officers conducted an initial investigation and said he apparently fell from a rooftop. No suicide note was found at the scene, they said. The cause of his death would have to be verified by an autopsy, they added.
Local media, including the South China Morning Post, said the man was Lucidi, 30. The Post cited an unnamed source saying he was last seen alive knocking on a penthouse window on the 68th floor of a residential tower on Thursday evening. The Associated Press has not been able to verify his identity.
Lucidi, who used the name “Remi Enigma” on social media, last posted a photo of Hong Kong’s night view a week ago on Instagram and tagged the location as Times Square in shopping district Causeway Bay. The photo appeared to be taken from above.
Supporters mourned him on social media.
Lucidi posted to Instagram as he climbed various tall structures around the world and took selfies, including one he captioned, “Above the Sky, 425m” and tagged Dubai as the location. | https://www.wdtn.com/news/u-s-world/ap-international/ap-french-daredevil-who-climbed-towers-around-world-believed-to-have-fallen-to-his-death-in-hong-kong/ | 2023-07-31T11:23:56 | 0 | https://www.wdtn.com/news/u-s-world/ap-international/ap-french-daredevil-who-climbed-towers-around-world-believed-to-have-fallen-to-his-death-in-hong-kong/ |
ORLANDO, Fla. — Central Florida will be very hot and humid Monday.
>>> STREAM CHANNEL 9 EYEWITNESS NEWS LIVE <<<
The high temperature will reach around 93 degrees in the afternoon.
Read: Man attacked by shark off west-central Florida beach
The heat index, or feels-like temperature; will be around 115 degrees when you factor in both heat and humidity.
Some storms will develop later in the day and some areas could see strong to severe storms.
Read: Back-to-school event will raise money for Seminole County schools
Our area will have a 60% chance of seeing rain and storms Monday.
Channel 9 meteorologists are also monitoring two areas that may show tropical development.
Read: ‘Gray Man’ ghost makes appearance before major hurricanes, legend says
If one of the two storms gets a name, it will be Emily.
Thankfully, neither of the storms are forecast to be a threat to the United States.
Click here to download the free WFTV news and weather apps, click here to download the WFTV Now app for your smart TV and click here to stream Channel 9 Eyewitness News live.
©2023 Cox Media Group | https://www.wftv.com/news/local/strong-storms-possible-during-hot-humid-monday-central-florida/CKCQMTI7EZD5TL3R2NWKNKBDUE/ | 2023-07-31T11:23:57 | 1 | https://www.wftv.com/news/local/strong-storms-possible-during-hot-humid-monday-central-florida/CKCQMTI7EZD5TL3R2NWKNKBDUE/ |
Juggernaut and Mr. Highman will continue as substantial shareholders of Bobbie. The acquisition positions the combined company as the third largest fully integrated infant and toddler brand in the U.S., creating a more resilient industry for American families
WASHINGTON, July 31, 2023 /PRNewswire/ -- Juggernaut Capital Partners, a leading middle market private equity investor primarily in the consumer and healthcare sectors, is pleased to announce the sale of Nature's One, the pediatric nutrition company founded by Jay Highman which set the bar for quality and innovation in formula over decades. Joining forces with Bobbie Baby, Inc., the nation's fastest growing infant formula company, the combined business will be the first of its kind in pediatric nutrition.
"Nature's One is a true pioneer in the pediatric nutrition space. Juggernaut partnered with founder, Jay Highman, to accelerate product development and vertical integration initiatives. Over the past five years, the company completed the first FDA-approved clinical feeding study of an organic infant formula and designed and constructed the first newly built infant formula facility in the U.S. in 35 years," said John Shulman, Founder and Managing Partner at Juggernaut. "It has been a pleasure to partner with Jay and his team. We believe the combination with Bobbie cements the organization as a continued disruptor and a next-generation industry leader. We are proud to continue as a meaningful shareholder in the go-forward company."
Founded in 1997, Nature's One introduced the first organic baby formula to the U.S. market. Recognized for its dedication to purity and quality, all of the company's formulas have received the Clean Label Project's Purity Award and have tested best in class for purity and nutrition when compared to popular baby formulas sold in the U.S. Nature's One operates the only independent, FDA audited organic infant nutrition facility in the U.S.
Nature's One was advised by CG / Sawaya Partners (operating under Canaccord Genuity) and Morgan Lewis & Bockius LLP. Bobbie was advised by Perella Weinberg Partners LP and Goodwin Procter LLP.
About Juggernaut Capital Partners:
Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies, primarily in the consumer and healthcare sectors. Juggernaut is currently investing out of Juggernaut Capital Partners V, L.P. For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.
About Nature's One:
Founded in 1997, Nature's One introduced the first organic formula, Baby's Only® Organic in the United States. Nature's One has dedicated 25 years to the research, development, and sourcing of pure ingredients. Recognized as the first and highest-ranked formulas for purity and nutritional superiority by the Clean Label Project, Baby's Only Formulas are preferred by parents who want to offer their child a "Better Start…for Life™." Baby's Only Formulas are sold nationally at Whole Foods, Target, Walmart, Sam's Club, and many fine natural food retailers, as well online at www.naturesone.com.
About Bobbie:
Bobbie is the mission-driven organic pediatric nutrition company that exists to build a parenting culture of confidence, not comparison. Founded in 2018, Bobbie hit the market with its flagship European-inspired formula in 2021 as the first direct-to-consumer, subscription-based infant formula in the U.S. Today, it's proud to be the only mom-founded and led infant formula brand in the world, and the fastest-growing in the U.S. since the 1980's. Bobbie is focused on providing purposefully sourced, USDA Organic products made with simple ingredients – crafted right here in America, for American families. For more information, visit www.hibobbie.com.
View original content:
SOURCE Juggernaut Capital Partners | https://www.wkyt.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ | 2023-07-31T11:24:00 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ |
NEW YORK (AP) — Six straight days of 12-hour driving. Single digit paychecks. The complaints come from workers in vastly different industries: UPS delivery drivers and Hollywood actors and writers.
But they point to an underlying factor driving a surge of labor unrest: The cost to workers whose jobs have changed drastically as companies scramble to meet customer expectations for speed and convenience in industries transformed by technology.
The COVID-19 pandemic accelerated those changes, pushing retailers to shift online and intensifying the streaming competition among entertainment companies. Now, from the picket lines, workers are trying to give consumers a behind-the-scenes look at what it takes to produce a show that can be binged any time or get dog food delivered to their doorstep with a phone swipe.
Overworked and underpaid employees is an enduring complaint across industries — from delivery drivers to Starbucks baristas and airline pilots — where surges in consumer demand have collided with persistent labor shortages. Workers are pushing back against forced overtime, punishing schedules or company reliance on lower-paid, part-time or contract forces.
At issue for Hollywood screenwriters and actors staging their first simultaneous strikes in 40 years is the way streaming has upended entertainment economics, slashing pay and forcing showrunners to produce content faster with smaller teams.
“This seems to happen to many places when the tech companies come in. Who are we crushing? It doesn’t matter,” said Danielle Sanchez-Witzel, a screenwriter and showrunner on the negotiating team for the Writers Guild of America, whose members have been on strike since May. Earlier this month, the Screen Actors Guild–American Federation of Television and Radio Artists joined the writers’ union on the picket line.
Actors and writers have long relied on residuals, or long-term payments, for reruns and other airings of films and televisions shows. But reruns aren’t a thing on streaming services, where series and films simply land and stay with no easy way, such as box office returns or ratings, to determine their popularity.
Consequently, whatever residuals streaming companies do pay often amount to a pittance, and screenwriters have been sharing tales of receiving single digit checks.
Adam Shapiro, an actor known for the Netflix hit “Never Have I Ever,” said many actors were initially content to accept lower pay for the plethora of roles that streaming suddenly offered. But the need for a more sustainable compensation model gained urgency when it became clear streaming is not a sideshow, but rather the future of the business, he said.
“Over the past 10 years, we realized: ‘Oh, that’s now how Hollywood works. Everything is streaming,’” Shapiro said during a recent union event.
Shapiro, who has been acting for 25 years, said he agreed to a contract offering 20% of his normal rate for “Never Have I Ever” because it seemed like “a great opportunity, and it’s going to be all over the world. And it was. It really was. Unfortunately, we’re all starting to realize that if we keep doing this we’re not going to be able to pay our bills.”
Then there’s the rising use of “mini rooms,” in which a handful of writers are hired to work only during pre-production, sometimes for a series that may take a year to be greenlit, or never get picked up at all.
Sanchez-Witzel, co-creator of the recently released Netflix series “Survival of the Thickest,” said television shows traditionally hire robust writing teams for the duration of production. But Netflix refused to allow her to keep her team of five writers past pre-production, forcing round-the-clock work on rewrites with just one other writer.
“It’s not sustainable and I’ll never do that again,” she said.
Sanchez-Witzel said she was struck by the similarities between her experience and those of UPS drivers, some of whom joined the WGA for protests as they threatened their own potentially crippling strike. UPS and the Teamsters last week reached a tentative contract staving off the strike.
Jeffrey Palmerino, a full-time UPS driver near Albany, New York, said forced overtime emerged as a top issue during the pandemic as drivers coped with a crush of orders on par with the holiday season. Drivers never knew what time they would get home or if they could count on two days off each week, while 14-hour days in trucks without air conditioning became the norm.
“It was basically like Christmas on steroids for two straight years. A lot of us were forced to work six days a week, and that is not any way to live your life,” said Palmerino, a Teamsters shop steward.
Along with pay raises and air conditioning, the Teamsters won concessions that Palmerino hopes will ease overwork. UPS agreed to end forced overtime on days off and eliminate a lower-paid category of drivers who work shifts that include weekends, converting them to full-time drivers. Union members have yet to ratify the deal.
The Teamsters and labor activists hailed the tentative deal as a game-changer that would pressure other companies facing labor unrest to raise their standards. But similar outcomes are far from certain in industries lacking the sheer economic indispensability of UPS or the clout of its 340,000-member union.
Efforts to organize at Starbucks and Amazon stalled as both companies aggressively fought against unionization.
Still, labor protests will likely gain momentum following the UPS contract, said Patricia Campos-Medina, executive director of the Worker Institute at the School of Industrial and Labor Relations at Cornell University, which released a report this year that found the number of labor strikes rose 52% in 2022.
“The whole idea that consumer convenience is above everything broke down during the pandemic. We started to think, ‘I’m at home ordering, but there is actually a worker who has to go the grocery store, who has to cook this for me so that I can be comfortable,’” Campos-Medina said. | https://www.wdtn.com/news/u-s-world/customers-want-instant-gratification-workers-say-theyre-on-the-brink/ | 2023-07-31T11:24:02 | 0 | https://www.wdtn.com/news/u-s-world/customers-want-instant-gratification-workers-say-theyre-on-the-brink/ |
HOUSTON, July 31, 2023 /PRNewswire/ -- McDermott has been awarded a project management consultancy (PMC) and engineering, procurement, and construction management (EPCM) contract for the Naphtha Cracker Expansion (Phase II) polypropylene expansion and new ethylene derivative unit project from Indian Oil Corporation Limited (IOCL). The project is located at the Panipat Refinery and Petrochemical Complex, located 62 miles (100 kilometers) from New Delhi, India.
The project will increase the ethylene production capacity of the naphtha cracker unit (NCU) by approximately 20 percent. The additional ethylene and propylene production will act as feed for downstream polymer units. The polymer products will be used for the manufacture of household and industrial items, including containers, automobile parts, furniture, and heavy-duty films.
"McDermott is currently executing four other projects for IOCL, including the maleic anhydride (MAH) unit at the same site, allowing us to leverage our local resources and expertise while realizing synergies," said Vaseem Khan, Senior Vice President, Global Operations. "Furthermore, the project supports the growing demand for ethylene and propylene which will reduce imports and accelerate economic development in the area."
McDermott will provide comprehensive EPCM services and overall project management for the duration of the project, which will be executed from its Center of Excellence in Gurugram, India.
About McDermott
McDermott is a premier, fully-integrated provider of engineering and construction solutions to the energy industry. Our customers trust our technology-driven approach engineered to responsibly harness and transform global energy resources into the products the world needs. From concept to commissioning, McDermott's innovative expertise and capabilities advance the next generation of global energy infrastructure—empowering a brighter, more sustainable future for us all. Operating in over 54 countries, McDermott's locally-focused and globally-integrated resources include more than 30,000 employees, a diversified fleet of specialty marine construction vessels and fabrication facilities around the world. To learn more, visit www.mcdermott.com.
Forward-Looking Statements
McDermott cautions that statements in this press release which are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties. These forward-looking statements include, among other things, statements about the expected scope and execution of the project discussed in this press release. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, among others: adverse changes in the markets in which we operate or credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope or timing of contracts, contract cancellations, change orders and other modifications and actions by our customers and other business counterparties; changes in industry norms; actions by lenders, other creditors, customers and other business counterparties of McDermott; and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of McDermott's management as of the date hereof. Except to the extent required by applicable law, McDermott undertakes no obligation to update or revise any forward-looking statement.
Contacts:
Global Media Relations
Reba Reid
Senior Director, Global Communications and Marketing
+1 281 588 5636
RReid@McDermott.com
Business Line Media Relations
Barbara Knight
Senior Director, Business Line Communications and Marketing
+971 56 403 2903
BBKnight@McDermott.com
View original content to download multimedia:
SOURCE McDermott International, Ltd | https://www.1011now.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ | 2023-07-31T11:24:02 | 0 | https://www.1011now.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ |
ORANGE COUNTY, Fla. — The Florida Highway Patrol said it responded to a deadly crash in Orange County Sunday night.
>>> STREAM CHANNEL 9 EYEWITNESS NEWS LIVE <<<
Around 9 p.m., troopers were dispatched to John Young Parkway just south of the Beachline Expressway.
Investigators worked into the overnight hours but wrapped up their crash investigation around 4 a.m. Monday.
READ: Two found dead after shooting in Orange County, deputies say
Channel 9 has reached out to FHP to learn more about who was involved and what led to the fatal crash.
Stay with WFTV.com and watch Eyewitness News for updates.
READ: Man injured, suspect at large after shooting in East Orange County, deputies say
Click here to download the free WFTV news and weather apps, click here to download the WFTV Now app for your smart TV and click here to stream Channel 9 Eyewitness News live.
©2023 Cox Media Group | https://www.wftv.com/news/local/troopers-investigate-deadly-crash-john-young-parkway-orange-county/COMFJMNVT5ECPPKVU7IXOLHT6Y/ | 2023-07-31T11:24:04 | 0 | https://www.wftv.com/news/local/troopers-investigate-deadly-crash-john-young-parkway-orange-county/COMFJMNVT5ECPPKVU7IXOLHT6Y/ |
BURLINGTON, N.C., July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 14, 2023, in New York City, beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET.
This event will highlight Labcorp's go-forward strategy from Labcorp Chairman & CEO Adam Schechter, followed by business overviews and a longer-term financial outlook. Presentations will be followed by a Q&A session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 1:00 p.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
View original content to download multimedia:
SOURCE Labcorp | https://www.wkyt.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ | 2023-07-31T11:24:07 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ |
(The Hill) – Dozens of former Cabinet officials under former President Trump’s administration declined to publicly support the former president’s third bid for the White House, NBC News reported.
NBC News reached out to 44 people who previously served in Trump’s Cabinet during his four years in office to gauge whether they would support the former president during the 2024 presidential election. The outlet reported that most of the people declined to comment or ignored the requests and that only four said publicly they would support Trump for the presidency.
Trump’s Cabinet saw a higher rate of turnover compared with many of his predecessors, with many new officials rotating in and out of his administration over the four years. The only four former Cabinet members who NBC News reached out to who said they would support Trump are former acting Attorney General Matthew Whitaker, former chief of staff Mark Meadows, former Office of Management and Budget (OMB) director Russell Vought and former acting director of national intelligence Richard Grenell.
A spokesperson for Meadows told NBC News that he “fully” supports Trump. In May, Vought posted on X, the site formerly known as Twitter, that the former president is “the only person I trust to take a wrecking ball to the Deep State.”
Other former administration officials were reluctant to support Trump or have publicly said they will not support him. Former Attorney General Bill Barr told NBC News that he opposes Trump getting the 2024 GOP nomination but declined whether to say he would support him in the general election if pitted against President Biden.
Top Stories from The Hill
- White House takes the gloves off ahead of 2024
- Trump attorney calls him ‘the most ethical American I know’ in wake of superseding indictment
- Murphy says Alito’s Supreme Court seat ‘exists only because of an act passed by Congress’
- Trump attorney calls him ‘the most ethical American I know’ in wake of superseding indictment
Former chief of staff Mick Mulvaney also said that he does not want Trump to get the Republican nomination for president.
“I am working hard to make sure that someone else is the nominee,” Mulvaney told NBC News. “I think he’s the Republican who is most likely to lose in a general election, of all our leading candidates. If anyone can lose to Joe Biden, it would be him.”
Other former officials who have not endorsed Trump yet include former Secretary of State Mike Pompeo, former Defense Secretary Patrick Shanahan, former chief of staff John Kelly and Joseph Maguire and Dan Coats, who each once served as director of national intelligence. Coats told NBC News that he would be supporting former Vice President Mike Pence for the GOP primary.
The Hill has reached out to Trump’s campaign for comment. | https://www.wdtn.com/news/u-s-world/dozens-of-former-trump-cabinet-officials-wont-publicly-support-his-2024-bid/ | 2023-07-31T11:24:08 | 0 | https://www.wdtn.com/news/u-s-world/dozens-of-former-trump-cabinet-officials-wont-publicly-support-his-2024-bid/ |
Recruiting Season Is in Full Swing for Professional Football Players to Join Virtual Fan Engagement Channel
NAPLES, Fla., July 31, 2023 /PRNewswire/ -- Notable Live is announcing that it has added three more Pro Football Hall of Fame players to the Notable Live line-up for the upcoming season. In addition to existing players Emmitt Smith and Ray Lewis, Notable Live is excited to add Cris Carter, Champ Bailey and Ed Reed to the Notable Live team. This comes as a fast follow to Notable Live's recent multi-year commercial agreement with eBay and its Series A financing round led by eBay Ventures.
Notable Live is a tech-enabled virtual engagement platform that connects fans to teams, leagues and players in a way they have always dreamed about through an immersive experience. Notable Live, co-founded in 2018 by Pro Football Hall of Famer Emmitt Smith and entrepreneurial veteran Mike Antonucci, helps players monetize their image and personal brands not just on game day, but every day.
Through one set of login credentials, the Notable Live platform unlocks an expansive catalog of one-to-many engagement experiences, including live events and on-demand content. On the platform's commerce-enabled exchange, players, teams and leagues can activate live auction or marketplace functions to sell physical memorabilia, digital content, in-person experiences or other unique offerings. All items offered on the Notable Live platform and its associated channels can be authentically bought and sold across the growing and loyal community of Notable Live fans.
"The multi-billion annual sports memorabilia market is rapidly evolving to include new digital experiences, and Notable Live continues to grow its comprehensive platform for both the college and professional sports markets. We are pleased to announce the continued expansion of our roster of NFL athletes on our platform," said Mike Antonucci, co-founder and CEO of Notable Live.
"The fans bring their passion for the game and for their favorite players, ensuring the memorabilia space remains more about the fans than about the athletes," added Emmitt Smith, co-founder of Notable Live. "We are excited to continue expanding our platform with fellow Hall of Famers and other athletes."
About Notable Live
Notable Live was co-founded in 2018 by avid sports fan Mike Antonucci and Pro Football Hall of Famer Emmitt Smith to create a unique platform providing sports fans with unparalleled access to their favorite notables via virtual interactive events. Notable Live, a mobile app available on the App Store and Google Play, grants fans real access to notables by putting them "in the room" together for memorable virtual experiences. Connect with Notable Live at www.notable.live or on Instagram, Facebook, Twitter, YouTube, Threads for iOS and Threads for Google Play.
View original content to download multimedia:
SOURCE Notable Live | https://www.1011now.com/prnewswire/2023/07/31/notable-live-adds-three-gold-jackets/ | 2023-07-31T11:24:08 | 0 | https://www.1011now.com/prnewswire/2023/07/31/notable-live-adds-three-gold-jackets/ |
NEW SMYRNA BEACH, Fla. — The Volusia County Sheriff’s Office wants to teach people how to protect kids from online danger.
>>> STREAM CHANNEL 9 EYEWITNESS NEWS LIVE <<<
The agency is hosting the first of five meetings Monday, focusing on predators on the internet.
Officials said the meetings were sparked by a recent incident involving a 29-year-old man and a 12-year-old girl.
Watch: Sheriff: 9 ‘online predators’ arrested for traveling to meet with minors in Osceola County
Deputies said a Brevard County man was arrested earlier this month after he traveled to Deltona to meet with a 12-year-old girl, he met on an app called Wink.
Now Volusia County law enforcement is stepping in to teach the community about online safety.
The internet can be a dangerous place for everyone, especially for children and teens.
Volusia County Sheriff Mike Chitwood wants to keep all of the community safe, even in a virtual world.
The sheriff’s office and Florida Department of Children and Families will be hosting five different meetings about online predators.
Watch: 3 Volusia County men caught in nationwide sting targeting online predators
“If your kids are spending their time online, you need to be aware of what’s out there,” Chitwood said in a news release.
The meeting will be held at 6 p.m. at A Family Church in New Smyrna Beach.
Click here to download the free WFTV news and weather apps, click here to download the WFTV Now app for your smart TV and click here to stream Channel 9 Eyewitness News live.
©2023 Cox Media Group | https://www.wftv.com/news/local/volusia-county-deputies-spread-awareness-protecting-kids-online-predators/INFJQV3JTRGIDEAQORMVTGBZOU/ | 2023-07-31T11:24:10 | 1 | https://www.wftv.com/news/local/volusia-county-deputies-spread-awareness-protecting-kids-online-predators/INFJQV3JTRGIDEAQORMVTGBZOU/ |
Adult Males are Slightly More Likely to Live with Parents Than Their Female Counterparts
58% of Gen Z Consumers Live with Family Members
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from the 24th edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS. The Household Finances Deep Dive Edition examines the impact of household composition on consumers' ability to manage expenses and put aside savings. The series draws on insights from a survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data.
The Paycheck-to-Paycheck Landscape
In June 2023, 61% of U.S. consumers lived paycheck to paycheck, unchanged from June 2022 — as is the share of those struggling to pay bills (at 21%) — even though more middle-income consumers cited living paycheck to paycheck in June 2023 than last year. Among consumers earning $50,000 to $100,000, 65% lived paycheck to paycheck as of June 2023, compared to 60% in June 2022. Meanwhile, the shares of high-income consumers — those earning more than $100,000 annually — and low-income consumers — those earning less than $50,000 annually — living paycheck to paycheck in June 2023 sit at 45% and 77%, respectively, relatively unchanged from June 2022.
This stability in the financial situation of U.S. households indicates that consumers continue to adapt to inflationary pressures, finding ways to manage their spending and live within their means.
Household Composition Determines Financial Lifestyle
Consumers living with only a partner or spouse are likely to face less financial hardship, while those with dependents and those living with friends or housemates are more likely to live paycheck to paycheck.
The research finds that 86% of consumers live with one or more people, and one-third of paycheck-to-paycheck consumers live in households of four or more people. Consumers not living paycheck to paycheck are most likely to reside in two-person households, at 41%. Meanwhile, 49% of millennials and 55% of bridge millennials live in households of four or more people, making them the age groups most likely to reside in the largest households.
There is also a direct correlation among household size, stage of life and financial lifestyle. As household size increases, the ratio of income earners to non-earners typically falls, attributable to households with dependent children. When looking at the share of paycheck-to-paycheck consumers who live in a two-member household, the data finds that 54% do so — 7 percentage points below the sample average. Meanwhile, at 66%, consumers with children under the age of 18 are 12% more likely to live paycheck to paycheck than those without children, at 59%. Among consumers living with friends or housemates, 77% live paycheck to paycheck — the most likely to do so. This suggests that those sharing expenses with a partner or spouse fare better, that is until they have children or even parents to support.
"As household size increases, the ratio of income earners to household members typically falls, creating a higher likelihood of financial distress," said Alia Dudum, LendingClub's Money Expert. "The relationship between household income and household composition explains why many families tend to struggle financially and why millennials and bridge millennials, many of whom are in their peak child-rearing years, tend to remain financially vulnerable."
Economic Considerations Top Reason to Stay in the Family Household
Economics are the main driver for consumers to live with family longer, with 43% wanting to save money and 30% unable to afford housing independently. Besides economic reasons, consumers remain at home to maintain family ties (24%), for transitional reasons (23%), and to provide care (22%).
At one-fifth (20%), adult males are slightly more likely to live with parents than their female counterparts (18%), a phenomenon that grows significantly among those financially struggling (26% of males compared to 18% of females). At 58%, Gen Z is the generation most likely to stay with family members, with 50% citing economic reasons. Members of Gen Z living with three or more people — often familial settings — spent 22% of their income on housing, compared to 30% of those living alone or with a partner.
That said, consumers living with family members to offset expenses are not planning extended stays. For example, one-third of those consumers expect to move out in the coming year, particularly millennials and bridge millennials.
Financial Transparency Determined by Relationship Status
Financial transparency within shared households is paramount to ensure bills are paid and expenses are covered, but the transparency level depends on who consumers live with. Couples living together share financial information 87% of the time and have a joint bank account 76% of the time. Parents are also likely to discuss finances with the children residing in their household, with 45% of parents sharing financial information with their children and 34% granting them access to a shared account. Bill splitting is the most common financial interaction for consumers living with friends or housemates, at 74%. Additionally, borrowing money from other household members is a financial option many use to make ends meet, with consumers mostly engaging in this practice with parents or siblings, at 47%, and friends and housemates, at 44%.
Families and couples maintain outstanding credit card balances that are significantly higher, on average, than those of consumers who live alone. Consumers with children under the age of 18 average 50% more credit card debt than those who live alone. Families represent the lion's share of credit card spending, holding average balances of $6,300 for consumers living with a partner and $7,200 for those living with children under 18. Living with a partner or children also significantly increases a consumer's likelihood of having an auto loan or mortgage.
"With today's inflationary pressures, sharing household finances has become not only common but crucial," continued Dudum. "The increasing complexity of modern lifestyles and the rising cost of living have necessitated a shift in the way consumers approach household finances. One person solely bearing the burden of managing all financial matters has become a minority practice. Instead, couples, families, and even roommates increasingly jointly navigate their economic realities, and it's a trend that is here to stay."
To view the full report, visit: https://www.pymnts.com/study/reality-check-paycheck-to-paycheck-inflation-household-spending-shared-expenses/
Methodology
New Reality Check: The Paycheck-to-Paycheck Report — The Household Finances Deep Dive Edition is based on a census-balanced survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data. The data in this report is not intended to be a representation of LendingClub's core member base. The Paycheck-to-Paycheck series expands on existing data published by government agencies, such as the Federal Reserve System and the Bureau of Labor Statistics, to provide a deep look into the core elements of American consumers' financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 51% of respondents identified as female, 33% were college-educated and 38% declared incomes of more than $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $85 billion in loans, our advanced credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4.7 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
Contact:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.wkyt.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ | 2023-07-31T11:24:13 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ |
DENVER (AP) — As Denver neared triple-digit temperatures, Ben Gallegos sat shirtless on his porch swatting flies off his legs and spritzing himself with a misting fan to try to get through the heat. Gallegos, like many in the nation’s poorest neighborhoods, doesn’t have air conditioning.
The 68-year-old covers his windows with mattress foam to insulate against the heat and sleeps in the concrete basement. He knows high temperatures can cause heat stroke and death, and his lung condition makes him more susceptible. But the retired brick layer, who survives on about $1,000 a month largely from Social Security, says air conditioning is out of reach.
“Take me about 12 years to save up for something like that,” he said. “If it’s hard to breathe, I’ll get down to emergency.”
As climate change fans hotter and longer heat waves, breaking record temperatures across the U.S. and leaving dozens dead, the poorest Americans suffer the hottest days with the fewest defenses. Air conditioning, once a luxury, is now a matter of survival.
As Phoenix weathered its 27th consecutive day above 110 degrees (43 Celsius) Wednesday, the nine who died indoors didn’t have functioning air conditioning, or it was turned off. Last year, all 86 heat-related deaths indoors were in uncooled environments.
“To explain it fairly simply: Heat kills,” said Kristie Ebi, a University of Washington professor who researches heat and health. “Once the heat wave starts, mortality starts in about 24 hours.”
It’s the poorest and people of color, from Kansas City to Detroit to New York City and beyond, who are far more likely to face grueling heat without air conditioning, according to a Boston University analysis of 115 U.S. metros.
“The temperature differences … between lower-income neighborhoods, neighborhoods of color and their wealthier, whiter counterparts have pretty severe consequences,” said Cate Mingoya-LaFortune of Groundwork USA, an environmental justice organization. “There are these really big consequences like death. … But there’s also ambient misery.”
Some have window units that can offer respite, but “in the dead of heat, it don’t do nothing,” said Melody Clark, who stopped Friday to get food at a nonprofit in Kansas City, Kansas, as temperatures soared to 101, and high humidity made it feel like 109. When the central air conditioning at her rental house went on the fritz, her landlord installed a window unit. But it doesn’t do much during the day.
So the 45-year-old wets her hair, cooks outside on a propane grill and keeps the lights off indoors. She’s taken the bus to the library to cool off. At night she flips the box unit on, hauling her bed into the room where it’s located to sleep.
As far as her two teenagers, she said: “They aren’t little bitty. We aren’t dying in the heat. … They don’t complain.”
While billions in federal funding have been allocated to subsidize utility costs and the installation of cooling systems, experts say they often only support a fraction of the most vulnerable families and some still require prohibitive upfront costs. Installing a centralized heat pump system for heating and cooling can easily reach $25,000.
President Joe Biden announced steps on Thursday to defend against extreme heat, highlighting the expansion of the Low Income Home Energy Assistance Program, which funnels money through states to help poorer households pay utility bills.
While the program is critical, said Michelle Graff, who studies the subsidy at Cleveland State University, only about 16% of the nation’s eligible population is actually reached. Nearly half of states don’t offer the federal dollars for summer cooling.
“So people are engaging in coping mechanisms, like they’re turning on their air conditioners later and leaving their homes hotter,” Graff said.
While frigid temperatures and high heating bills birthed the term “heat or eat,” she said, “we can now transition to AC or eat, where people are going to have to make difficult decisions.”
As temperatures rise, so does the cost of cooling. And temperatures are already hotter in America’s low-income neighborhoods like Gallegos’ Denver suburb of Globeville, where people live along stretches of asphalt and concrete that hold heat like a cast-iron skillet. Surface temperatures there can be roughly 8 degrees hotter than in Denver’s wealthier neighborhoods, where a sea of vegetation cools the area, according to the environmental advocacy group American Forests.
This disparity plays out nationwide. Researchers at the University of San Diego analyzed 1,056 counties and in over 70%, the poorest areas and those with higher Black, Hispanic and Asian populations were significantly hotter.
About one in 10 U.S. households have no air conditioning, a disparity compounded for marginalized groups, according to a study by the Brookings Institution. Less than 4% of Detroit’s white households don’t have air conditioning; it’s 15% for Black households.
At noon on Friday, Katrice Sullivan sat on the porch of her rented house on Detroit’s westside. It was hot and muggy, but even steamier inside the house. Even if she had air conditioning, Sullivan said she’d choose her moments to run it to keep her electricity bill down.
The 37-year-old factory worker pours water on her head, freezes towels to put around her neck, and sits in her car with the air conditioner on. “Some people here spend every dollar for food, so air conditioning is something they can’t afford,” she said.
Shannon Lewis, 38, lived in her Detroit home for nearly 20 years without air conditioning. Lewis’s bedroom was the only place with a window unit, so she’d squeeze her teenager, 8-year-old and 3-year-old-twins into her queen-size bed to sleep, eat meals and watch television.
“So it was like cool in one room and a heat stroke in another,” Lewis said. For the first time, Lewis now has air conditioning through a local non-profit, she said. “We don’t have to sleep or eat in the same room, we are able to come out, sit at the dining room table, eat like a family.”
After at least 54 died during a 2021 heat wave, mostly elderly people without air conditioning, in the Portland area, Oregon passed a law prohibiting landlords from placing blanket bans on air conditioning units. By and large, however, states don’t have laws requiring landlords to provide cooling.
In the federal Inflation Reduction Act, billions were set aside for tax credits and rebates to help families install energy-efficient cooling systems, but some of those are yet to be available. For people like Gallegos, who doesn’t pay taxes, the available credits are worthless.
The law also offers rebates, the kind of state and federal point-of-sale discounts that Amanda Morian has looked into for her 640-square-foot home.
Morian, who has a 13-week-old baby susceptible to hot weather, is desperate to keep her house in Denver’s Globeville suburb cool. She bought thermal curtains, ceiling fans and runs a window unit. At night she tries to do skin-to-skin touch to regulate the baby’s body temperature. When the back door opens in the afternoon, she said, the indoor temperature jumps a degree.
“All of those are just to take the edge off, it’s not enough to actually make it cool. It’s enough to keep us from dying,” she said.
She got estimates from four different companies for installing a cooling system, but every project was between $20,000 and $25,000, she said. Even with subsidies she can’t afford it.
“I’m finding that you have to afford the project in the first place and then it’s like having a bonus coupon to take $5,000 off of the sticker price,” she said.
Lucy Molina, a single mom in Commerce City, one of Denver’s poorest areas, said her home has reached 107 degrees without air conditioning. Nearby, Molina’s two teenage children slurped popsicles to cool off, lingering in front of the open freezer.
For Molina, who bustled around her kitchen on a recent day when temperatures reached 99 degrees outdoors, it’s hard to see any path to a cooling respite.
“We’re just too poor,” she said. | https://www.wdtn.com/news/u-s-world/were-just-too-poor-record-heat-waves-reveal-plight-of-americans-without-air-conditioning/ | 2023-07-31T11:24:14 | 0 | https://www.wdtn.com/news/u-s-world/were-just-too-poor-record-heat-waves-reveal-plight-of-americans-without-air-conditioning/ |
BALTIMORE, July 31, 2023 /PRNewswire/ -- Opteev Technologies, Inc., a pioneering technology company at the forefront of diagnostics, has filed a patent (Patent Application #63/513,007) for a revolutionary multiplex biochip for respiratory infection diagnostics. The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute. This game-changing technology paves the way for an ultra-rapid, portable, and accurate syndromic diagnostic device to empower healthcare providers with immediate results at their fingertips.
The tiny biochip can directly detect whole viruses in real-time in both processed and unprocessed samples such as saliva or nasal swab and has demonstrated an unprecedented accuracy rate of 99.49% with an impressive limit of detection in its analytical performance evaluation. Furthermore, the biosensor achieves fine-tuned specificity by carefully selecting specific virus-binding peptides, enabling accurate identification of target viruses in complex samples. To ensure precise and reliable virus detection, the biochip utilizes artificial intelligence to optimize the frequency range effectively mitigating the impact of interfering noise signals.
Unlike conventional respiratory panels that cost tens of thousands of dollars and take days to provide results, Opteev's multiplex biochip will offer healthcare providers affordable syndromic testing with the ability to process samples at the point of care, allowing for the simultaneous detection and specific identification of multiple pathogens instantaneously. This breakthrough technology will eliminate the need for speculation by providing healthcare providers with the critical information needed to deliver the most effective treatment options at the point of care.
"With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics," said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies. "The potential of this technology to transform patient care, streamline operations, and reduce costs is truly remarkable."
As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company welcomes potential collaborations and partnerships to further develop and commercialize its multiplex biochip. "Together, we can shape the future of diagnostics and unlock the massive potential of our game-changing multiplex biochip," said Conrad Bessemer, Opteev's Chairman and Co-founder.
For more information about Opteev Technologies and its groundbreaking multiplex biochip, please visit www.opteev.com.
Opteev Technologies, Inc., headquartered in Baltimore, MD, is a pioneering technology company at the forefront of diagnostics. With a strong focus on respiratory pathogen detection, Opteev is committed to developing innovative solutions that revolutionize the field of point-of-care diagnostics. As a subsidiary of Novatec, Inc., a trusted manufacturer and supplier of machinery and sensor technology, Opteev leverages decades of experience to drive advancements in healthcare.
Media Contact:
Dana Gardner
Vice President
dgardner@opteev.com
Phone: 443-457-5214
View original content to download multimedia:
SOURCE Opteev Technologies, Inc | https://www.1011now.com/prnewswire/2023/07/31/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-respiratory-pathogens-under-1-minute/ | 2023-07-31T11:24:15 | 0 | https://www.1011now.com/prnewswire/2023/07/31/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-respiratory-pathogens-under-1-minute/ |
BEIJING — (AP) — China imposed restrictions Monday on exports of long-range civilian drones, citing Russia’s war in Ukraine and concern that drones might be converted to military use.
Chinese leader Xi Jinping’s government is friendly with Moscow but says it is neutral in the 18-month-old war. It has been stung by reports that both sides might be using Chinese-made drones for reconnaissance and possibly attacks.
Export controls will take effect Tuesday to prevent use of drones for “non-peaceful purposes,” the Ministry of Commerce said in a statement. It said exports still will be allowed but didn’t say what restrictions would apply.
China is a leading developer and exporter of drones. DJI Technology Co., one of the global industry's top competitors, announced in April 2022 it was pulling out of Russia and Ukraine to prevent its drones from being used in combat.
“The risk of some high specification and high-performance civilian unmanned aerial vehicles being converted to military use is constantly increasing,” the Ministry of Commerce said.
Restrictions will apply to drones that can fly beyond the natural sight distance of operators or stay aloft more than 30 minutes, have attachments that can throw objects and weigh more than seven kilograms (15½ pounds), according to the ministry.
“Since the crisis in Ukraine, some Chinese civilian drone companies have voluntarily suspended their operations in conflict areas,” the Ministry of Commerce said. It accused the United States and Western media of spreading “false information” about Chinese drone exports.
The government on Friday defended its dealings with Russia as “normal economic and trade cooperation” after a U.S. intelligence report said Beijing possibly provided equipment used in Ukraine that might have military applications.
The report cited Russian customs data that showed Chinese state-owned military contractors supplied drones, navigation equipment, fighter jet parts and other goods.
The Biden administration has warned Beijing of unspecified consequences if it supports the Kremlin's war effort. Last week's report didn't say whether any of the trade cited might trigger U.S. retaliation.
Xi and Russian President Vladimir Putin declared before the February 2022 invasion that their governments had a "no-limits" friendship. Beijing has blocked efforts to censure Moscow in the United Nations and has repeated Russian justifications for the attack.
China has “always opposed the use of civilian drones for military purposes,” the Ministry of Commerce said. “The moderate expansion of drone control by China this time is an important measure to demonstrate the responsibility of a responsible major country.”
The Ukrainian government appealed to DJI in March 2022 to stop selling drones it said the Russian ministry was using to target missile attacks. DJI rejected claims it leaked data on Ukraine’s military positions to Russia.
Copyright 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. | https://www.wftv.com/news/world/china-imposes-curbs/V44KQ2QOKPN7VUNIDUMFTXM62Y/ | 2023-07-31T11:24:16 | 1 | https://www.wftv.com/news/world/china-imposes-curbs/V44KQ2QOKPN7VUNIDUMFTXM62Y/ |
HOUSTON, July 31, 2023 /PRNewswire/ -- McDermott has been awarded a project management consultancy (PMC) and engineering, procurement, and construction management (EPCM) contract for the Naphtha Cracker Expansion (Phase II) polypropylene expansion and new ethylene derivative unit project from Indian Oil Corporation Limited (IOCL). The project is located at the Panipat Refinery and Petrochemical Complex, located 62 miles (100 kilometers) from New Delhi, India.
The project will increase the ethylene production capacity of the naphtha cracker unit (NCU) by approximately 20 percent. The additional ethylene and propylene production will act as feed for downstream polymer units. The polymer products will be used for the manufacture of household and industrial items, including containers, automobile parts, furniture, and heavy-duty films.
"McDermott is currently executing four other projects for IOCL, including the maleic anhydride (MAH) unit at the same site, allowing us to leverage our local resources and expertise while realizing synergies," said Vaseem Khan, Senior Vice President, Global Operations. "Furthermore, the project supports the growing demand for ethylene and propylene which will reduce imports and accelerate economic development in the area."
McDermott will provide comprehensive EPCM services and overall project management for the duration of the project, which will be executed from its Center of Excellence in Gurugram, India.
About McDermott
McDermott is a premier, fully-integrated provider of engineering and construction solutions to the energy industry. Our customers trust our technology-driven approach engineered to responsibly harness and transform global energy resources into the products the world needs. From concept to commissioning, McDermott's innovative expertise and capabilities advance the next generation of global energy infrastructure—empowering a brighter, more sustainable future for us all. Operating in over 54 countries, McDermott's locally-focused and globally-integrated resources include more than 30,000 employees, a diversified fleet of specialty marine construction vessels and fabrication facilities around the world. To learn more, visit www.mcdermott.com.
Forward-Looking Statements
McDermott cautions that statements in this press release which are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties. These forward-looking statements include, among other things, statements about the expected scope and execution of the project discussed in this press release. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, among others: adverse changes in the markets in which we operate or credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope or timing of contracts, contract cancellations, change orders and other modifications and actions by our customers and other business counterparties; changes in industry norms; actions by lenders, other creditors, customers and other business counterparties of McDermott; and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of McDermott's management as of the date hereof. Except to the extent required by applicable law, McDermott undertakes no obligation to update or revise any forward-looking statement.
Contacts:
Global Media Relations
Reba Reid
Senior Director, Global Communications and Marketing
+1 281 588 5636
RReid@McDermott.com
Business Line Media Relations
Barbara Knight
Senior Director, Business Line Communications and Marketing
+971 56 403 2903
BBKnight@McDermott.com
View original content to download multimedia:
SOURCE McDermott International, Ltd | https://www.wkyt.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ | 2023-07-31T11:24:19 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ |
The tech giant made the line of sneakers as a one-time gift for its employees in the '90s. A size 10.5 pair has found its way onto the Sotheby's website, where it's on sale for $50,000.
Copyright 2023 NPR
The tech giant made the line of sneakers as a one-time gift for its employees in the '90s. A size 10.5 pair has found its way onto the Sotheby's website, where it's on sale for $50,000.
Copyright 2023 NPR | https://www.wlrn.org/npr-breaking-news/npr-breaking-news/2023-07-31/a-pair-of-white-sneakers-made-specifically-for-apple-employees-is-up-for-auction | 2023-07-31T11:24:19 | 0 | https://www.wlrn.org/npr-breaking-news/npr-breaking-news/2023-07-31/a-pair-of-white-sneakers-made-specifically-for-apple-employees-is-up-for-auction |
DAYTON, Ohio (WDTN) — In the last few years, the aviation industry has struggled finding workers. The Aviation Program at Sinclair Community College is helping fast-track students with real-world training and getting them into the pilot seat faster to help meet the increasing demand.
Sanjing Yin is a non-traditional student with English as her second language. The single mom of two is in her second year at Sinclair.
After spending time in the sky as a flight attendant for Delta since 2018, she wanted a front seat with a dream of becoming a pilot.
“That is how I was born and raised. We always aim for the best we can,” says Sanjing. “We should never stop and stop chasing our dream.”
Enrolling in Sinclair’s Aviation Program, she’s on a non-stop path to achieving that her dream.
“As a mom I want to set a great example for my two girls,” says Sanjing.
With real-world experience at their fingertips, students get a feel for the pilot seat from people who’ve been in that seat before, like Aviation Program Coordinator Donna Hanshew.
“The faculty are retired military pilots, airline pilots. They have a wide variety of experience,” says Donna.
For Sanjing, Donna is more than a teacher, and she affectionately calls her her “Aviation Mom.”
“She is absolutely a go-getter. She’s fun to be around because she’s very excited about the program and what she’s doing here,” says Donna.
Offering everything from helicopter training to fixed-wing training, the program is taking students to the next level.
“Flying is fun, but learning to fly is hard,” says Sanjing.
Sanjing has her Commercial Pilot Certification and is on target to finish in about two years.
“She’s working on her multi-engine now, and then she’ll move on to her flight instructor rating,” says Donna.
When she graduates, the sky is the limit.
“Many of the students go to PSA Airlines here in Dayton, and they also go to Republic Airlines in Indianapolis,” describes Donna. “Some of them have gone to FedEx. Some of them have gone to American. The program works. They get everything they need.”
Sanjing says her long-term goal is to work for a major cargo airline, but she’s also keeping her options open. | https://www.wdtn.com/skills2succeed/aviation-program-taking-students-to-new-heights/ | 2023-07-31T11:24:20 | 1 | https://www.wdtn.com/skills2succeed/aviation-program-taking-students-to-new-heights/ |
The tech giant made the line of sneakers as a one-time gift for its employees in the '90s. A size 10.5 pair has found its way onto the Sotheby's website, where it's on sale for $50,000.
Copyright 2023 NPR
The tech giant made the line of sneakers as a one-time gift for its employees in the '90s. A size 10.5 pair has found its way onto the Sotheby's website, where it's on sale for $50,000.
Copyright 2023 NPR | https://www.wqcs.org/2023-07-31/a-pair-of-white-sneakers-made-specifically-for-apple-employees-is-up-for-auction | 2023-07-31T11:24:20 | 1 | https://www.wqcs.org/2023-07-31/a-pair-of-white-sneakers-made-specifically-for-apple-employees-is-up-for-auction |
Home
News
Valley student recognized on Reading Rainbow
A Rio Grande Valley student was featured on Reading Rainbow, an American educational children's television series, last year. Cali Navarro, 11, sang a song on...
Willacy County residents unite in search efforts for missing goat
It's been two weeks since a Willacy County...
McAllen police: Suspect hospitalized after officer-involved shooting during traffic stop
A Brownsville man was hospitalized Sunday morning after...
Additional Links
Heart of the Valley
Coronavirus Updates
Elections
Education
Mexico
Local News
Immigration/Border Wall
SpaceX
5 On Your Side
Made in the 956
Photographer's Perspective
National News
Consumer News
Find The Link
Submit a Tip
Pump Patrol
KRGV 5.1 News Live Stream
Weather
Saturday, July 29, 2023: Chance of thunderstorms with highs in the 90s
Download our free KRGV FIRST WARN 5 Weather app for the latest updates right on your phone. You can also follow our KRGV First Warn...
Friday, July 28, 2023: Possible thunderstorms, highs in the 90s
Download our free KRGV FIRST WARN 5 Weather...
Thursday, July 27, 2023: Mostly dry, temps in the 100s
Download our free KRGV FIRST WARN 5 Weather...
Additional Links
Hourly Forecast
Latest Weathercast
Interactive Radar
Traffic Maps
Winds
Tide Information
Lake Levels
Water Restrictions
Hurricane Central
Weather Alerts
Weather Links
Send A Weather Question
Weather Team
Submit A Weather Photo
Sports
RGV FC has two players sent off in 2-1 loss to FC Tulsa
TULSA, Oklahoma (Friday, July 21, 2023) – Rio Grande Valley FC (5-6-9) snapped their unbeaten streak as they dropped the match at FC Tulsa (7-7-7) 2-1...
Weslaco Intermediate All-Star Headed to Little League Regional Tournament
WESLACO, TEXAS -- The Weslaco 13U Little League...
Weslaco Little League All-Stars baseball team competing at Southwest Regional Tournament in Sugarland
The Weslaco 13U Little League All-Stars will be...
Additional Links
High School Football
First & Goal
Playmakers
5th Quarter
Two-A-Day Tours
5 Star Plays
Power Poll
Band of the Week
Valley HS Football Preview Show
This Week's Schedule
Send A Sports Tip
Sports Staff
Programming
Additional Links
TV Listings
Antennas
Ratings Guide
Community
Pump Patrol: Friday, July 28, 2023
Zoo Guest: Cornelius the corn snake
Pump Patrol: Thursday, July 27, 2023
Additional Links
5/1 Day
KRGVida Community Calendar
5's Fans for Friends
Tim's Coats
Zoo Guest
Pet of the Week
Student of the Week
Connect
Additional Links
Contact Us
Advertising Information
FCC Reports
Frequently Asked Questions
Jobs at KRGV
News Staff
Sales Staff
Apps and Social Media
Station Information
Contests
Noticias RGV
Continúa la búsqueda de la cabra Willy en el condado Willacy
La búsqueda de una cabra en el rodeo del condado Willacy continúa luego de 13 días de su fuga. Willy se escapó de la ganadería Show...
La Entrevista: Extreme Pizza ofrece pizza estilo Nueva York en el Valle del Río Grande
Una franquicia de pizza estilo Nueva York está...
Desde el Zoológico: ¡Conozcan a Cornelius, la serpiente de maíz!
Alejandra Rodríguez nos visita desde el zoológico, Gladys...
Additional Links
Noticias RGV Transmision en Vivo
Clima
Elecciones
Pandemia de Coronavirus
Deportes
La Entrevista
Salud y Vida
Cuidando El Planeta
Estudiante de la semana
Corazon del Valle
Temporada de huracanes
Canal 5.2
Take 5
Submit a Tip
Search
Home
News
Heart of the Valley
Coronavirus Updates
Elections
Education
Mexico
Local News
Immigration/Border Wall
SpaceX
5 On Your Side
Made in the 956
Photographer's Perspective
National News
Consumer News
Find The Link
Submit a Tip
Pump Patrol
KRGV 5.1 News Live Stream
Weather
Hourly Forecast
Latest Weathercast
Interactive Radar
Traffic Maps
Winds
Tide Information
Lake Levels
Water Restrictions
Hurricane Central
Weather Alerts
Weather Links
Send A Weather Question
Weather Team
Submit A Weather Photo
Sports
High School Football
First & Goal
Playmakers
5th Quarter
Two-A-Day Tours
5 Star Plays
Power Poll
Band of the Week
Valley HS Football Preview Show
This Week's Schedule
Send A Sports Tip
Sports Staff
Programming
TV Listings
Antennas
Ratings Guide
Community
5/1 Day
KRGVida Community Calendar
5's Fans for Friends
Tim's Coats
Zoo Guest
Pet of the Week
Student of the Week
Connect
Contact Us
Advertising Information
FCC Reports
Frequently Asked Questions
Jobs at KRGV
News Staff
Sales Staff
Apps and Social Media
Station Information
Contests
Noticias RGV
Noticias RGV Transmision en Vivo
Clima
Elecciones
Pandemia de Coronavirus
Deportes
La Entrevista
Salud y Vida
Cuidando El Planeta
Estudiante de la semana
Corazon del Valle
Temporada de huracanes
Canal 5.2
Take 5
Submit a Tip
Search
SEARCH
x
Diabetes Awareness Month
Share:
Radar
7 Days
News Video
McAllen police: Suspect hospitalized after officer-involved shooting during traffic stop
Valley student recognized on Reading Rainbow
Willacy County residents unite in search efforts for missing goat
Sheriff's office: Suspect in Laguna Heights murder investigation flees to Mexico
UTRGV awarded $1.2 million grant from NASA for their STEM program
Sports Video
Border Wars Tonight at the Payne Arena
Garcia loses to Zambrano by TKO in Marines Boxing Event
RGV FC has two players sent off in 2-1 loss to FC...
Weslaco Intermediate All-Star Headed to Little League Regional Tournament
Weslaco All-Stars competing at Southwest Regional Tournament in Sugarland | https://www.krgv.com/videos/diabetes-awareness-month | 2023-07-31T11:24:20 | 1 | https://www.krgv.com/videos/diabetes-awareness-month |
Mobile Visual Processing Solutions Coupled with Dedicated Game Tuning Services Take Mobile Gaming Experience to a Brand-New Level
SHANGHAI, July 31, 2023 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative visual processing solutions, today announced the official launch of its new IRX gaming experience brand. As a brand targeted at smartphone users, IRX is grounded on Pixelworks' mobile visual processing solutions and coupled with in-depth game tuning services. This combination leverages Pixelworks' expertise to achieve ultra-smooth gaming experience and the highest picture quality for different types of games on mobile devices. In addition, it exercises effective control of power consumption, latency and other performance variables to ensure stable and long-lasting gaming with optimal visual performance, providing end users with unparalleled mobile gaming experiences.
The IRX gaming experience is enabled by a portfolio of technology advantages and product application experiences based on the Company's innovative distributed rendering architecture. More specifically, Pixelworks' ultra-low latency MotionEngine® technology, low power super-resolution technology, AI Always-on HDR and other technologies bring optimized rendering capabilities to smartphones that exceed what can be achieved by a traditional chipset. Together with Pixelworks' profound tuning experience for different games on various mobile devices the result is a meaningfully enriched visual experience for smartphone users, which is the core foundation for the IRX gaming experience.
The IRX gaming experience brand will be supported by a certification program for mobile devices that incorporates Pixelworks visual processors. The certification program will be backed by a suite of visual quality evaluation systems agreed upon with smartphone manufacturers to ensure that Pixelworks powered smartphones provide the most outstanding gaming performance and utmost visual quality for consumers.
The IRX branded certification program is comprised of both device certification and game tuning services. Pixelworks will optimize the rendering capabilities and display quality of top games on mobile devices based on its visual processors' capabilities as well as the devices' performance characteristics. Smartphones that meet the technical requirements as well as Pixelworks' visual processing standards will be granted the IRX branded certification, and games that meet Pixelworks' visual quality requirements will be included in the IRX-supported game list. To date, there are 20 top games being enlisted on the IRX-supported game list, which can be found on Pixelworks' official IRX gaming experience website. Furthermore, Pixelworks plans to establish expanded communication channels with consumers to help further educate end users on the benefits of the IRX gaming experience.
"IRX is a gaming experience brand from Pixelworks targeted directly towards mobile device users." said Ting Xiong, President of Pixelworks China. "Pixelworks would like to empower smartphone manufacturers to break the ceiling of mobile gaming experience from content optimization to performance enhancement with its innovative rendering technologies and years of game tuning and optimization experience. Additionally, we are also aiming to develop and promote consumer awareness around how to better evaluate visual display quality and the mobile gaming experience, enabling them to make smarter choices when purchasing a smartphone. By utilizing professional technologies and services to build more links across both products and users, we hope to drive mutual growth through in-depth interactions while bringing display performance and the mobile gaming experience to a brand-new level."
About Pixelworks
Pixelworks provides industry-leading content creation, video delivery and display processing solutions and technology that enable highly authentic viewing experiences with superior visual quality, across all screens – from cinema to smartphone and beyond. The Company has more than 20 years of history delivering image processing innovation to leading providers of consumer electronics, professional displays and video streaming services.
For more information, please visit the company's web site at www.pixelworks.com.
Note: Pixelworks, MotionEngine and the Pixelworks logo are trademarks of Pixelworks, Inc. All other trademarks are the property of their respective owners.
View original content to download multimedia:
SOURCE Pixelworks, Inc. | https://www.1011now.com/prnewswire/2023/07/31/pixelworks-announces-launch-irx-gaming-experience-brand/ | 2023-07-31T11:24:21 | 1 | https://www.1011now.com/prnewswire/2023/07/31/pixelworks-announces-launch-irx-gaming-experience-brand/ |
HONG KONG — (AP) — A French man is believed to have fallen to his death from a high-rise residential building in Hong Kong last week, police said on Monday, with local media outlets identifying him as daredevil Remi Lucidi.
Police said a 30-year-old man's body was found on a patio in the city's upscale Mid-Levels area. He was believed to have engaged in extreme sports, police said, without identifying him.
Officers conducted an initial investigation and said he apparently fell from a rooftop. No suicide note was found at the scene, they said. The cause of his death would have to be verified by an autopsy, they added.
Local media, including the South China Morning Post, said the man was Lucidi, 30. The Post cited an unnamed source saying he was last seen alive knocking on a penthouse window on the 68th floor of a residential tower on Thursday evening. The Associated Press has not been able to verify his identity.
Lucidi, who used the name “Remi Enigma” on social media, last posted a photo of Hong Kong's night view a week ago on Instagram and tagged the location as Times Square in shopping district Causeway Bay. The photo appeared to be taken from above.
Supporters mourned him on social media.
Lucidi posted to Instagram as he climbed various tall structures around the world and took selfies, including one he captioned, “Above the Sky, 425m” and tagged Dubai as the location.
Copyright 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. | https://www.wftv.com/news/world/french-daredevil-who/BOCSWEPJTUXJ76KWYQUFU7VAUU/ | 2023-07-31T11:24:22 | 0 | https://www.wftv.com/news/world/french-daredevil-who/BOCSWEPJTUXJ76KWYQUFU7VAUU/ |
Recruiting Season Is in Full Swing for Professional Football Players to Join Virtual Fan Engagement Channel
NAPLES, Fla., July 31, 2023 /PRNewswire/ -- Notable Live is announcing that it has added three more Pro Football Hall of Fame players to the Notable Live line-up for the upcoming season. In addition to existing players Emmitt Smith and Ray Lewis, Notable Live is excited to add Cris Carter, Champ Bailey and Ed Reed to the Notable Live team. This comes as a fast follow to Notable Live's recent multi-year commercial agreement with eBay and its Series A financing round led by eBay Ventures.
Notable Live is a tech-enabled virtual engagement platform that connects fans to teams, leagues and players in a way they have always dreamed about through an immersive experience. Notable Live, co-founded in 2018 by Pro Football Hall of Famer Emmitt Smith and entrepreneurial veteran Mike Antonucci, helps players monetize their image and personal brands not just on game day, but every day.
Through one set of login credentials, the Notable Live platform unlocks an expansive catalog of one-to-many engagement experiences, including live events and on-demand content. On the platform's commerce-enabled exchange, players, teams and leagues can activate live auction or marketplace functions to sell physical memorabilia, digital content, in-person experiences or other unique offerings. All items offered on the Notable Live platform and its associated channels can be authentically bought and sold across the growing and loyal community of Notable Live fans.
"The multi-billion annual sports memorabilia market is rapidly evolving to include new digital experiences, and Notable Live continues to grow its comprehensive platform for both the college and professional sports markets. We are pleased to announce the continued expansion of our roster of NFL athletes on our platform," said Mike Antonucci, co-founder and CEO of Notable Live.
"The fans bring their passion for the game and for their favorite players, ensuring the memorabilia space remains more about the fans than about the athletes," added Emmitt Smith, co-founder of Notable Live. "We are excited to continue expanding our platform with fellow Hall of Famers and other athletes."
About Notable Live
Notable Live was co-founded in 2018 by avid sports fan Mike Antonucci and Pro Football Hall of Famer Emmitt Smith to create a unique platform providing sports fans with unparalleled access to their favorite notables via virtual interactive events. Notable Live, a mobile app available on the App Store and Google Play, grants fans real access to notables by putting them "in the room" together for memorable virtual experiences. Connect with Notable Live at www.notable.live or on Instagram, Facebook, Twitter, YouTube, Threads for iOS and Threads for Google Play.
View original content to download multimedia:
SOURCE Notable Live | https://www.wkyt.com/prnewswire/2023/07/31/notable-live-adds-three-gold-jackets/ | 2023-07-31T11:24:25 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/notable-live-adds-three-gold-jackets/ |
FUKUOKA, Japan (WCMH) — Former Ohio State swimmer Hunter Armstrong claimed his first individual world championships gold medal in a thrilling 50m backstroke final.
The Dover, Ohio native took first in the sprint race with a time of 24.05 seconds, just 0.19 seconds faster than his American teammate and the reigning world champion Justin Ress. China’s Xu Jiayu completed the podium with the bronze medal.
His gold medal on Sunday was the second medal he won at the 2023 world championships after earning the bronze medal in the 100m backstroke on Tuesday. Last year, the 22-year-old thought he won gold in the 50m backstroke after a supposed disqualification for Ress, who finished 1st. After an appeal from Team USA, Armstrong’s gold turned to silver.
Armstrong has now claimed seven world championship medals in the last two years with his 50m backstroke win in Fukuoka increasing his gold medal tally to three. In 2022, Armstrong won five medals with both golds coming in relays.
The 50m backstroke is not in the Olympic swimming program but Armstrong is expected to go to Paris for next year’s Olympic Games and compete in the 100m backstroke and could feature on relays teams. The former Buckeye won gold as part of the USA’s medley relay team, though he did not race in the final. | https://www.wdtn.com/sports/former-buckeye-hunter-armstrong-wins-first-individual-world-title-in-50m-backstroke/ | 2023-07-31T11:24:26 | 1 | https://www.wdtn.com/sports/former-buckeye-hunter-armstrong-wins-first-individual-world-title-in-50m-backstroke/ |
The bear was spotted chilling in a Burbank jacuzzi while resting its paws on the side of the backyard spa. The California homeowners says the trespasser fled the scene as soon as the police showed up.
Copyright 2023 NPR
The bear was spotted chilling in a Burbank jacuzzi while resting its paws on the side of the backyard spa. The California homeowners says the trespasser fled the scene as soon as the police showed up.
Copyright 2023 NPR | https://www.wqcs.org/2023-07-31/as-temperatures-climbed-into-the-90s-a-black-bear-cooled-off-in-a-jacuzzi | 2023-07-31T11:24:26 | 1 | https://www.wqcs.org/2023-07-31/as-temperatures-climbed-into-the-90s-a-black-bear-cooled-off-in-a-jacuzzi |
Home
News
Valley student recognized on Reading Rainbow
A Rio Grande Valley student was featured on Reading Rainbow, an American educational children's television series, last year. Cali Navarro, 11, sang a song on...
Willacy County residents unite in search efforts for missing goat
It's been two weeks since a Willacy County...
McAllen police: Suspect hospitalized after officer-involved shooting during traffic stop
A Brownsville man was hospitalized Sunday morning after...
Additional Links
Heart of the Valley
Coronavirus Updates
Elections
Education
Mexico
Local News
Immigration/Border Wall
SpaceX
5 On Your Side
Made in the 956
Photographer's Perspective
National News
Consumer News
Find The Link
Submit a Tip
Pump Patrol
KRGV 5.1 News Live Stream
Weather
Saturday, July 29, 2023: Chance of thunderstorms with highs in the 90s
Download our free KRGV FIRST WARN 5 Weather app for the latest updates right on your phone. You can also follow our KRGV First Warn...
Friday, July 28, 2023: Possible thunderstorms, highs in the 90s
Download our free KRGV FIRST WARN 5 Weather...
Thursday, July 27, 2023: Mostly dry, temps in the 100s
Download our free KRGV FIRST WARN 5 Weather...
Additional Links
Hourly Forecast
Latest Weathercast
Interactive Radar
Traffic Maps
Winds
Tide Information
Lake Levels
Water Restrictions
Hurricane Central
Weather Alerts
Weather Links
Send A Weather Question
Weather Team
Submit A Weather Photo
Sports
RGV FC has two players sent off in 2-1 loss to FC Tulsa
TULSA, Oklahoma (Friday, July 21, 2023) – Rio Grande Valley FC (5-6-9) snapped their unbeaten streak as they dropped the match at FC Tulsa (7-7-7) 2-1...
Weslaco Intermediate All-Star Headed to Little League Regional Tournament
WESLACO, TEXAS -- The Weslaco 13U Little League...
Weslaco Little League All-Stars baseball team competing at Southwest Regional Tournament in Sugarland
The Weslaco 13U Little League All-Stars will be...
Additional Links
High School Football
First & Goal
Playmakers
5th Quarter
Two-A-Day Tours
5 Star Plays
Power Poll
Band of the Week
Valley HS Football Preview Show
This Week's Schedule
Send A Sports Tip
Sports Staff
Programming
Additional Links
TV Listings
Antennas
Ratings Guide
Community
Pump Patrol: Friday, July 28, 2023
Zoo Guest: Cornelius the corn snake
Pump Patrol: Thursday, July 27, 2023
Additional Links
5/1 Day
KRGVida Community Calendar
5's Fans for Friends
Tim's Coats
Zoo Guest
Pet of the Week
Student of the Week
Connect
Additional Links
Contact Us
Advertising Information
FCC Reports
Frequently Asked Questions
Jobs at KRGV
News Staff
Sales Staff
Apps and Social Media
Station Information
Contests
Noticias RGV
Continúa la búsqueda de la cabra Willy en el condado Willacy
La búsqueda de una cabra en el rodeo del condado Willacy continúa luego de 13 días de su fuga. Willy se escapó de la ganadería Show...
La Entrevista: Extreme Pizza ofrece pizza estilo Nueva York en el Valle del Río Grande
Una franquicia de pizza estilo Nueva York está...
Desde el Zoológico: ¡Conozcan a Cornelius, la serpiente de maíz!
Alejandra Rodríguez nos visita desde el zoológico, Gladys...
Additional Links
Noticias RGV Transmision en Vivo
Clima
Elecciones
Pandemia de Coronavirus
Deportes
La Entrevista
Salud y Vida
Cuidando El Planeta
Estudiante de la semana
Corazon del Valle
Temporada de huracanes
Canal 5.2
Take 5
Submit a Tip
Search
Home
News
Heart of the Valley
Coronavirus Updates
Elections
Education
Mexico
Local News
Immigration/Border Wall
SpaceX
5 On Your Side
Made in the 956
Photographer's Perspective
National News
Consumer News
Find The Link
Submit a Tip
Pump Patrol
KRGV 5.1 News Live Stream
Weather
Hourly Forecast
Latest Weathercast
Interactive Radar
Traffic Maps
Winds
Tide Information
Lake Levels
Water Restrictions
Hurricane Central
Weather Alerts
Weather Links
Send A Weather Question
Weather Team
Submit A Weather Photo
Sports
High School Football
First & Goal
Playmakers
5th Quarter
Two-A-Day Tours
5 Star Plays
Power Poll
Band of the Week
Valley HS Football Preview Show
This Week's Schedule
Send A Sports Tip
Sports Staff
Programming
TV Listings
Antennas
Ratings Guide
Community
5/1 Day
KRGVida Community Calendar
5's Fans for Friends
Tim's Coats
Zoo Guest
Pet of the Week
Student of the Week
Connect
Contact Us
Advertising Information
FCC Reports
Frequently Asked Questions
Jobs at KRGV
News Staff
Sales Staff
Apps and Social Media
Station Information
Contests
Noticias RGV
Noticias RGV Transmision en Vivo
Clima
Elecciones
Pandemia de Coronavirus
Deportes
La Entrevista
Salud y Vida
Cuidando El Planeta
Estudiante de la semana
Corazon del Valle
Temporada de huracanes
Canal 5.2
Take 5
Submit a Tip
Search
SEARCH
x
Migrantes esperan en largas filas al aire libre por una excepción para ingresar a los Estados Unidos
Share:
Radar
7 Days
News Video
McAllen police: Suspect hospitalized after officer-involved shooting during traffic stop
Valley student recognized on Reading Rainbow
Willacy County residents unite in search efforts for missing goat
Sheriff's office: Suspect in Laguna Heights murder investigation flees to Mexico
UTRGV awarded $1.2 million grant from NASA for their STEM program
Sports Video
Border Wars Tonight at the Payne Arena
Garcia loses to Zambrano by TKO in Marines Boxing Event
RGV FC has two players sent off in 2-1 loss to FC...
Weslaco Intermediate All-Star Headed to Little League Regional Tournament
Weslaco All-Stars competing at Southwest Regional Tournament in Sugarland | https://www.krgv.com/videos/migrantes-esperan-en-largas-filas-al-aire-libre-por-una-excepci-n-para-ingresar-a-los-estados-unidos | 2023-07-31T11:24:26 | 0 | https://www.krgv.com/videos/migrantes-esperan-en-largas-filas-al-aire-libre-por-una-excepci-n-para-ingresar-a-los-estados-unidos |
Introducing the industry's first-ever utility side-by-side with a 1500cc 3-cylinder engine for more power to make tough jobs easier and the industry's only STEELDRIVE transmission for greater durability
MINNEAPOLIS, July 31, 2023 /PRNewswire/ -- Polaris Off Road, the global leader in powersports and off-road innovation, is once again breaking new ground with the industry's first extreme duty utility side-by-side: the all-new RANGER XD 1500. With its unprecedented capability, brute strength and unmatched comfort, the new extreme duty class of RANGER side-by-sides are engineered with the first-ever ProStar 1500cc 3-cylinder engine that offers an industry-leading 110 horsepower, the industry-exclusive STEELDRIVE automatic transmission for greater durability and precise control, and over 70 new accessories for enhanced customization, highlighted by Polaris' exclusive Lock & Ride MAX system. The RANGER XD 1500 establishes a new benchmark for utility side-by-sides.
"We spent over five years meeting with farmers, ranchers, large acreage property owners and big game hunters to develop an extreme duty vehicle that was missing from the market. From its ProStar 1500cc engine to the industry's only STEELDRIVE transmission, RANGER XD 1500 is unlike anything else offered today and is yet another example of our relentless commitment to advancing the industry with fresh thinking and innovative solutions that meet the real-world needs of our utility customers," said Steve Menneto, President of Polaris Off Road.
"Polaris RANGER has been the No. 1 selling utility side-by-side brand for more than 15 years and with the introduction of RANGER Extreme Duty, we've taken the industry's hardest-working lineup and expanded it," said Chris Judson, Vice President of Off Road Utility. "A segment of our utility customers said they are facing exceptionally large tasks and they simply need a machine with more power, more torque, more hauling and towing capacity, and more durability. And our team set out to deliver just that, incorporating dozens of new features and the latest engineering to make the RANGER XD 1500 more capable, stronger, and more comfortable than any other utility side-by-side out there."
Unprecedented Capability
Farmers, ranchers, and large landowners routinely haul and tow heavy loads around the property, and they've been asking for a solution when it comes to their heaviest tasks. The RANGER XD 1500 delivers unprecedented capability for hard-working customers to haul more, tow more, and get more done in less time. With the industry's only 1500cc utility engine, the RANGER XD 1500 provides over 30% more power and over 50% more torque than the next closest competitor.
- ProStar 1500cc 3-Cylinder Engine – Effortless towing, hauling, and confidence in tough terrain with an industry-leading 110HP and 105 lb-ft torque.
- 1,500 lb Cargo Box Capacity – Three-quarter ton box capacity providing nearly 50% more box volume than existing models for maximum productivity with fewer trips and bigger loads.
- 3,500 lb Towing Capacity – For those routinely towing heavy loads on the property, drive better productivity with nearly 40% more towing than existing models.
- Industry-leading Ground Clearance – All RANGER XD 1500 models get 15" of ground clearance with high-clearance arched A-arms to overcome large obstacles.
Brute Strength
Utility customers asked for a more durable, longer lasting offering to maximize their uptime and drive efficiency. Designed to last longer than any model before it, RANGER XD 1500 is the industry's most durable utility side-by-side and has been engineered from the ground up to be stronger and stand up to the demands of the longest days.
- Industry-exclusive STEELDRIVE transmission – Offers a 100 percent steel constructed belt that delivers smooth, precise operation and a fully sealed, liquid-cooled design for unmatched durability.
- High-Strength Steel Heavy Duty Frame – RANGER XD 1500 has a high-strength steel one-piece chassis featuring 160 percent more torsional stiffness for a smoother ride and better cab sealing.
- Industry-leading Service Intervals – RANGER XD 1500 offers the industry's longest service intervals so customers can maximize their uptime.
Unmatched Comfort
- From the farm to remote backcountry, utility customers work from before the sun rises to after it sets, and need something that delivers all-day comfort. Beyond industry-leading capability and durability, the RANGER XD 1500 prioritizes comfort across the entire lineup to keep customers going strong on the longest days.
- Most Spacious Interior – Equipped with the most spacious and premium cab available in utility side-by-sides, the XD 1500 offers increased leg and shoulder room, making it easy to enter and exit the vehicle. Adjustable seating and a telescopic steering wheel lets drivers find the perfect fit for height and riding preferences.
- Premium Seating – Contoured seating with added bolstering provides more rider comfort along with a center seat that flips down into an armrest with additional cup holders.
- Available Heated Seats – For comfort on the coldest days, RANGER XD 1500 NorthStar Ultimate is the first utility side-by-side that comes from the factory with heated seats.
- Drive Modes – RANGER XD 1500 comes with an intuitive and easy-to-use rotary drive mode selector that lets customers choose from four different drive modes, including:
- Heating and Air Conditioning (HVAC) – Riders can stay comfortable in harsh weather conditions in the RANGER XD 1500 NorthStar Edition, featuring an all-new HVAC system and a fully-enclosed, next generation ProShield cab that's been redesigned with improved sealing to prevent dust and water intrusion, while locking in the temperature from the climate-controlled cab.
- Sun Visors – All-new integrated sun visors provide improved visibility throughout the day for added confidence while driving.
- RIDE COMMAND – Available 7" waterproof touchscreen display powered by RIDE COMMAND technology featuring a back-up camera, GPS navigation regardless of cell service, and AM/FM radio with Bluetooth® streaming capability.
- RIDE COMMAND+ – Customers can keep tabs on their vehicle directly from the Polaris App and access critical vehicle information like vehicle location, maintenance reminders, and issue diagnostics right from the palm of their hand with the industry's only connected-vehicle technology. Available from the factory on NorthStar Ultimate.
Customization
Customers have been asking for increased versatility, durability, and ease of use for the different work applications they face throughout the day. With over 70 new Polaris Engineered Accessory options designed specifically for the RANGER XD 1500, plus options from partners brands including JBL®, Rhino Rack®, Pro Armor, Kolpin, and HD Parts, customers have more opportunity than ever before to make their vehicle fit their specific needs.
- Lock & Ride MAX – Polaris' easiest to use, most versatile, and confident accessory attachment platform ever. With customizable configurations and the ability to reconfigure on the fly with no tools required, this new accessory platform allows users to prepare for their day, their way. Customers can simply choose and place their accessory, lock it in place, and ride confidently knowing their gear is secure.
- New JBL® Audio – Polaris partnered with JBL® to create the highest performing audio system ever included in a RANGER from the factory. For customers wanting to turn it up a notch, the JBL® Trail Pro 4200 audio upgrade adds rear speakers and two subwoofers for an immersive audio experience.
- Glacier Pro HD Plow – New 84" plow designed for faster, more efficient plowing during the winter months. A hydraulic plow lift and angle kit can be paired with an all-new plow controller to manage the largest plow Polaris has ever offered, all without ever leaving the comfort of the cab.
2024 RANGER XD 1500 Premium: Starting at US $29,999 / CAN $36,199
The RANGER XD 1500 Premium commands a large presence thanks to heavy-duty components and the industry's largest bumper, providing complete front-end protection. The vehicle comes equipped with one of the most comprehensive standard packages in a side-by-side to date including 29" tires, tilt steering and seat slider for customizable comfort, four drive modes, high output LED headlights for enhanced visibility, and USB ports with multiple charging capabilities. The vehicle also comes equipped with boosted brakes and heavy-duty suspension to ensure performance across a variety of off-road environments.
2024 RANGER XD 1500 NorthStar Premium: Starting at US $39,999 / CAN $48,799
The next step up is the RANGER XD 1500 NorthStar Premium. This machine features a fully enclosed cab with HVAC temperature and five different mode controls, lockable full doors with power windows and a fixed front glass windshield. Additional features include an electronically controlled power tilt bed to dump heavy loads with ease, an overhead switch panel for easy accessorization, and an overhead rear work light to illuminate the cargo box in low-light conditions. NorthStar Premium comes stock with 30" Kenda® CrossTrail tires and available 32" tires to overcome large obstacles and tough terrain.
2024 RANGER XD 1500 NorthStar Ultimate: Starting at US $44,999 / CAN $54,499
Rounding out the lineup is the RANGER XD 1500 NorthStar Ultimate, which features everything from the NorthStar Premium trim, plus the 7" infotainment display powered by RIDE COMMAND and heated seats. The NorthStar Ultimate trim also delivers an immersive sound experience, featuring full AM/FM radio with Bluetooth® streaming capability and industry-exclusive JBL® speakers for precise audio and premium sound. Finally, the vehicle comes standard with RIDE COMMAND+, allowing for vehicle health monitoring and more.
The 2024 RANGER XD 1500 lineup is expected to begin shipping to dealers in late summer. To learn more about the 2024 RANGER family, please visit https://ranger.polaris.com/en-us/ or join the conversation and follow on Facebooksm, Instagramsm, YouTubesm and Twittersm.
About Polaris
As the global leader in powersports, Polaris Inc. (NYSE: PII) pioneers product breakthroughs and enriching experiences and services that have invited people to discover the joy of being outdoors since our founding in 1954. Polaris' high-quality product line-up includes the Polaris RANGER®, RZR® and Polaris GENERAL™ side-by-side off-road vehicles; Sportsman® all-terrain off-road vehicles; military and commercial off-road vehicles; snowmobiles; Indian Motorcycle® mid-size and heavyweight motorcycles; Slingshot® moto-roadsters; Aixam quadricycles; Goupil electric vehicles; and pontoon and deck boats, including industry-leading Bennington pontoons. Polaris enhances the riding experience with a robust portfolio of parts, garments, and accessories. Proudly headquartered in Minnesota, Polaris serves more than 100 countries across the globe. www.polaris.com
Warning: vehicle rollaway can cause serious injury or death. This vehicle can roll whenever the gear selector is not in the park position. Always shift to park when stopping the engine or leaving the vehicle. When leaving the vehicle on an incline is unavoidable, use extra care. If leaving the vehicle unattended, block the rear wheels on the downhill side and keep children, pets, and others away form the gear selector. Notice: Vehicle payload and trailer weight will affect the angle of hill on which the vehicle will hold.
Kenda® is a registered trademark of Kenda Rubber Industrial Co, Ltd.
Bluetooth® is a registered trademark of Bluetooth Sig, Inc.
JBL® is a registered trademark of Harman International Industries, Incorporated
Rhino-Rack® is a registered trademark of Rhino Rack Australia Pty Limited
Unless noted, trademarks are the property of Polaris Industries Inc.
View original content to download multimedia:
SOURCE Polaris Inc. | https://www.1011now.com/prnewswire/2023/07/31/polaris-expands-its-ranger-lineup-with-all-new-ranger-xd-1500-an-entirely-new-class-extreme-duty-utility-side-by-sides/ | 2023-07-31T11:24:28 | 1 | https://www.1011now.com/prnewswire/2023/07/31/polaris-expands-its-ranger-lineup-with-all-new-ranger-xd-1500-an-entirely-new-class-extreme-duty-utility-side-by-sides/ |
KYIV, Ukraine — (AP) — Russian missiles slammed into an apartment complex and a university building in the central Ukrainian city of Kryvyi Rih, killing four people and wounding dozens of others Monday as the blasts trapped residents beneath rubble, Ukraine's interior minister said.
One of the two missiles destroyed a section of the apartment building between the fourth and ninth floors, Interior Minister Ihor Klymenko said. Video showed black smoke billowing from corner units and burned out or damaged cars on a tree-lined street.
A 10-year-old child was among those killed, Klymenko said. Serhii Kruk, head of Ukraine’s State Emergency Service, said 44 people were wounded in the morning attack, which also destroyed part of the four-story university building.
Meanwhile, a Ukrainian artillery strike on partially occupied Donetsk province killed two people and wounded six in the regional capital, according to Denis Pushilin, the Moscow-installed leader of the illegally annexed province.
A bus was also hit as Ukrainian forces shelled the city of Donetsk multiple times Monday, Pushilin said.
Neither side's claims could be independently verified.
A Ukrainian counteroffensive aimed at driving Russian forces out of occupied areas intensified last week. At the same time, Ukraine has sought to take the war deep into Russia, reportedly using drones to hit targets as far away as Moscow.
Ukrainian drone attacks on Russia and Moscow-annexed territory, especially Crimea, have become more frequent. The latest strike, on Sunday, damaged two office buildings a few miles (kilometers) from the Kremlin.
In Kryvyi Rih, which is the hometown of Ukrainian President Volodymyr Zelenskyy, rescue crews searched Monday for people who were trapped in the wreckage of the two hit buildings. The Kremlin's forces have occasionally targeted the city since they invaded Ukraine in February 2022.
Bombarding populated areas with missiles, artillery and drones has been a hallmark of Moscow’s military strategy during the war, an approach that has continued during the Ukrainian counteroffensive that started in June.
Russian officials insist they only take aim at legitimate military targets, but Ukraine and its supporters say mass civilian deaths during previous attacks provide evidence of war crimes.
“In recent days, the enemy has been stubbornly attacking cities, city centers, shelling civilian objects and housing,” Zelenskyy said in a statement on social media. “But this terror will not frighten us or break us.”
Russian shelling Monday also killed a 70-year-old woman in her home in a Kharkiv province village near Izyum, as well as a civilian in the southern Ukrainian city of Kherson, local authorities said.
In eastern Ukraine’s Donetsk province, one person was reported killed and seven people were injured after Russia shelled 12 cities and villages, according to Gov. Pavlo Kirilenko.
Ukrainian officials didn’t acknowledge Sunday's drone attacks in the Moscow region. In his nightly video address, Zelenskyy said: “Gradually, the war is returning to the territory of Russia — to its symbolic centers and military bases, and this is an inevitable, natural and absolutely fair process.”
Meanwhile, Russian mercenary leader Yevgeny Prigozhin said Monday his Wagner Group is not currently recruiting fighters.
In an audio message published on a Telegram channel associated with the Wagner chief, Prigozhin said the company had suspended recruitment as there is currently “no shortage of personnel.”
Prigozhin previously agreed with Western estimates that he lost more than 20,000 men in the long battle for the Ukrainian city Bakhmut.
Prigozhin last month led a short-lived mutiny against Moscow, demanding a leadership change in the Russian military. In an attempt to control him, Russian authorities insisted that Wagner fighters can only return to Ukraine if they join Russia's regular army.
___
Follow AP's coverage of the war in Ukraine at https://apnews.com/hub/russia-ukraine
Copyright 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. | https://www.wftv.com/news/world/russian-missiles/UAN3SRIW33CWD42EBFI6PYAGUU/ | 2023-07-31T11:24:28 | 1 | https://www.wftv.com/news/world/russian-missiles/UAN3SRIW33CWD42EBFI6PYAGUU/ |
A weekend that featured storms and sunshine and the heat has come to an end. The sun will remain, but temperatures will be cooler early in the week with dew points in the 50s, providing great opportunities to get outside and enjoy the comfortable weather. Highs in the upper 70s and lower 80s today with lots of sunshine. Overnight will be quiet with mostly clear skies and lows in the 50s. Sun will continue through Wednesday before a chance of storms arrive Thursday into Friday with temperatures nearing the 90s and in some areas reaching the 90s. Dry into the weekend. | https://www.wdtn.com/weather/daily-forecast/dry-weather-is-here-but-will-it-last-all-week/ | 2023-07-31T11:24:32 | 1 | https://www.wdtn.com/weather/daily-forecast/dry-weather-is-here-but-will-it-last-all-week/ |
Senate Minority Leader Mitch McConnell's recent health episodes have sparked concerns about his possible successor. NPR's A Martinez talks to Austin Horn, a reporter at the Lexington Herald-Leader.
Copyright 2023 NPR
Senate Minority Leader Mitch McConnell's recent health episodes have sparked concerns about his possible successor. NPR's A Martinez talks to Austin Horn, a reporter at the Lexington Herald-Leader.
Copyright 2023 NPR | https://www.wqcs.org/2023-07-31/kentucky-law-dictates-a-republican-would-replace-mcconnell-if-he-vacates-senate-seat | 2023-07-31T11:24:32 | 1 | https://www.wqcs.org/2023-07-31/kentucky-law-dictates-a-republican-would-replace-mcconnell-if-he-vacates-senate-seat |
BALTIMORE, July 31, 2023 /PRNewswire/ -- Opteev Technologies, Inc., a pioneering technology company at the forefront of diagnostics, has filed a patent (Patent Application #63/513,007) for a revolutionary multiplex biochip for respiratory infection diagnostics. The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute. This game-changing technology paves the way for an ultra-rapid, portable, and accurate syndromic diagnostic device to empower healthcare providers with immediate results at their fingertips.
The tiny biochip can directly detect whole viruses in real-time in both processed and unprocessed samples such as saliva or nasal swab and has demonstrated an unprecedented accuracy rate of 99.49% with an impressive limit of detection in its analytical performance evaluation. Furthermore, the biosensor achieves fine-tuned specificity by carefully selecting specific virus-binding peptides, enabling accurate identification of target viruses in complex samples. To ensure precise and reliable virus detection, the biochip utilizes artificial intelligence to optimize the frequency range effectively mitigating the impact of interfering noise signals.
Unlike conventional respiratory panels that cost tens of thousands of dollars and take days to provide results, Opteev's multiplex biochip will offer healthcare providers affordable syndromic testing with the ability to process samples at the point of care, allowing for the simultaneous detection and specific identification of multiple pathogens instantaneously. This breakthrough technology will eliminate the need for speculation by providing healthcare providers with the critical information needed to deliver the most effective treatment options at the point of care.
"With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics," said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies. "The potential of this technology to transform patient care, streamline operations, and reduce costs is truly remarkable."
As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company welcomes potential collaborations and partnerships to further develop and commercialize its multiplex biochip. "Together, we can shape the future of diagnostics and unlock the massive potential of our game-changing multiplex biochip," said Conrad Bessemer, Opteev's Chairman and Co-founder.
For more information about Opteev Technologies and its groundbreaking multiplex biochip, please visit www.opteev.com.
Opteev Technologies, Inc., headquartered in Baltimore, MD, is a pioneering technology company at the forefront of diagnostics. With a strong focus on respiratory pathogen detection, Opteev is committed to developing innovative solutions that revolutionize the field of point-of-care diagnostics. As a subsidiary of Novatec, Inc., a trusted manufacturer and supplier of machinery and sensor technology, Opteev leverages decades of experience to drive advancements in healthcare.
Media Contact:
Dana Gardner
Vice President
dgardner@opteev.com
Phone: 443-457-5214
View original content to download multimedia:
SOURCE Opteev Technologies, Inc | https://www.wkyt.com/prnewswire/2023/07/31/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-respiratory-pathogens-under-1-minute/ | 2023-07-31T11:24:32 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-respiratory-pathogens-under-1-minute/ |
The Avocados From Mexico® Chocolate Dulce De Leche Cupcake will be available at Sprinkles bakeries nationwide for one week beginning July 31
DALLAS, July 31, 2023 /PRNewswire/ -- Talk about a perfect pairing! Avocados From Mexico®, the number one selling avocado brand in the U.S., is making National Avocado Day even better by partnering with renowned dessert bakery chain Sprinkles for a delicious collaboration – a limited-edition cupcake featuring fresh Mexican avocados.
The Avocados From Mexico® Chocolate Dulce De Leche Sprinkles cupcake is a delectable banana cupcake that's studded with pecans and generously filled with a soft dulce de leche core. And to top it all off? A zesty frosting that blends rich cream cheese and chocolate made with fresh Mexican avocados for a delightful, creamy finish.
"The new Avocados From Mexico Chocolate Dulce De Leche cupcake features the highest quality and best-tasting ingredients," said Sprinkles Vice President, Culinary, Charles Craig. "By blending fresh avocado and smooth cream cheese alongside the banana and dulce de leche cupcake, we were able to elevate all the ingredients resulting in a cupcake that is out-of-this world. We can't wait for fans to try it!"
Beginning on July 31, National Avocado Day, consumers can make their week better by enjoying Avocados From Mexico in cupcake form — available at Sprinkles nationwide through August 6.
"Avocados From Mexico make everything better, and we're so proud that our avocados will get to shine in a unique way on National Avocado Day," said Kelly Burke, Director of Brand Marketing at Avocados From Mexico. "Our brand is known for bringing the good times with great tasting avocados. We are excited to partner with a beloved brand like Sprinkles to spark good times in a new way with everyone's favorite sweet treat."
"Sprinkles Cupcakes has always taken an innovative approach to classic desserts, and this new collaboration with Avocados From Mexico is no exception," said Sprinkles CMO, Michelle Wong. "Avocados From Mexico was an obvious choice for their quality and taste, and we can't wait for our guests to discover our latest cupcake, starring this beloved fruit."
To learn more about Avocados From Mexico, visit https://avocadosfrommexico.com, Facebook (facebook.com/avocadosfrommexico), Instagram (@avocadosfrommexico) or Twitter (@AvosFromMexico). #MakeItBetter #AFMxSprinkles
About Avocados From Mexico
Avocados From Mexico is a wholly-owned subsidiary of the Mexican Hass Avocado Importers Association (MHAIA), formed for the purpose of advertising, promotion, public relations and research for all stakeholders of Avocados From Mexico. Under agreements, MHAIA and the Association of Avocado Exporting Producers & Packers of Mexico (APEAM) have combined resources to fund and manage Avocados From Mexico, with the intent to provide a focused, highly- effective and efficient marketing program in the United States. Avocados From Mexico is headquartered in Irving, Texas.
About Sprinkles
Sprinkles offers premium cupcakes, cakes and cookies that are baked fresh in small batches throughout the day and handcrafted with only the finest ingredients. Sprinkles opened its first bakery in Beverly Hills in 2005, drawing long lines of loyal cupcake fans and celebrity endorsements. Sprinkles prides themselves in being passionate innovators and since debuting the world's first Cupcake ATM, the brand has introduced layer cakes, cookies and brownies, launched a national shipping platform and has grown to over 70 bakeries and ATMs coast-to-coast. Sprinkles launched domestic and international franchising in 2022. For additional information on Sprinkles, follow @sprinklescupcakes on social and visit www.sprinkles.com.
CONTACT: Ana Ambrosi, aambrosi@avocadosfrommexico.com
View original content to download multimedia:
SOURCE Avocados From Mexico | https://www.1011now.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ | 2023-07-31T11:24:34 | 0 | https://www.1011now.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ |
The House and Senate left Washington for the month of August with a lengthy, time-sensitive to-do list waiting when they return, including multiple key health care priorities.
There will only be three weeks before the end of the fiscal year to get everything done, and just 11 legislative days when both chambers will be in session at the same time.
Congress faces a Sept. 30 deadline to reauthorize a sweeping pandemic preparedness bill, fund community health centers and renew opioid addiction services.
But the largest looming deadline is the appropriations bills to fund the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS), which are tied up in the House amid disagreements over abortion and spending levels.
GOP leaders scuttled a vote planned for Friday on legislation funding the FDA and the Department of Agriculture after moderate Republicans objected to a provision that would reverse the FDA’s decision to allow the abortion pill mifepristone drug to be dispensed through the mail and in retail pharmacies.
House Freedom Caucus members have also been demanding even deeper spending cuts than agreed to in the bipartistan debt ceiling deal.
The Labor-HHS bill advanced through a House Appropriations subcommittee earlier this month, but hadn’t even made it to the full committee before recess. The Republican-led House bill would slash or eliminate funding from a range of programs that deal with everything from family planning to teen pregnancy and even HIV.
Both FDA and HHS funding bills face a major fight in the Democratic-controlled Senate, where the Appropriations Committee has already passed its own version by near unanimous margins, owing to an agreement by Democratic and Republican leaders not to insert “poison pill” amendments.
House Democratic Whip Katherine Clark (Mass.) argued in a floor speech that lawmakers should stay in Washington to strip out the “toxic, divisive, bigoted riders” in the bills, and ripped Republicans for delaying votes until September.
Pandemic preparedness
The House and Senate are taking different tracks in the reauthorization of the pandemic preparedness bill, complicating its path forward.
The Senate advanced a bipartisan version of the Pandemic All-Hazards Preparedness Act out of committee, but the House is divided. House Energy and Commerce Committee Republicans advanced a bill on party lines after Democrats introduced their own version.
The primary disagreement is over drug shortages. Democrats are clamoring to give FDA more oversight authority to address the shortages, but Republicans are insisting on keeping the issues separate.
The Senate version contains some provisions addressing drug shortages, but only one involves beefing up FDA authority.
Congress is under pressure to stem drug shortages amid reports of doctors rationing cancer drugs and other medicine. Republicans on the Energy and Commerce Committee have said they are committed to dealing with the problems, but that it shouldn’t be part of the preparedness bill.
Energy and Commerce Committee GOP leaders released a discussion draft on Friday of drug shortage legislation focusing on the economic reasons for shortages, including giving some generic drug manufacturers the ability to raise the cost of their drugs if hospitals keep prices “artificially low” to the point where there’s no economic incentive.
Health centers
Legislation to reauthorize funding for community health centers also faces partisan challenges. But in this case, the House cleared its bill on a bipartisan basis, while the Senate is still working through disagreements, highlighting the work to be done.
Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, originally wanted tens of billions of dollars more for the centers. He was asking for $130 billion to fund the centers over the next five years as well as $60 billion to help grow the health care workforce.
But Sanders ended up canceling a planned markup during the last week of July. Raising some eyebrows, Sanders said he is working with Sen. Roger Marshall (R-Kan.) to craft a bipartisan bill that will be “ready by the first week of September.”
Separately, Sanders and Senate Finance Committee Chairman Ron Wyden (D-Ore.) issued a joint statement pledging to partner and work towards legislation in the fall aimed at addressing primary care and other health care workforce shortages.
Opioids
At issue are several provisions of sweeping legislation signed into law in 2018 called the Support Act, which aimed to tackle the country’s drug overdose epidemic.
The House Energy and Commerce Committee advanced a bipartisan reauthorization and expansion bill, but advocates are concerned the Senate is behind.
HELP Committee ranking member Bill Cassidy (R-La.) introduced his own version of the bill on July 20, but hearings won’t be scheduled until September. Cassidy has warned that the committee is wasting time on partisan bills instead of easy bipartisan wins, such as the Support Act.
Insulin/PBM reform
Senate Majority Leader Chuck Schumer (D-N.Y.) has said for months that he wants to move legislation that would cap the cost of insulin at $35 per month for people with private insurance.
There’s hope to combine it with legislation reforming the pharmacy benefit manager (PBM) industry into a package that could get bipartisan support.
But there’s no looming deadline and no guarantee it will get taken up in September.
Sen. Jeanne Shaheen (D-N.H.), who is a co-sponsor of one of the insulin bills with Sen. Susan Collins (R-Maine), said she still has Schumer’s support heading into the fall, but has not heard anything about timing.
Multiple committees have advanced PBM reform bills in both the House and Senate, so they will all need to be combined into one floor-friendly package. | https://www.wearegreenbay.com/hill-politics/lawmakers-set-to-face-ticking-clock-on-health-care-priorities/ | 2023-07-31T11:24:36 | 0 | https://www.wearegreenbay.com/hill-politics/lawmakers-set-to-face-ticking-clock-on-health-care-priorities/ |
Mobile Visual Processing Solutions Coupled with Dedicated Game Tuning Services Take Mobile Gaming Experience to a Brand-New Level
SHANGHAI, July 31, 2023 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative visual processing solutions, today announced the official launch of its new IRX gaming experience brand. As a brand targeted at smartphone users, IRX is grounded on Pixelworks' mobile visual processing solutions and coupled with in-depth game tuning services. This combination leverages Pixelworks' expertise to achieve ultra-smooth gaming experience and the highest picture quality for different types of games on mobile devices. In addition, it exercises effective control of power consumption, latency and other performance variables to ensure stable and long-lasting gaming with optimal visual performance, providing end users with unparalleled mobile gaming experiences.
The IRX gaming experience is enabled by a portfolio of technology advantages and product application experiences based on the Company's innovative distributed rendering architecture. More specifically, Pixelworks' ultra-low latency MotionEngine® technology, low power super-resolution technology, AI Always-on HDR and other technologies bring optimized rendering capabilities to smartphones that exceed what can be achieved by a traditional chipset. Together with Pixelworks' profound tuning experience for different games on various mobile devices the result is a meaningfully enriched visual experience for smartphone users, which is the core foundation for the IRX gaming experience.
The IRX gaming experience brand will be supported by a certification program for mobile devices that incorporates Pixelworks visual processors. The certification program will be backed by a suite of visual quality evaluation systems agreed upon with smartphone manufacturers to ensure that Pixelworks powered smartphones provide the most outstanding gaming performance and utmost visual quality for consumers.
The IRX branded certification program is comprised of both device certification and game tuning services. Pixelworks will optimize the rendering capabilities and display quality of top games on mobile devices based on its visual processors' capabilities as well as the devices' performance characteristics. Smartphones that meet the technical requirements as well as Pixelworks' visual processing standards will be granted the IRX branded certification, and games that meet Pixelworks' visual quality requirements will be included in the IRX-supported game list. To date, there are 20 top games being enlisted on the IRX-supported game list, which can be found on Pixelworks' official IRX gaming experience website. Furthermore, Pixelworks plans to establish expanded communication channels with consumers to help further educate end users on the benefits of the IRX gaming experience.
"IRX is a gaming experience brand from Pixelworks targeted directly towards mobile device users." said Ting Xiong, President of Pixelworks China. "Pixelworks would like to empower smartphone manufacturers to break the ceiling of mobile gaming experience from content optimization to performance enhancement with its innovative rendering technologies and years of game tuning and optimization experience. Additionally, we are also aiming to develop and promote consumer awareness around how to better evaluate visual display quality and the mobile gaming experience, enabling them to make smarter choices when purchasing a smartphone. By utilizing professional technologies and services to build more links across both products and users, we hope to drive mutual growth through in-depth interactions while bringing display performance and the mobile gaming experience to a brand-new level."
About Pixelworks
Pixelworks provides industry-leading content creation, video delivery and display processing solutions and technology that enable highly authentic viewing experiences with superior visual quality, across all screens – from cinema to smartphone and beyond. The Company has more than 20 years of history delivering image processing innovation to leading providers of consumer electronics, professional displays and video streaming services.
For more information, please visit the company's web site at www.pixelworks.com.
Note: Pixelworks, MotionEngine and the Pixelworks logo are trademarks of Pixelworks, Inc. All other trademarks are the property of their respective owners.
View original content to download multimedia:
SOURCE Pixelworks, Inc. | https://www.wkyt.com/prnewswire/2023/07/31/pixelworks-announces-launch-irx-gaming-experience-brand/ | 2023-07-31T11:24:39 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/pixelworks-announces-launch-irx-gaming-experience-brand/ |
SHENZHEN, China, July 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company" or "Taoping"), today announced that the board of directors of the Company approved a one-for-ten reverse stock split of the Company's issued and outstanding ordinary shares, no par value (the "Ordinary Shares"). Beginning August 1, 2023, the Company's Ordinary Shares will be trading on a split-adjusted basis under the same symbol "TAOP" but with new CUSIP number, G8675V 127.
As a result of the share consolidation, each ten Ordinary Shares outstanding will automatically combine and convert to one issued and outstanding Ordinary Share without any action on the part of shareholders who hold their shares in brokerage accounts or "street name". Shareholders holding certificates of Ordinary Shares are expected to receive instructions from the Company's transfer agent, Transhare Corporation, regarding procedures for exchanging share certificates. All outstanding options, warrants and other rights to purchase the Company's Ordinary Shares will be adjusted proportionately as a result of the reverse stock split. No fractional shares will be issued as a result of the reverse stock split, and instead, all such fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
The reverse stock split is intended to increase the per share trading price of the Ordinary Shares to satisfy the $1.00 minimum bid price requirement for continued listing on the NASDAQ Stock Market. Following the reverse stock split the Company will have approximately 1.86 million Ordinary Shares issued and outstanding, exclusive of shares issuable under outstanding options and warrants. The reverse stock split will not affect the number of total authorized Ordinary Shares of the Company.
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us via LinkedIn, Twitter or YouTube.
Safe Harbor Statement
This press release contains "forward-looking statements" that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, such as statements regarding our estimated future results of operations and financial position, our strategy and plans, and our objectives or goals, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking statements. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: our potential inability to achieve or sustain profitability or reasonably predict our future results due to our limited operating history of providing smart cloud services, the effects of the global Covid-19 pandemic, the emergence of additional competing technologies, changes in domestic and foreign laws, regulations and taxes, uncertainties related to China's legal system and economic, political and social events in China, the volatility of the securities markets; and other risks including, but not limited to, those that we discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 20-F as well as in our other reports filed or furnished from time to time with the SEC. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
View original content to download multimedia:
SOURCE Taoping Inc. | https://www.1011now.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ | 2023-07-31T11:24:41 | 1 | https://www.1011now.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ |
BELLEVUE, Wis. (WFRV) – An 82-year-old Brown County man is dead after reportedly being hit by three different vehicles early Monday morning.
In a release from the Brown County Sheriff’s Office, deputies responded at 12:56 a.m. to 3144 Main Street in Bellevue for a report of a man on the road that may have been hit by a vehicle.
When deputies arrived they found the body of an 82-year-old man that lived nearby and was believed to be hit by three different vehicles.
Through further investigation, authorities say they have identified and found the first vehicle and driver to hit the man but still need help to identify the other two vehicles.
The first vehicle is a light-colored SUV, but the make and model are unknown. The second vehicle is an unknown make and model of a dark-colored pickup truck pulling a trailer that didn’t have working lights.
Officials say both vehicles fled the scene after hitting the man and anyone with information is asked to contact the Brown County Sheriff’s Office.
No names are being released and the incident remains under investigation. Local Five will update this story when more information is released. | https://www.wearegreenbay.com/news/local-news/82-year-old-brown-county-man-dies-after-being-hit-by-3-different-vehicles/ | 2023-07-31T11:24:42 | 0 | https://www.wearegreenbay.com/news/local-news/82-year-old-brown-county-man-dies-after-being-hit-by-3-different-vehicles/ |
Introducing the industry's first-ever utility side-by-side with a 1500cc 3-cylinder engine for more power to make tough jobs easier and the industry's only STEELDRIVE transmission for greater durability
MINNEAPOLIS, July 31, 2023 /PRNewswire/ -- Polaris Off Road, the global leader in powersports and off-road innovation, is once again breaking new ground with the industry's first extreme duty utility side-by-side: the all-new RANGER XD 1500. With its unprecedented capability, brute strength and unmatched comfort, the new extreme duty class of RANGER side-by-sides are engineered with the first-ever ProStar 1500cc 3-cylinder engine that offers an industry-leading 110 horsepower, the industry-exclusive STEELDRIVE automatic transmission for greater durability and precise control, and over 70 new accessories for enhanced customization, highlighted by Polaris' exclusive Lock & Ride MAX system. The RANGER XD 1500 establishes a new benchmark for utility side-by-sides.
"We spent over five years meeting with farmers, ranchers, large acreage property owners and big game hunters to develop an extreme duty vehicle that was missing from the market. From its ProStar 1500cc engine to the industry's only STEELDRIVE transmission, RANGER XD 1500 is unlike anything else offered today and is yet another example of our relentless commitment to advancing the industry with fresh thinking and innovative solutions that meet the real-world needs of our utility customers," said Steve Menneto, President of Polaris Off Road.
"Polaris RANGER has been the No. 1 selling utility side-by-side brand for more than 15 years and with the introduction of RANGER Extreme Duty, we've taken the industry's hardest-working lineup and expanded it," said Chris Judson, Vice President of Off Road Utility. "A segment of our utility customers said they are facing exceptionally large tasks and they simply need a machine with more power, more torque, more hauling and towing capacity, and more durability. And our team set out to deliver just that, incorporating dozens of new features and the latest engineering to make the RANGER XD 1500 more capable, stronger, and more comfortable than any other utility side-by-side out there."
Unprecedented Capability
Farmers, ranchers, and large landowners routinely haul and tow heavy loads around the property, and they've been asking for a solution when it comes to their heaviest tasks. The RANGER XD 1500 delivers unprecedented capability for hard-working customers to haul more, tow more, and get more done in less time. With the industry's only 1500cc utility engine, the RANGER XD 1500 provides over 30% more power and over 50% more torque than the next closest competitor.
- ProStar 1500cc 3-Cylinder Engine – Effortless towing, hauling, and confidence in tough terrain with an industry-leading 110HP and 105 lb-ft torque.
- 1,500 lb Cargo Box Capacity – Three-quarter ton box capacity providing nearly 50% more box volume than existing models for maximum productivity with fewer trips and bigger loads.
- 3,500 lb Towing Capacity – For those routinely towing heavy loads on the property, drive better productivity with nearly 40% more towing than existing models.
- Industry-leading Ground Clearance – All RANGER XD 1500 models get 15" of ground clearance with high-clearance arched A-arms to overcome large obstacles.
Brute Strength
Utility customers asked for a more durable, longer lasting offering to maximize their uptime and drive efficiency. Designed to last longer than any model before it, RANGER XD 1500 is the industry's most durable utility side-by-side and has been engineered from the ground up to be stronger and stand up to the demands of the longest days.
- Industry-exclusive STEELDRIVE transmission – Offers a 100 percent steel constructed belt that delivers smooth, precise operation and a fully sealed, liquid-cooled design for unmatched durability.
- High-Strength Steel Heavy Duty Frame – RANGER XD 1500 has a high-strength steel one-piece chassis featuring 160 percent more torsional stiffness for a smoother ride and better cab sealing.
- Industry-leading Service Intervals – RANGER XD 1500 offers the industry's longest service intervals so customers can maximize their uptime.
Unmatched Comfort
- From the farm to remote backcountry, utility customers work from before the sun rises to after it sets, and need something that delivers all-day comfort. Beyond industry-leading capability and durability, the RANGER XD 1500 prioritizes comfort across the entire lineup to keep customers going strong on the longest days.
- Most Spacious Interior – Equipped with the most spacious and premium cab available in utility side-by-sides, the XD 1500 offers increased leg and shoulder room, making it easy to enter and exit the vehicle. Adjustable seating and a telescopic steering wheel lets drivers find the perfect fit for height and riding preferences.
- Premium Seating – Contoured seating with added bolstering provides more rider comfort along with a center seat that flips down into an armrest with additional cup holders.
- Available Heated Seats – For comfort on the coldest days, RANGER XD 1500 NorthStar Ultimate is the first utility side-by-side that comes from the factory with heated seats.
- Drive Modes – RANGER XD 1500 comes with an intuitive and easy-to-use rotary drive mode selector that lets customers choose from four different drive modes, including:
- Heating and Air Conditioning (HVAC) – Riders can stay comfortable in harsh weather conditions in the RANGER XD 1500 NorthStar Edition, featuring an all-new HVAC system and a fully-enclosed, next generation ProShield cab that's been redesigned with improved sealing to prevent dust and water intrusion, while locking in the temperature from the climate-controlled cab.
- Sun Visors – All-new integrated sun visors provide improved visibility throughout the day for added confidence while driving.
- RIDE COMMAND – Available 7" waterproof touchscreen display powered by RIDE COMMAND technology featuring a back-up camera, GPS navigation regardless of cell service, and AM/FM radio with Bluetooth® streaming capability.
- RIDE COMMAND+ – Customers can keep tabs on their vehicle directly from the Polaris App and access critical vehicle information like vehicle location, maintenance reminders, and issue diagnostics right from the palm of their hand with the industry's only connected-vehicle technology. Available from the factory on NorthStar Ultimate.
Customization
Customers have been asking for increased versatility, durability, and ease of use for the different work applications they face throughout the day. With over 70 new Polaris Engineered Accessory options designed specifically for the RANGER XD 1500, plus options from partners brands including JBL®, Rhino Rack®, Pro Armor, Kolpin, and HD Parts, customers have more opportunity than ever before to make their vehicle fit their specific needs.
- Lock & Ride MAX – Polaris' easiest to use, most versatile, and confident accessory attachment platform ever. With customizable configurations and the ability to reconfigure on the fly with no tools required, this new accessory platform allows users to prepare for their day, their way. Customers can simply choose and place their accessory, lock it in place, and ride confidently knowing their gear is secure.
- New JBL® Audio – Polaris partnered with JBL® to create the highest performing audio system ever included in a RANGER from the factory. For customers wanting to turn it up a notch, the JBL® Trail Pro 4200 audio upgrade adds rear speakers and two subwoofers for an immersive audio experience.
- Glacier Pro HD Plow – New 84" plow designed for faster, more efficient plowing during the winter months. A hydraulic plow lift and angle kit can be paired with an all-new plow controller to manage the largest plow Polaris has ever offered, all without ever leaving the comfort of the cab.
2024 RANGER XD 1500 Premium: Starting at US $29,999 / CAN $36,199
The RANGER XD 1500 Premium commands a large presence thanks to heavy-duty components and the industry's largest bumper, providing complete front-end protection. The vehicle comes equipped with one of the most comprehensive standard packages in a side-by-side to date including 29" tires, tilt steering and seat slider for customizable comfort, four drive modes, high output LED headlights for enhanced visibility, and USB ports with multiple charging capabilities. The vehicle also comes equipped with boosted brakes and heavy-duty suspension to ensure performance across a variety of off-road environments.
2024 RANGER XD 1500 NorthStar Premium: Starting at US $39,999 / CAN $48,799
The next step up is the RANGER XD 1500 NorthStar Premium. This machine features a fully enclosed cab with HVAC temperature and five different mode controls, lockable full doors with power windows and a fixed front glass windshield. Additional features include an electronically controlled power tilt bed to dump heavy loads with ease, an overhead switch panel for easy accessorization, and an overhead rear work light to illuminate the cargo box in low-light conditions. NorthStar Premium comes stock with 30" Kenda® CrossTrail tires and available 32" tires to overcome large obstacles and tough terrain.
2024 RANGER XD 1500 NorthStar Ultimate: Starting at US $44,999 / CAN $54,499
Rounding out the lineup is the RANGER XD 1500 NorthStar Ultimate, which features everything from the NorthStar Premium trim, plus the 7" infotainment display powered by RIDE COMMAND and heated seats. The NorthStar Ultimate trim also delivers an immersive sound experience, featuring full AM/FM radio with Bluetooth® streaming capability and industry-exclusive JBL® speakers for precise audio and premium sound. Finally, the vehicle comes standard with RIDE COMMAND+, allowing for vehicle health monitoring and more.
The 2024 RANGER XD 1500 lineup is expected to begin shipping to dealers in late summer. To learn more about the 2024 RANGER family, please visit https://ranger.polaris.com/en-us/ or join the conversation and follow on Facebooksm, Instagramsm, YouTubesm and Twittersm.
About Polaris
As the global leader in powersports, Polaris Inc. (NYSE: PII) pioneers product breakthroughs and enriching experiences and services that have invited people to discover the joy of being outdoors since our founding in 1954. Polaris' high-quality product line-up includes the Polaris RANGER®, RZR® and Polaris GENERAL™ side-by-side off-road vehicles; Sportsman® all-terrain off-road vehicles; military and commercial off-road vehicles; snowmobiles; Indian Motorcycle® mid-size and heavyweight motorcycles; Slingshot® moto-roadsters; Aixam quadricycles; Goupil electric vehicles; and pontoon and deck boats, including industry-leading Bennington pontoons. Polaris enhances the riding experience with a robust portfolio of parts, garments, and accessories. Proudly headquartered in Minnesota, Polaris serves more than 100 countries across the globe. www.polaris.com
Warning: vehicle rollaway can cause serious injury or death. This vehicle can roll whenever the gear selector is not in the park position. Always shift to park when stopping the engine or leaving the vehicle. When leaving the vehicle on an incline is unavoidable, use extra care. If leaving the vehicle unattended, block the rear wheels on the downhill side and keep children, pets, and others away form the gear selector. Notice: Vehicle payload and trailer weight will affect the angle of hill on which the vehicle will hold.
Kenda® is a registered trademark of Kenda Rubber Industrial Co, Ltd.
Bluetooth® is a registered trademark of Bluetooth Sig, Inc.
JBL® is a registered trademark of Harman International Industries, Incorporated
Rhino-Rack® is a registered trademark of Rhino Rack Australia Pty Limited
Unless noted, trademarks are the property of Polaris Industries Inc.
View original content to download multimedia:
SOURCE Polaris Inc. | https://www.wkyt.com/prnewswire/2023/07/31/polaris-expands-its-ranger-lineup-with-all-new-ranger-xd-1500-an-entirely-new-class-extreme-duty-utility-side-by-sides/ | 2023-07-31T11:24:46 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/polaris-expands-its-ranger-lineup-with-all-new-ranger-xd-1500-an-entirely-new-class-extreme-duty-utility-side-by-sides/ |
OSHKOSH, Wis (WFRV) – Tragedy strikes the 70th annual Experimental Aircraft Association Airshow, two accidents involving airshow attendees took place on the same day resulting in multiple deaths.
EAA communications director Dick Knapinski says authorities have identified the victims of the crash.
“About 12:24 pm on Saturday we did have the gyrocopter and the helicopter have a midair collision down at the Southend of the Regional Whittman Airport flight line, we have identified the two deceased who were both in the router way helicopter, the pilot Mark Peterson age 69 of Foley, Alabama, his passenger was Thomas Volz age 72 of Amelia, Ohio, “stated Knapinski.
“They did identify the victims from the t-26 accident Saturday morning, the pilot would be 30-year-old Devyn Reilly of Guadalupe, Texas, and the passenger 20-year-old Zach Koly Merano we do not have an immediate hometown on him,” said Knapinski.
Knapinski says authorities are investigating the cause of the accidents.
“The NTSB is investigating obviously somebody was in the wrong place at the wrong time, now we have to find out why they were in the wrong place at the wrong time,” explained Knapinski.
EAA chief executive officer Jack Pelton pays his respects to those who lost their lives while flying.
“We’ve been working with the families that were involved and I think we did a good job of responding and making the first response and dealing with the families as best we could, it’s tough there’s a family here as you know and you never like to see anything happen to anybody and we’ll recover and figure out the next steps,” stated Pelton.
We will keep you updated with this story on air and online as more information is presented. | https://www.wearegreenbay.com/news/local-news/tragedy-strikes-70th-experimental-aircraft-association-airshow-multiple-plane-crashes-resulting-in-4-deaths/ | 2023-07-31T11:24:48 | 0 | https://www.wearegreenbay.com/news/local-news/tragedy-strikes-70th-experimental-aircraft-association-airshow-multiple-plane-crashes-resulting-in-4-deaths/ |
16TH annual event features turtles named after characters in Disney's frighteningly fun adventure movie, "Haunted Mansion," now playing in theaters.
VERO BEACH, Fla., July 31, 2023 /PRNewswire/ -- Over the weekend at Disney's Vero Beach Resort, researchers from the Sea Turtle Conservancy (STC) and Disney Conservation released two sea turtles as part of the 16th annual Tour de Turtles "migration marathon." Tour de Turtles is a fun, educational event that follows the migration of sea turtles from their nesting beaches to their feeding grounds and, ultimately, provides scientific data on how best to protect their species.
The Disney Conservation Fund (DCF) and Disney Cruise Line are each sponsoring a turtle this year, whose names, Madame Leota and Harriet, are the names of characters in Disney's frighteningly fun adventure movie "Haunted Mansion," now playing in theaters. Not unlike Gabbie, another character in the film who enlists a motley crew of so-called spiritual experts to help rid their home of supernatural squatters – Tour de Turtles brings together a team of researchers from the STC and Disney Conservation annually to undertake a daunting mission - using satellite telemetry to track two female turtles to determine where and how far they swim during the migration season.
Each turtle swims to raise awareness about various threats to sea turtle survival. The turtle to swim the furthest distance will win the Tour de Turtles race.
"Disney's commitment to sea turtle conservation in Vero Beach spans 20 years, and we are very proud to have recently watched our 1.5 millionth sea turtle hatchling leave the nest and shuffle its way to the ocean," said Mark Penning, Vice President of Disney's Animals, Science and Environment. "Southeast Florida hosts one of the largest nesting aggregations of loggerhead sea turtles, making up to 40 percent of the global loggerhead population. The team has recorded more than 20,000 sea turtle nests on our survey route since the program began."
The data collected during Tour de Turtles helps researchers, conservationists and governing agencies make more informed decisions about sea turtle conservation and management. Since the launch of the event in 2008, STC and Disney have collaborated to study 29 sea turtles outfitted with satellite transmitters and released from Disney's Vero Beach Resort. Continuing its commitment to strengthen youth education programs in port communities around the world, Disney Cruise Line proudly supported local students from Club Esteem from Melbourne, Florida, to participate in this year's event. DCF also has directed more than $5.1 million to support global sea turtle conservation efforts.
"Disney is a fantastic collaborator," said David Godfrey, STC Executive Director. "Disney's commitment to conservation, passion for environmental education, and effectiveness at communicating with audiences have made the Tour de Turtles a fun and successful program since it was launched over a decade ago."
In addition to Tour de Turtles, the Disney Conservation team has dedicated nearly 19,000 hours to studying and monitoring sea turtle nests during the summer nesting season along the five-mile coastline at Disney's Vero Beach Resort. From approximately May to October, Disney Vacation Club members and resort guests also have the opportunity to assist the team by joining outings to observe real-time sea turtle research while learning how they can take action to protect sea turtles. So far this year, the Disney Conservation team has a record-breaking number of nests along their survey route – nearly 2,000 by August, well above the average 1,500 normally counted in an entire season.
Tour de Turtles is a research and education program of the Sea Turtle Conservancy and Disney's support is just one example of bringing Disney Planet Possible to life by taking action to make a happier, healthier planet possible for all. To learn more and follow the turtles' migration, visit the Tour de Turtles website at www.tourdeturtles.org
ABOUT DISNEY'S VERO BEACH RESORT
Disney's Vero Beach Resort, a Disney Vacation Club Resort, offers spacious vacation villas along the pristine Atlantic coastline. The resort is located less than a two-hour drive from the Walt Disney World Resort, and its design reflects the Treasure Coast region where it is situated. Disney Vacation Club, a leader in vacation ownership, debuted in 1991 with a flexible, vacation points-based system rather than the traditional fixed-week timeshare model. Disney Vacation Club Members are able to choose from among a variety of exciting vacation destinations, including a stay at any Disney Vacation Club Resort or one of thousands of other vacation options in destinations around the world.
ABOUT DISNEY'S "HAUNTED MANSION"
Inspired by the classic theme park attraction, Disney's "Haunted Mansion" is about a woman and her son who enlist a motley crew of so-called spiritual experts to help rid their home of supernatural squatters.
Directed by Justin Simien, the film features an all-star cast ensemble including LaKeith Stanfield, Tiffany Haddish, Owen Wilson, Danny DeVito, Rosario Dawson, Chase W. Dillon and Daniel Levy, with Jamie Lee Curtis and Jared Leto as The Hatbox Ghost. The film's producers are Dan Lin and Jonathan Eirich, with Nick Reynolds and Tom Peitzman serving as executive producers.
View original content to download multimedia:
SOURCE Walt Disney World | https://www.1011now.com/prnewswire/2023/07/31/tour-de-turtles-celebrates-sea-turtles-supernatural-science-disneys-vero-beach-resort/ | 2023-07-31T11:24:47 | 1 | https://www.1011now.com/prnewswire/2023/07/31/tour-de-turtles-celebrates-sea-turtles-supernatural-science-disneys-vero-beach-resort/ |
Highlights Include the Return of Polaris Sportsman 570 and XP 1000 Hunt Editions, Along with a Host of
Aesthetic and Performance Upgrades Across the Lineup
MINNEAPOLIS, July 31, 2023 /PRNewswire/ -- On the heels of debuting its innovative Polaris XPEDITION and the all new Extreme Duty RANGER XD 1500, Polaris Off Road today unveiled updates for 2024 to the off-road industry's most expansive lineup. The 2024 lineup features a host of rider-inspired updates and refreshed styling and new colors. Additionally, the customer-favorite Polaris Sportsman 570 and XP 1000 Hunt editions make a return, and a Premium trim offering is now available on the 2024 GENERAL 1000 to provide customers with an upgrade in style and performance. RIDE COMMAND+ also received enhanced features for 2024, delivering unmatched connectivity and peace of mind to riders through all-new Location Bump Alerts and Check-In Messages.
"From the completely redesigned 2024 RZR XP and the industry's first "adventure side-by-side" Polaris XPEDITION, to our introduction of the all-new RANGER XD 1500, this year has been a powerful showcase of our ongoing commitment to lead the industry and innovate for our riders," said Steve Menneto, President of Polaris Off Road. "While those revolutionary product debuts are pivotal, our unwavering focus on refining and enhancing our current offerings based on customer needs and feedback remains essential, and that's what the 2024 updates represent."
From fresh new styles and colorways, to improved trim levels that appeal to a wide variety of riders, the Polaris Off Road 2024 model year lineup and RIDE COMMAND+ technology enhancements include the following:
RIDE COMMAND+:
Making its debut last fall, RIDE COMMAND+, the industry's first connected-vehicle technology, continues to roll out new enhancements to its service for 2024. With new features like Location Alerts, that will notify the owner if its vehicle has been bumped or moved from its last location, owners can now protect their vehicle more than ever before. RIDE COMMAND+ is now available as a factory option for 2024 RZR Pro R Ultimate, RANGER XD 1500 NorthStar, RANGER XP 1000 NorthStar, Polaris XPEDITION NorthStar and Sportsman XP 1000 RIDE COMMAND Edition. This service is also available on most 2024 RZR, RANGER, Sportsman and Polaris XPEDITION models as an accessory install.
Sportsman
Polaris Sportsman, the long-standing No. 1 selling automatic 4x4 ATV, is reintroducing the Sportsman 570 and XP 1000 Hunt Editions, while also implementing key improvements across the core 2024 lineup. A customer favorite, specifically designed to meet the unique needs of hunters, the Sportsman 570 and XP 1000 Hunt editions include accessories such as the 3,500 lb Polaris Winch, Kolpin Gun Scabbard & Mount, Kolpin Ratchet Claws and more.
Additionally, the 2024 Sportsman 450 and 570 lineup boasts several quality refinements for a better riding experience including a new rear brake pedal for reduced pedal effort and feel, improved sealing around the shifter, and enhanced seat fitment delivering a more comfortable ride. The 570 EPS trim and above will also include enhanced PVT clutch sealing with a higher intake location for better performance in wet conditions.
For added utility, the model year 2024 Sportsman 570 lineup will be equipped with new LED lights for the Premium and Utility HD for added visibility from dawn to dusk.
New color options also are available for the 570 Premium and Trail, 570 Ride Command Edition, Sportsman 850 Premium and Ultimate Trail, Sportsman XP 1000 Ultimate Trail, Sportsman XP 1000 High Lifter Edition, Scrambler XP 1000 S and Sportsman XP 1000 S.
The 2024 Sportsman lineup starts at $6,999 US MSRP and will begin shipping to dealers this early fall. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/sportsman/
GENERAL
Polaris GENERAL is the industry's most versatile crossover side-by-side, capable of tackling tough trails, while also knocking out tasks around the property. For 2024, the GENERAL 1000 receives a new Premium trim offering that provides both style and performance enhancements. Featuring 14" wheels with 27" Coronado tires, and FOX® Podium QS3® shocks that riders can adjust between soft, medium and firm based on terrain changes, the new Premium trim will deliver a smooth ride over rugged terrain, while LED headlights provide greater visibility at morning and night. These upgrades will help riders knock out more tasks and hit the trails confidently in the GENERAL 1000.
Additionally, new colorways on the GENERAL 1000 model include Ghost Gray and Volcanic Orange. The Premium and Ultimate trim levels for the GENERAL XP will feature new colors and graphics in Matte Silver Quartz and Polaris Blue.
The 2024 GENERAL lineup starts at $17,499 US MSRP and will begin shipping to dealers this summer. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/general/
RZR
Polaris RZR, the No. 1 sport side-by-side brand, receives fresh new colors and graphics across its lineup, helping riders make a bold statement when hitting the trails. The 2024 RZR Trail and RZR Trail S are now available in Storm Blue on the Sport trim and two-tone Storm Blue with White Lightning on the Ultimate. Both Sport and Ultimate trim levels now receive the same upgraded steering wheel offered in the fully-redesigned 2024 RZR XP that provides a sportier feel while driving on trails. New for 2024, the RZR Trail and Trail S Sport level feature electric power steering and LED headlights standard, providing riders easier steering input on tight trail corners and enhanced visibility. Additionally for 2024, the RZR Trail S Ultimate trim now features Walker Evans Racing® shocks, while the Sport trim moved to ZF Sachs shocks, both offering riders plush suspension performance against the rugged terrain.
For 2024, the RZR Pro XP Sport and Premium models feature Walker Evans Racing® shocks, while the Ultimate will continue to be equipped with FOX® Live Valve shocks with DYNAMIX active suspension. Both the Premium and Ultimate trim received a refresh with new graphics on the Super Graphite colorway.
Lastly and by consumer demand, the Wide Open lineup of RZR Pro R and RZR Turbo R receives refreshed color options for 2024. For the first time since launching, the RZR Pro R Ultimate is available in an all-new Matte Onyx Black with Lifted Lime accents or Matte Heavy Metal, while the Premium trim level is offered in Matte Heavy Metal. The 2024 RZR Turbo R also welcomes vibrant new colors like Velocity Blue with Green Burst accents and Military Tan with Orange Burst accents.
The 2024 RZR lineup starts at $15,999 US MSRP and will begin shipping to dealers this fall. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/rzr/
RANGER
In addition to the newly launched Extreme Duty RANGER XD 1500, the Polaris RANGER lineup receives a variety of rider-inspired upgrades and quality refinements for 2024. RANGER SP 570 gets new color options, while the NorthStar Edition gets exclusive tailgate badging and new 25" 8-ply Pro Armor X-Terrain tires for added durability and enhanced puncture resistance.
Additionally, Polaris expands the color options for the RANGER 1000 Premium which will now be offered in the sleek Granite Grey color and graphics, while the XP 1000 will be featured in two new options: Desert Sand and Super Graphite with orange burst accents. Furthermore, the RANGER XP 1000 NorthStar Ultimate model boasts connectivity features such as vehicle health, issue diagnostics, and maintenance reminders enabled by RIDE COMMAND+.
The 2024 RANGER lineup starts at $11,699 US MSRP and will begin shipping to dealers this fall. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/ranger/
Youth
Dedicated to inspiring the next generation of riders, Polaris Off Road delivers the industry's largest and most varied lineup of youth offerings. For 2024, the Polaris ORV Youth lineup receives a refresh with eye-catching new colors and graphics. This lineup continues to provide industry-leading safety features that give parents peace of mind and help instill confidence in growing riders, including pin code start, adjustable speed limiter, geofencing, helmet aware technology and industry-exclusive safety gear kit.
Specifically, the 2024 RZR 200 EFI is now offered in Storm Gray and a new graphic pattern with bright red accents. The Outlaw 70 EFI ATV is offered in Velocity Blue with either Lifted Lime or Fierce Fuchsia accents, while the Outlaw 110 EFI is now offered in both Bright White with Polaris Blue and Bright White with Radiant Green details.
The 2024 Polaris Youth lineup starts at $2,999 US MSRP and will begin shipping to dealers this winter. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/shop-by-use/youth/
Polaris XPEDITION
The Polaris XPEDITION, which recently launched in May 2023, is the first-of-its-kind adventure side-by-side, combining the all-terrain capabilities of traditional side-by-sides with comfort and cargo capabilities typically associated with overlanding at the highest level. With a host of standard features and optional configurations to accommodate the greatest range of outdoor pursuits and enable consumers to keep chasing the wild, the 2024 Polaris XPEDITION XP and ADV are the most adaptable, comfortable and capable adventure machine on the market.
The 2024 Polaris XPEDITION lineup starts at $28,999 US MSRP and is currently shipping to dealers. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/polaris-xpedition/
To learn more about the Polaris ORV 2024 lineup and to stay up to date on testing and demo opportunities, please visit https://offroad.polaris.com/en-us/ or join the conversation and follow on FacebookSM, InstagramSM, YouTubeSM and TwitterSM. Walker Evans Racing® is a registered trademark of Walker Evans Enterprises Incorporated; FOX® is a registered trademark of Fox Factory Inc.
About Polaris
As the global leader in powersports, Polaris Inc. (NYSE: PII) pioneers product breakthroughs and enriching experiences and services that have invited people to discover the joy of being outdoors since our founding in 1954. Polaris' high-quality product line-up includes the Polaris RANGER®, RZR® and Polaris GENERAL™ side-by-side off-road vehicles; Sportsman® all-terrain off-road vehicles; military and commercial off-road vehicles; snowmobiles; Indian Motorcycle® mid-size and heavyweight motorcycles; Slingshot® moto-roadsters; Aixam quadricycles; Goupil electric vehicles; and pontoon and deck boats, including industry-leading Bennington pontoons. Polaris enhances the riding experience with a robust portfolio of parts, garments, and accessories. Proudly headquartered in Minnesota, Polaris serves more than 100 countries across the globe. www.polaris.com
View original content to download multimedia:
SOURCE Polaris Inc. | https://www.wkyt.com/prnewswire/2023/07/31/polaris-off-road-stays-gas-with-2024-lineup-featuring-rider-inspired-updates-amp-refreshed-styles-its-industry-leading-range-side-by-sides-atvs/ | 2023-07-31T11:24:53 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/polaris-off-road-stays-gas-with-2024-lineup-featuring-rider-inspired-updates-amp-refreshed-styles-its-industry-leading-range-side-by-sides-atvs/ |
NEW YORK (AP) — Six straight days of 12-hour driving. Single digit paychecks. The complaints come from workers in vastly different industries: UPS delivery drivers and Hollywood actors and writers.
But they point to an underlying factor driving a surge of labor unrest: The cost to workers whose jobs have changed drastically as companies scramble to meet customer expectations for speed and convenience in industries transformed by technology.
The COVID-19 pandemic accelerated those changes, pushing retailers to shift online and intensifying the streaming competition among entertainment companies. Now, from the picket lines, workers are trying to give consumers a behind-the-scenes look at what it takes to produce a show that can be binged any time or get dog food delivered to their doorstep with a phone swipe.
Overworked and underpaid employees is an enduring complaint across industries — from delivery drivers to Starbucks baristas and airline pilots — where surges in consumer demand have collided with persistent labor shortages. Workers are pushing back against forced overtime, punishing schedules or company reliance on lower-paid, part-time or contract forces.
At issue for Hollywood screenwriters and actors staging their first simultaneous strikes in 40 years is the way streaming has upended entertainment economics, slashing pay and forcing showrunners to produce content faster with smaller teams.
“This seems to happen to many places when the tech companies come in. Who are we crushing? It doesn’t matter,” said Danielle Sanchez-Witzel, a screenwriter and showrunner on the negotiating team for the Writers Guild of America, whose members have been on strike since May. Earlier this month, the Screen Actors Guild–American Federation of Television and Radio Artists joined the writers’ union on the picket line.
Actors and writers have long relied on residuals, or long-term payments, for reruns and other airings of films and televisions shows. But reruns aren’t a thing on streaming services, where series and films simply land and stay with no easy way, such as box office returns or ratings, to determine their popularity.
Consequently, whatever residuals streaming companies do pay often amount to a pittance, and screenwriters have been sharing tales of receiving single digit checks.
Adam Shapiro, an actor known for the Netflix hit “Never Have I Ever,” said many actors were initially content to accept lower pay for the plethora of roles that streaming suddenly offered. But the need for a more sustainable compensation model gained urgency when it became clear streaming is not a sideshow, but rather the future of the business, he said.
“Over the past 10 years, we realized: ‘Oh, that’s now how Hollywood works. Everything is streaming,’” Shapiro said during a recent union event.
Shapiro, who has been acting for 25 years, said he agreed to a contract offering 20% of his normal rate for “Never Have I Ever” because it seemed like “a great opportunity, and it’s going to be all over the world. And it was. It really was. Unfortunately, we’re all starting to realize that if we keep doing this we’re not going to be able to pay our bills.”
Then there’s the rising use of “mini rooms,” in which a handful of writers are hired to work only during pre-production, sometimes for a series that may take a year to be greenlit, or never get picked up at all.
Sanchez-Witzel, co-creator of the recently released Netflix series “Survival of the Thickest,” said television shows traditionally hire robust writing teams for the duration of production. But Netflix refused to allow her to keep her team of five writers past pre-production, forcing round-the-clock work on rewrites with just one other writer.
“It’s not sustainable and I’ll never do that again,” she said.
Sanchez-Witzel said she was struck by the similarities between her experience and those of UPS drivers, some of whom joined the WGA for protests as they threatened their own potentially crippling strike. UPS and the Teamsters last week reached a tentative contract staving off the strike.
Jeffrey Palmerino, a full-time UPS driver near Albany, New York, said forced overtime emerged as a top issue during the pandemic as drivers coped with a crush of orders on par with the holiday season. Drivers never knew what time they would get home or if they could count on two days off each week, while 14-hour days in trucks without air conditioning became the norm.
“It was basically like Christmas on steroids for two straight years. A lot of us were forced to work six days a week, and that is not any way to live your life,” said Palmerino, a Teamsters shop steward.
Along with pay raises and air conditioning, the Teamsters won concessions that Palmerino hopes will ease overwork. UPS agreed to end forced overtime on days off and eliminate a lower-paid category of drivers who work shifts that include weekends, converting them to full-time drivers. Union members have yet to ratify the deal.
The Teamsters and labor activists hailed the tentative deal as a game-changer that would pressure other companies facing labor unrest to raise their standards. But similar outcomes are far from certain in industries lacking the sheer economic indispensability of UPS or the clout of its 340,000-member union.
Efforts to organize at Starbucks and Amazon stalled as both companies aggressively fought against unionization.
Still, labor protests will likely gain momentum following the UPS contract, said Patricia Campos-Medina, executive director of the Worker Institute at the School of Industrial and Labor Relations at Cornell University, which released a report this year that found the number of labor strikes rose 52% in 2022.
“The whole idea that consumer convenience is above everything broke down during the pandemic. We started to think, ‘I’m at home ordering, but there is actually a worker who has to go the grocery store, who has to cook this for me so that I can be comfortable,’” Campos-Medina said. | https://www.wearegreenbay.com/news/national/customers-want-instant-gratification-workers-say-theyre-on-the-brink/ | 2023-07-31T11:24:54 | 0 | https://www.wearegreenbay.com/news/national/customers-want-instant-gratification-workers-say-theyre-on-the-brink/ |
This Launch Marks the Latest Expansion of the Brand's Complexion Offerings as it Doubles Down on The Skincare-Meets-Makeup Hybrid Category
NEW YORK, July 31, 2023 /PRNewswire/ -- TULA Skincare, the leading clinically proven probiotic extract powered skincare brand has announced the expansion of its complexion offerings to include concealer.
After learning that TULA's customers were looking for a skin brightening eye treatment along with a concealer, the brand created a state-of-the-art clean skincare-makeup hybrid that delivers skin-boosting benefits with high-performance medium-to-full coverage.
Available in a 20-shade range, the dermatologist-tested, Radiant Skin Brightening Serum Concealer is infused with TULA's unique Rainbow Seabright™ Elixir. This clinically-proven serum-like formula instantly conceals dark circles and discoloration for longwearing, crease-proof results, while brightening the appearance of skin over time. Additional ingredients include TULA's S6Pro Complex® - a US patent pending super six blend of prebiotics and probiotic extracts to help soothe skin, improve skin smoothness and maintain skin balance, along with eye peptides and tea leaf caffeine to help improve the look of dark circles, skin texture, and eye bags. The Radiant Skin Brightening Serum Concealer can be paired with the brand's Radiant Skin Brightening Serum Skin Tint or Filter Primer Blurring & Moisturizing Primer to help build one's complexion wardrobe, or spot conceal for a no-makeup, makeup look.
"Expanding our complexion category to include a concealer was a natural next step for us, especially knowing the strong desire our customers have had for an eye treatment with brightening benefits." said TULA Skincare CEO, Savannah Sachs. " We are excited to have another offering for our glow getters that will surely be a staple in their skincare and beauty routines."
To mark the launch, TULA will be executing a multi-channel launch campaign across its digital platform, and organic social, paid media, and influencer channels. Efforts will include launching a custom "shade finder" on tula.com to help customers find their perfect match concealer shade, highlighting content speaking to the "no-makeup, makeup" and makeup-skincare hybrid trends across TikTok and Instagram, and partnering with a curated set of influencers and providing them with an early access link exclusively for their followers to purchase the concealer prior to launch. In addition to tula.com, the concealer will launch in Ulta Beauty stores nationwide and online and will be featured in an upcoming issue of the Ulta Beauty Magazine, with in-store complexion events planned in the coming months in multiple doors.
TULA's Radiant Skin Brightening Serum Concealer will be available for purchase on July 31 on tula.com, and will retail for $32.
About TULA Skincare
TULA is a doctor-founded skincare brand built on clinically proven formulas powered by probiotic extracts. We believe that the same types of ingredients which are good for your body are also great for your skin. We focus on being healthy, not perfect and on empowering everyone to feel confident in their skin.
Media Contact: Zoe Jeans at Bux + Bewl Communications: zoe@buxandbewl.com
View original content to download multimedia:
SOURCE TULA Skincare | https://www.1011now.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ | 2023-07-31T11:24:54 | 0 | https://www.1011now.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ |
The Avocados From Mexico® Chocolate Dulce De Leche Cupcake will be available at Sprinkles bakeries nationwide for one week beginning July 31
DALLAS, July 31, 2023 /PRNewswire/ -- Talk about a perfect pairing! Avocados From Mexico®, the number one selling avocado brand in the U.S., is making National Avocado Day even better by partnering with renowned dessert bakery chain Sprinkles for a delicious collaboration – a limited-edition cupcake featuring fresh Mexican avocados.
The Avocados From Mexico® Chocolate Dulce De Leche Sprinkles cupcake is a delectable banana cupcake that's studded with pecans and generously filled with a soft dulce de leche core. And to top it all off? A zesty frosting that blends rich cream cheese and chocolate made with fresh Mexican avocados for a delightful, creamy finish.
"The new Avocados From Mexico Chocolate Dulce De Leche cupcake features the highest quality and best-tasting ingredients," said Sprinkles Vice President, Culinary, Charles Craig. "By blending fresh avocado and smooth cream cheese alongside the banana and dulce de leche cupcake, we were able to elevate all the ingredients resulting in a cupcake that is out-of-this world. We can't wait for fans to try it!"
Beginning on July 31, National Avocado Day, consumers can make their week better by enjoying Avocados From Mexico in cupcake form — available at Sprinkles nationwide through August 6.
"Avocados From Mexico make everything better, and we're so proud that our avocados will get to shine in a unique way on National Avocado Day," said Kelly Burke, Director of Brand Marketing at Avocados From Mexico. "Our brand is known for bringing the good times with great tasting avocados. We are excited to partner with a beloved brand like Sprinkles to spark good times in a new way with everyone's favorite sweet treat."
"Sprinkles Cupcakes has always taken an innovative approach to classic desserts, and this new collaboration with Avocados From Mexico is no exception," said Sprinkles CMO, Michelle Wong. "Avocados From Mexico was an obvious choice for their quality and taste, and we can't wait for our guests to discover our latest cupcake, starring this beloved fruit."
To learn more about Avocados From Mexico, visit https://avocadosfrommexico.com, Facebook (facebook.com/avocadosfrommexico), Instagram (@avocadosfrommexico) or Twitter (@AvosFromMexico). #MakeItBetter #AFMxSprinkles
About Avocados From Mexico
Avocados From Mexico is a wholly-owned subsidiary of the Mexican Hass Avocado Importers Association (MHAIA), formed for the purpose of advertising, promotion, public relations and research for all stakeholders of Avocados From Mexico. Under agreements, MHAIA and the Association of Avocado Exporting Producers & Packers of Mexico (APEAM) have combined resources to fund and manage Avocados From Mexico, with the intent to provide a focused, highly- effective and efficient marketing program in the United States. Avocados From Mexico is headquartered in Irving, Texas.
About Sprinkles
Sprinkles offers premium cupcakes, cakes and cookies that are baked fresh in small batches throughout the day and handcrafted with only the finest ingredients. Sprinkles opened its first bakery in Beverly Hills in 2005, drawing long lines of loyal cupcake fans and celebrity endorsements. Sprinkles prides themselves in being passionate innovators and since debuting the world's first Cupcake ATM, the brand has introduced layer cakes, cookies and brownies, launched a national shipping platform and has grown to over 70 bakeries and ATMs coast-to-coast. Sprinkles launched domestic and international franchising in 2022. For additional information on Sprinkles, follow @sprinklescupcakes on social and visit www.sprinkles.com.
CONTACT: Ana Ambrosi, aambrosi@avocadosfrommexico.com
View original content to download multimedia:
SOURCE Avocados From Mexico | https://www.wkyt.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ | 2023-07-31T11:24:59 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ |
(The Hill) – Dozens of former Cabinet officials under former President Trump’s administration declined to publicly support the former president’s third bid for the White House, NBC News reported.
NBC News reached out to 44 people who previously served in Trump’s Cabinet during his four years in office to gauge whether they would support the former president during the 2024 presidential election. The outlet reported that most of the people declined to comment or ignored the requests and that only four said publicly they would support Trump for the presidency.
Trump’s Cabinet saw a higher rate of turnover compared with many of his predecessors, with many new officials rotating in and out of his administration over the four years. The only four former Cabinet members who NBC News reached out to who said they would support Trump are former acting Attorney General Matthew Whitaker, former chief of staff Mark Meadows, former Office of Management and Budget (OMB) director Russell Vought and former acting director of national intelligence Richard Grenell.
A spokesperson for Meadows told NBC News that he “fully” supports Trump. In May, Vought posted on X, the site formerly known as Twitter, that the former president is “the only person I trust to take a wrecking ball to the Deep State.”
Other former administration officials were reluctant to support Trump or have publicly said they will not support him. Former Attorney General Bill Barr told NBC News that he opposes Trump getting the 2024 GOP nomination but declined whether to say he would support him in the general election if pitted against President Biden.
Top Stories from The Hill
- White House takes the gloves off ahead of 2024
- Trump attorney calls him ‘the most ethical American I know’ in wake of superseding indictment
- Murphy says Alito’s Supreme Court seat ‘exists only because of an act passed by Congress’
- Trump attorney calls him ‘the most ethical American I know’ in wake of superseding indictment
Former chief of staff Mick Mulvaney also said that he does not want Trump to get the Republican nomination for president.
“I am working hard to make sure that someone else is the nominee,” Mulvaney told NBC News. “I think he’s the Republican who is most likely to lose in a general election, of all our leading candidates. If anyone can lose to Joe Biden, it would be him.”
Other former officials who have not endorsed Trump yet include former Secretary of State Mike Pompeo, former Defense Secretary Patrick Shanahan, former chief of staff John Kelly and Joseph Maguire and Dan Coats, who each once served as director of national intelligence. Coats told NBC News that he would be supporting former Vice President Mike Pence for the GOP primary.
The Hill has reached out to Trump’s campaign for comment. | https://www.wearegreenbay.com/news/national/dozens-of-former-trump-cabinet-officials-wont-publicly-support-his-2024-bid/ | 2023-07-31T11:25:00 | 1 | https://www.wearegreenbay.com/news/national/dozens-of-former-trump-cabinet-officials-wont-publicly-support-his-2024-bid/ |
Launch demonstrates companies' commitment to bringing complex generic medicines to the market to help increase patient access
PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.
Viatris Head of North America Jose Cotarelo said: "We are excited to bring Breyna to the U.S. market for the many Americans living with asthma and COPD. This launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain. Being the first to bring an FDA-approved generic version of Symbicort to patients is a true example of how access is the cornerstone of our mission to empower people worldwide to live healthier at every stage of life."
The indications for Breyna include asthma in patients six years of age and older, and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD, including chronic bronchitis and/or emphysema. Breyna is not indicated for the relief of acute bronchospasm. The 160 mcg/4.5 mcg is the only strength indicated for the treatment of COPD. COPD is a term used to describe a certain kind of chronic lung disease and is characterized by breathlessness; it affects more than 16 million Americans. Asthma causes swelling of the airways resulting in difficulty breathing, and approximately 25 million Americans have the chronic condition.
Milton Boyer, CEO of Kindeva Drug Delivery, added: "The launch of Breyna represents a significant milestone as it is the first FDA-approved generic version of Symbicort in the U.S., one of the most prescribed complex drug-device combination products to treat asthma and COPD. We are pleased for Viatris as well as the many Kindeva colleagues who have worked tirelessly to leverage our complex drug-delivery expertise for this important respiratory product — supporting a persistent need to continue bringing more quality medicines for asthma and COPD to patients."
To further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply. The program offers $30/month or up to $360 per year with 12 refills annually. The program will be available in August.
About Breyna
Breyna is indicated for the treatment of asthma in patients 6 years and older not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonists (LABA). Breyna 160 mcg/4.5 mcg dosage is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and Breyna 160 mcg/4.5 mcg is also indicated to reduce exacerbations of COPD. Breyna is NOT indicated for the relief of acute bronchospasm.
Important Safety Information
Breyna is contraindicated in the primary treatment of status asthmaticus or other acute episode of asthma or COPD where intensive measures are required, and in hypersensitivity to any of the ingredients in Breyna. Use of long-acting beta2-adrenergic agonists (LABA) as monotherapy (without inhaled corticosteroids [ICS]) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinial trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA. When LABA are used in fixed dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone. Breyna is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms. Breyna should not be initiated in patients during rapidly deteriorating episodes of asthma or COPD. Patients who are receiving Breyna should not use additional formoterol or other LABA for any reason. Localized infections of the mouth and pharynx with Candida albicans has occurred in patients treated with Breyna. Patients should rinse the mouth after inhalation of Breyna. Lower respiratory tract infections, including pneumonia, have been reported following the administration of ICS. Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients. It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may occur, particularly at higher doses. Particular care is needed for patients who are transferred from systemically active corticosteroids to ICS. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available ICS. Caution should be exercised when considering administration of Breyna in patients on long-term ketoconazole and other known potent CYP3A4 inhibitors. As with other inhaled medications, paradoxical bronchospasm may occur with Breyna. Immediate hypersensitivity reactions may occur, as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm. Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. Breyna should be used with caution in patients with cardiovascular disorders especially coronary insufficiency, cardiac arrhythmias, and hypertension. Long-term use of ICS may result in a decrease in bone mineral density (BMD Assessment of BMD is recommended prior to initiating Breyna and periodically thereafter. ICS may result in a reduction in growth velocity when administered to pediatric patients. Glaucoma, increased intracolular pressure, and cataracts have been reported following the administration of ICS, including budesonide, a component of Breyna. Close monitoring for glaucoma and cataracts is warranted in patients with a change in vision or history of increased intraocular pressure. In rare cases, patients on ICS may present with systemic eosinophilic conditions. Breyna should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines. The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis. The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection. Breyna should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents. Beta-blockers may not only block the pulmonary effect of beta-agonists, such as formoterol, but may produce severe bronchospasm in patients with asthma. ECG changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. Use caution with the coadministration of Breyna.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development manufacturing organization focused on drug-device combination products. Kindeva Drug Delivery develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary & nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva Drug Delivery serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements that the launch of Breyna demonstrates the companies' commitment to bringing complex generic medicines to the market to help increase patient access; Breyna will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths; this launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain; to further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply; and, the program will be available in August. Factors that could cause or contribute to such differences include, but are not limited to: the possibility that the Company may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives; the possibility that the Company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with acquisitions, divestitures, or its global restructuring program, within the expected timeframe or at all; impairment charges or other losses related to the divestiture or sale of businesses or assets; the Company's failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by COVID-19; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, inflation and exchange rates; failure to execute stock repurchases consistent with current expectations; stock price volatility; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.
View original content to download multimedia:
SOURCE Viatris Inc. | https://www.1011now.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ | 2023-07-31T11:25:00 | 0 | https://www.1011now.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ |
SHENZHEN, China, July 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company" or "Taoping"), today announced that the board of directors of the Company approved a one-for-ten reverse stock split of the Company's issued and outstanding ordinary shares, no par value (the "Ordinary Shares"). Beginning August 1, 2023, the Company's Ordinary Shares will be trading on a split-adjusted basis under the same symbol "TAOP" but with new CUSIP number, G8675V 127.
As a result of the share consolidation, each ten Ordinary Shares outstanding will automatically combine and convert to one issued and outstanding Ordinary Share without any action on the part of shareholders who hold their shares in brokerage accounts or "street name". Shareholders holding certificates of Ordinary Shares are expected to receive instructions from the Company's transfer agent, Transhare Corporation, regarding procedures for exchanging share certificates. All outstanding options, warrants and other rights to purchase the Company's Ordinary Shares will be adjusted proportionately as a result of the reverse stock split. No fractional shares will be issued as a result of the reverse stock split, and instead, all such fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
The reverse stock split is intended to increase the per share trading price of the Ordinary Shares to satisfy the $1.00 minimum bid price requirement for continued listing on the NASDAQ Stock Market. Following the reverse stock split the Company will have approximately 1.86 million Ordinary Shares issued and outstanding, exclusive of shares issuable under outstanding options and warrants. The reverse stock split will not affect the number of total authorized Ordinary Shares of the Company.
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us via LinkedIn, Twitter or YouTube.
Safe Harbor Statement
This press release contains "forward-looking statements" that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, such as statements regarding our estimated future results of operations and financial position, our strategy and plans, and our objectives or goals, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking statements. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: our potential inability to achieve or sustain profitability or reasonably predict our future results due to our limited operating history of providing smart cloud services, the effects of the global Covid-19 pandemic, the emergence of additional competing technologies, changes in domestic and foreign laws, regulations and taxes, uncertainties related to China's legal system and economic, political and social events in China, the volatility of the securities markets; and other risks including, but not limited to, those that we discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 20-F as well as in our other reports filed or furnished from time to time with the SEC. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
View original content to download multimedia:
SOURCE Taoping Inc. | https://www.wkyt.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ | 2023-07-31T11:25:05 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ |
DENVER (AP) — As Denver neared triple-digit temperatures, Ben Gallegos sat shirtless on his porch swatting flies off his legs and spritzing himself with a misting fan to try to get through the heat. Gallegos, like many in the nation’s poorest neighborhoods, doesn’t have air conditioning.
The 68-year-old covers his windows with mattress foam to insulate against the heat and sleeps in the concrete basement. He knows high temperatures can cause heat stroke and death, and his lung condition makes him more susceptible. But the retired brick layer, who survives on about $1,000 a month largely from Social Security, says air conditioning is out of reach.
“Take me about 12 years to save up for something like that,” he said. “If it’s hard to breathe, I’ll get down to emergency.”
As climate change fans hotter and longer heat waves, breaking record temperatures across the U.S. and leaving dozens dead, the poorest Americans suffer the hottest days with the fewest defenses. Air conditioning, once a luxury, is now a matter of survival.
As Phoenix weathered its 27th consecutive day above 110 degrees (43 Celsius) Wednesday, the nine who died indoors didn’t have functioning air conditioning, or it was turned off. Last year, all 86 heat-related deaths indoors were in uncooled environments.
“To explain it fairly simply: Heat kills,” said Kristie Ebi, a University of Washington professor who researches heat and health. “Once the heat wave starts, mortality starts in about 24 hours.”
It’s the poorest and people of color, from Kansas City to Detroit to New York City and beyond, who are far more likely to face grueling heat without air conditioning, according to a Boston University analysis of 115 U.S. metros.
“The temperature differences … between lower-income neighborhoods, neighborhoods of color and their wealthier, whiter counterparts have pretty severe consequences,” said Cate Mingoya-LaFortune of Groundwork USA, an environmental justice organization. “There are these really big consequences like death. … But there’s also ambient misery.”
Some have window units that can offer respite, but “in the dead of heat, it don’t do nothing,” said Melody Clark, who stopped Friday to get food at a nonprofit in Kansas City, Kansas, as temperatures soared to 101, and high humidity made it feel like 109. When the central air conditioning at her rental house went on the fritz, her landlord installed a window unit. But it doesn’t do much during the day.
So the 45-year-old wets her hair, cooks outside on a propane grill and keeps the lights off indoors. She’s taken the bus to the library to cool off. At night she flips the box unit on, hauling her bed into the room where it’s located to sleep.
As far as her two teenagers, she said: “They aren’t little bitty. We aren’t dying in the heat. … They don’t complain.”
While billions in federal funding have been allocated to subsidize utility costs and the installation of cooling systems, experts say they often only support a fraction of the most vulnerable families and some still require prohibitive upfront costs. Installing a centralized heat pump system for heating and cooling can easily reach $25,000.
President Joe Biden announced steps on Thursday to defend against extreme heat, highlighting the expansion of the Low Income Home Energy Assistance Program, which funnels money through states to help poorer households pay utility bills.
While the program is critical, said Michelle Graff, who studies the subsidy at Cleveland State University, only about 16% of the nation’s eligible population is actually reached. Nearly half of states don’t offer the federal dollars for summer cooling.
“So people are engaging in coping mechanisms, like they’re turning on their air conditioners later and leaving their homes hotter,” Graff said.
While frigid temperatures and high heating bills birthed the term “heat or eat,” she said, “we can now transition to AC or eat, where people are going to have to make difficult decisions.”
As temperatures rise, so does the cost of cooling. And temperatures are already hotter in America’s low-income neighborhoods like Gallegos’ Denver suburb of Globeville, where people live along stretches of asphalt and concrete that hold heat like a cast-iron skillet. Surface temperatures there can be roughly 8 degrees hotter than in Denver’s wealthier neighborhoods, where a sea of vegetation cools the area, according to the environmental advocacy group American Forests.
This disparity plays out nationwide. Researchers at the University of San Diego analyzed 1,056 counties and in over 70%, the poorest areas and those with higher Black, Hispanic and Asian populations were significantly hotter.
About one in 10 U.S. households have no air conditioning, a disparity compounded for marginalized groups, according to a study by the Brookings Institution. Less than 4% of Detroit’s white households don’t have air conditioning; it’s 15% for Black households.
At noon on Friday, Katrice Sullivan sat on the porch of her rented house on Detroit’s westside. It was hot and muggy, but even steamier inside the house. Even if she had air conditioning, Sullivan said she’d choose her moments to run it to keep her electricity bill down.
The 37-year-old factory worker pours water on her head, freezes towels to put around her neck, and sits in her car with the air conditioner on. “Some people here spend every dollar for food, so air conditioning is something they can’t afford,” she said.
Shannon Lewis, 38, lived in her Detroit home for nearly 20 years without air conditioning. Lewis’s bedroom was the only place with a window unit, so she’d squeeze her teenager, 8-year-old and 3-year-old-twins into her queen-size bed to sleep, eat meals and watch television.
“So it was like cool in one room and a heat stroke in another,” Lewis said. For the first time, Lewis now has air conditioning through a local non-profit, she said. “We don’t have to sleep or eat in the same room, we are able to come out, sit at the dining room table, eat like a family.”
After at least 54 died during a 2021 heat wave, mostly elderly people without air conditioning, in the Portland area, Oregon passed a law prohibiting landlords from placing blanket bans on air conditioning units. By and large, however, states don’t have laws requiring landlords to provide cooling.
In the federal Inflation Reduction Act, billions were set aside for tax credits and rebates to help families install energy-efficient cooling systems, but some of those are yet to be available. For people like Gallegos, who doesn’t pay taxes, the available credits are worthless.
The law also offers rebates, the kind of state and federal point-of-sale discounts that Amanda Morian has looked into for her 640-square-foot home.
Morian, who has a 13-week-old baby susceptible to hot weather, is desperate to keep her house in Denver’s Globeville suburb cool. She bought thermal curtains, ceiling fans and runs a window unit. At night she tries to do skin-to-skin touch to regulate the baby’s body temperature. When the back door opens in the afternoon, she said, the indoor temperature jumps a degree.
“All of those are just to take the edge off, it’s not enough to actually make it cool. It’s enough to keep us from dying,” she said.
She got estimates from four different companies for installing a cooling system, but every project was between $20,000 and $25,000, she said. Even with subsidies she can’t afford it.
“I’m finding that you have to afford the project in the first place and then it’s like having a bonus coupon to take $5,000 off of the sticker price,” she said.
Lucy Molina, a single mom in Commerce City, one of Denver’s poorest areas, said her home has reached 107 degrees without air conditioning. Nearby, Molina’s two teenage children slurped popsicles to cool off, lingering in front of the open freezer.
For Molina, who bustled around her kitchen on a recent day when temperatures reached 99 degrees outdoors, it’s hard to see any path to a cooling respite.
“We’re just too poor,” she said. | https://www.wearegreenbay.com/news/national/were-just-too-poor-record-heat-waves-reveal-plight-of-americans-without-air-conditioning/ | 2023-07-31T11:25:06 | 0 | https://www.wearegreenbay.com/news/national/were-just-too-poor-record-heat-waves-reveal-plight-of-americans-without-air-conditioning/ |
New nuclear unit now serving customers with clean, reliable energy 24/7
ATLANTA, July 31, 2023 /PRNewswire/ -- Georgia Power declared today that Plant Vogtle Unit 3 has entered commercial operation and is now serving customers and the State of Georgia. The new unit represents a long-term investment in the state's clean energy future and will provide reliable, emissions-free energy to customers for decades to come.
"The Plant Vogtle 3 & 4 nuclear expansion is another incredible example of how Georgia Power is building a reliable and resilient energy future for our state," said Kim Greene, chairman, president and CEO of Georgia Power. "It is important that we make these kinds of long-term investments and see them through so we can continue providing clean, safe, reliable and affordable energy to our 2.7 million customers. Today's achievement is a testament to our commitment to doing just that, and it marks the first day of the next 60 to 80 years that Vogtle Unit 3 will serve our customers with clean, reliable energy."
Vogtle Unit 3 is the first newly-constructed nuclear unit in the U.S. in over 30 years and can power an estimated 500,000 homes and businesses. Once all four units are online, the Plant Vogtle site will be the largest generator of clean energy in the nation and support continued growth in Georgia as more industries, businesses and families come to the state.
"Today is a historic day for the State of Georgia, Southern Company, and the entire energy sector, as we continue transforming the way we power the lives of millions of Americans," said Chris Womack, president and CEO of Southern Company. "With Unit 3 completed, and Unit 4 in the final stages of construction and testing, this project shows just how new nuclear can and will play a critical role in achieving a clean energy future for the United States. Bringing this unit safely into service is a credit to the hard work and dedication of our teams at Southern Company and the thousands of additional workers who have helped build that future at this site, as well as all of the partners who have helped make this day a reality."
Nuclear energy is the only zero-emission baseload energy source available today, offering high reliability, and efficient operations around the clock. Nuclear energy currently provides approximately 25% of Georgia Power's overall energy mix, including the existing units at Plant Vogtle and Georgia's other nuclear facility at Plant Hatch in Baxley, Georgia.
"The Vogtle expansion is an American energy success story and would not be possible without the support of strong public and private partners like our partners at North America's Building Trades Unions," said Tom Fanning, chairman of the Board of Directors for Southern Company. "We continue to appreciate their support and those who have stood with us at the local, state and federal levels to complete this new clean energy source to serve electric customers. Providing leadership in our industry and a commitment to safety and quality are in Southern Company's DNA. Today's milestone at the Vogtle expansion site underscores this legacy, and I couldn't be prouder of the dedication our teams have shown in seeing Unit 3 through to completion."
The final stages of construction and testing continue at Vogtle Unit 4, with the unit projected to be placed in service during the late fourth quarter 2023 or the first quarter of 2024. The unit completed hot functional testing in May, in significantly less time than Unit 3 as the team continues leveraging best practices and learnings from the earlier unit. The Vogtle site has also received nuclear fuel for Unit 4, with a total of 157 fuel assemblies necessary for the safe and reliable startup of the unit.
Also, last week, Georgia Power announced the receipt of the 103(g) finding from the Nuclear Regulatory Commission (NRC) for Vogtle Unit 4. This finding was confirmed in an official letter received by Southern Nuclear and signifies that the new unit has been constructed and will be operated in conformance with the Combined License and NRC regulations. No further NRC findings are necessary in order for Southern Nuclear to load fuel or begin the startup sequence for the new unit.
The new Vogtle units are an essential part of Georgia Power's commitment to delivering clean, safe, reliable and affordable energy to its 2.7 million customers. Southern Nuclear will operate the new units on behalf of the co-owners: Georgia Power, Oglethorpe Power, MEAG Power and Dalton Utilities.
About Georgia Power
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America's premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company's promise to 2.7 million customers in all but four of Georgia's 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), Twitter (Twitter.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).
Cautionary Note Regarding Forward-Looking Statements
Certain information contained in this release is forward-looking information based on current expectations and plans that involve risks and uncertainties. Forward-looking information includes, among other things, statements concerning the projected in-service date for Plant Vogtle Unit 4 and the future operations of Plant Vogtle Units 3 and 4. Georgia Power cautions that there are certain factors that can cause actual results to differ materially from the forward-looking information that has been provided. The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of Georgia Power; accordingly, there can be no assurance that such suggested results will be realized. The following factors, in addition to those discussed in Georgia Power's Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent securities filings, could cause actual results to differ materially from management expectations as suggested by such forward-looking information: the ability to control costs and avoid cost and schedule overruns during the development, construction, and operation of facilities or other projects, including Plant Vogtle Unit 4, which includes components based on new technology that only within the last few years began initial operation in the global nuclear industry at this scale, due to current and/or future challenges which include, but are not limited to, changes in labor costs, availability and productivity, challenges with the management of contractors or vendors, subcontractor performance, adverse weather conditions, shortages, delays, increased costs, or inconsistent quality of equipment, materials, and labor, contractor or supplier delay, the impacts of inflation, delays due to judicial or regulatory action, nonperformance under construction, operating, or other agreements, operational readiness, including specialized operator training and required site safety programs, engineering or design problems or any remediation related thereto, design and other licensing-based compliance matters, challenges with start-up activities, including major equipment failure, or system integration, and/or operational performance, continued challenges related to the COVID-19 pandemic or future pandemic health events, continued public and policymaker support for projects, environmental and geological conditions, delays or increased costs to interconnect facilities to transmission grids, and increased financing costs as a result of changes in market interest rates or as a result of project delays; the ability to overcome or mitigate the current challenges, or challenges yet to be identified, at Plant Vogtle Unit 4, that could further impact the cost and schedule for the project; legal proceedings and regulatory approvals and actions related to construction projects, such as Plant Vogtle Unit 4, including Georgia Public Service Commission approvals and U.S. Nuclear Regulatory Commission ("NRC") actions; under certain specified circumstances, a decision by holders of more than 10% of the ownership interests of Plant Vogtle Unit 3 and 4 not to proceed with construction; the notices of tender by Oglethorpe Power Corporation and the City of Dalton of a portion of their ownership interests in Plant Vogtle Units 3 and 4 to Georgia Power, including related litigation; the ability to construct facilities in accordance with the requirements of permits and licenses (including satisfaction of NRC requirements), to satisfy any environmental performance standards and the requirements of tax credits and other incentives, and to integrate facilities into the Southern Company system upon completion of construction; the inherent risks involved in operating and constructing nuclear generating facilities; the ability of counterparties of Georgia Power to make payments as and when due and to perform as required; the direct or indirect effect on Georgia Power's business resulting from cyber intrusion or physical attack and the threat of cyber and physical attacks; catastrophic events such as fires, earthquakes, explosions, floods, tornadoes, hurricanes and other storms, droughts, pandemic health events, political unrest, wars or other similar occurrences; the potential effects of the continued COVID-19 pandemic; and the direct or indirect effects on Georgia Power's business resulting from incidents affecting the U.S. electric grid or operation of generating or storage resources. Georgia Power expressly disclaim any obligation to update any forward–looking information.
View original content to download multimedia:
SOURCE Georgia Power | https://www.1011now.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ | 2023-07-31T11:25:07 | 0 | https://www.1011now.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ |
16TH annual event features turtles named after characters in Disney's frighteningly fun adventure movie, "Haunted Mansion," now playing in theaters.
VERO BEACH, Fla., July 31, 2023 /PRNewswire/ -- Over the weekend at Disney's Vero Beach Resort, researchers from the Sea Turtle Conservancy (STC) and Disney Conservation released two sea turtles as part of the 16th annual Tour de Turtles "migration marathon." Tour de Turtles is a fun, educational event that follows the migration of sea turtles from their nesting beaches to their feeding grounds and, ultimately, provides scientific data on how best to protect their species.
The Disney Conservation Fund (DCF) and Disney Cruise Line are each sponsoring a turtle this year, whose names, Madame Leota and Harriet, are the names of characters in Disney's frighteningly fun adventure movie "Haunted Mansion," now playing in theaters. Not unlike Gabbie, another character in the film who enlists a motley crew of so-called spiritual experts to help rid their home of supernatural squatters – Tour de Turtles brings together a team of researchers from the STC and Disney Conservation annually to undertake a daunting mission - using satellite telemetry to track two female turtles to determine where and how far they swim during the migration season.
Each turtle swims to raise awareness about various threats to sea turtle survival. The turtle to swim the furthest distance will win the Tour de Turtles race.
"Disney's commitment to sea turtle conservation in Vero Beach spans 20 years, and we are very proud to have recently watched our 1.5 millionth sea turtle hatchling leave the nest and shuffle its way to the ocean," said Mark Penning, Vice President of Disney's Animals, Science and Environment. "Southeast Florida hosts one of the largest nesting aggregations of loggerhead sea turtles, making up to 40 percent of the global loggerhead population. The team has recorded more than 20,000 sea turtle nests on our survey route since the program began."
The data collected during Tour de Turtles helps researchers, conservationists and governing agencies make more informed decisions about sea turtle conservation and management. Since the launch of the event in 2008, STC and Disney have collaborated to study 29 sea turtles outfitted with satellite transmitters and released from Disney's Vero Beach Resort. Continuing its commitment to strengthen youth education programs in port communities around the world, Disney Cruise Line proudly supported local students from Club Esteem from Melbourne, Florida, to participate in this year's event. DCF also has directed more than $5.1 million to support global sea turtle conservation efforts.
"Disney is a fantastic collaborator," said David Godfrey, STC Executive Director. "Disney's commitment to conservation, passion for environmental education, and effectiveness at communicating with audiences have made the Tour de Turtles a fun and successful program since it was launched over a decade ago."
In addition to Tour de Turtles, the Disney Conservation team has dedicated nearly 19,000 hours to studying and monitoring sea turtle nests during the summer nesting season along the five-mile coastline at Disney's Vero Beach Resort. From approximately May to October, Disney Vacation Club members and resort guests also have the opportunity to assist the team by joining outings to observe real-time sea turtle research while learning how they can take action to protect sea turtles. So far this year, the Disney Conservation team has a record-breaking number of nests along their survey route – nearly 2,000 by August, well above the average 1,500 normally counted in an entire season.
Tour de Turtles is a research and education program of the Sea Turtle Conservancy and Disney's support is just one example of bringing Disney Planet Possible to life by taking action to make a happier, healthier planet possible for all. To learn more and follow the turtles' migration, visit the Tour de Turtles website at www.tourdeturtles.org
ABOUT DISNEY'S VERO BEACH RESORT
Disney's Vero Beach Resort, a Disney Vacation Club Resort, offers spacious vacation villas along the pristine Atlantic coastline. The resort is located less than a two-hour drive from the Walt Disney World Resort, and its design reflects the Treasure Coast region where it is situated. Disney Vacation Club, a leader in vacation ownership, debuted in 1991 with a flexible, vacation points-based system rather than the traditional fixed-week timeshare model. Disney Vacation Club Members are able to choose from among a variety of exciting vacation destinations, including a stay at any Disney Vacation Club Resort or one of thousands of other vacation options in destinations around the world.
ABOUT DISNEY'S "HAUNTED MANSION"
Inspired by the classic theme park attraction, Disney's "Haunted Mansion" is about a woman and her son who enlist a motley crew of so-called spiritual experts to help rid their home of supernatural squatters.
Directed by Justin Simien, the film features an all-star cast ensemble including LaKeith Stanfield, Tiffany Haddish, Owen Wilson, Danny DeVito, Rosario Dawson, Chase W. Dillon and Daniel Levy, with Jamie Lee Curtis and Jared Leto as The Hatbox Ghost. The film's producers are Dan Lin and Jonathan Eirich, with Nick Reynolds and Tom Peitzman serving as executive producers.
View original content to download multimedia:
SOURCE Walt Disney World | https://www.wkyt.com/prnewswire/2023/07/31/tour-de-turtles-celebrates-sea-turtles-supernatural-science-disneys-vero-beach-resort/ | 2023-07-31T11:25:09 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/tour-de-turtles-celebrates-sea-turtles-supernatural-science-disneys-vero-beach-resort/ |
The Nation's Largest Network for Affordable Housing Protects Consumers from Unfair Fees and Costs
BOCA RATON, Fla., July 31, 2023 /PRNewswire/ -- AffordableHousing.com today announced it will join the White House and a compendium of government agencies and other private sector companies in large-scale efforts to end junk fees and ensure that Americans are provided with honest, transparent pricing. More than 100 million property searches per year are performed on AffordableHousing.com–the largest platform for affordable housing in the nation.
"For decades, families have relied on us to help them find affordable housing," says Richard Cupelli, CEO at AffordableHousing.com. "We take pride in advocating for these families, so it was a natural fit for us to join forces with the Administration and other socially responsible companies to help protect consumers in our industry."
On July 19, 2023, the White House published a Fact Sheet announcing its crack-down on junk fees in the rental market, highlighting private-sector commitments supporting this initiative made by the three major rental housing platforms: AffordableHousing.com, Zillow, and Apartments.com.
Late last year, the President called on federal agencies, Congress, and private companies to take action to address junk fees across the economy. The initiative aims to ensure Americans are provided with honest, transparent pricing. By February 2023, the Consumer Financial Protection Bureau (CFPB) announced proposed rules limiting credit card late fees. The Federal Communications Commission (FCC) finalized a rule requiring cable and internet providers to list fees up front. And the Department of Transportation (DOT) proposed a requirement for airlines and booking services show the full price of a plane ticket, including baggage and other fees.
In March, HUD Secretary Marcia Fudge released an open letter to housing providers and state and local governments, encouraging them to adopt policies promoting greater fairness and transparency of fees faced by renters. Substantial research shows such fees obstruct comparison shopping, impede competition, and lead to consumers paying more.
A long-standing resource for families seeking affordable housing, AffordableHousing.com has policies in place supporting this transparency and protecting its customers from unfair fees.
Renters can search available properties free on AffordableHousing.com, and property owners are required to be upfront about all refundable and non-refundable rental fees and costs. AffordableHousing.com also does not charge rental application fees.
"Our socially responsible technology platform has allowed us to establish the largest network of affordable housing in the nation," says Cupelli. "We understand the accountability that comes with our standing in the industry and the trust that our customers place in us."
As a hub for housing agencies across the nation, AffordableHousing.com also allows state and local governments to have their own customized website that serves their local community, enforces their specific regulatory requirements, centralizes all affordable housing, and simplifies the application and approval process.
"We are working with AffordableHousing.com to implement the Vermont Affordable Housing Hub, which will allow families to easily find and apply to all affordable housing in the state," says Kathleen Berk, Executive Director at Vermont State Housing Authority. "By utilizing AffordableHousing.com's custom housing hub to build our state-specific site, we can streamline compliance with state laws, which have strict application fee guidelines. We can also add safeguards to protect our families by providing the Clear and Fair Lease template for property owners to use. These leases will also comply with affordable housing programs, like Section 8."
AffordableHousing.com also rewards reputable property owners. Those with a history of good standing can qualify for a Trusted Owner Badge, which ensures their credibility to prospective renters on the site and increases consumer confidence. Trusted Owners also receive prominent listing status.
Earning and maintaining status as a Trusted Owner requires providing various levels of documentation to verify qualifications and authenticity, adhering to all relevant federal, state, and local laws, and complying with the site's reasonable fee guidelines.
Together with its research partner, Learning Collider (www.learningcollider.org), AffordableHousing.com is conducting research into the real cost of administrative fees, the impact of fee transparency in rental listings, and the effectiveness of platform features like the common application for rental and government programs—an endeavor that the company has been urging agencies to adopt for years.
"Our research partnership with AffordableHousing.com has allowed us to analyze the impacts of rental fees on low-income families in real-time," says Peter Bergman, Professor at UT Austin and Director of the Learning Collider research lab. "Together, we are advancing research to identify junk fees and establish transparent fee practices, easing the path to affordable rentals for families across the U.S."
The President announced in latest White House Fact Sheet, released on July 27, 2023, further plans to protect renters, naming AffordableHousing.com as an ally in the initiative and endorsing the site's plans to deploy additional consumer protection tools by the end of the year, including "Clear and Fair" digital leases, which will align with the principles outlined in the White House Blueprint for a Renter Bill of Rights. Property owners who use these "Clear and Fair" digital leases will be acknowledged on AffordableHousing.com.
About AffordableHousing.com: For more than 20 years, AffordableHousing.com has provided innovative technology and real solutions that help solve some of the most complex challenges impacting the availability of affordable housing in the United States. By simplifying access to available resources, AffordableHousing.com boosts participation in government programs, increasing the much-needed supply of affordable housing nationwide, and providing more homes to more families.
View original content to download multimedia:
SOURCE AffordableHousing.com | https://www.1011now.com/prnewswire/2023/07/31/white-house-announces-partnership-with-affordablehousingcom-end-junk-fees/ | 2023-07-31T11:25:10 | 0 | https://www.1011now.com/prnewswire/2023/07/31/white-house-announces-partnership-with-affordablehousingcom-end-junk-fees/ |
This Launch Marks the Latest Expansion of the Brand's Complexion Offerings as it Doubles Down on The Skincare-Meets-Makeup Hybrid Category
NEW YORK, July 31, 2023 /PRNewswire/ -- TULA Skincare, the leading clinically proven probiotic extract powered skincare brand has announced the expansion of its complexion offerings to include concealer.
After learning that TULA's customers were looking for a skin brightening eye treatment along with a concealer, the brand created a state-of-the-art clean skincare-makeup hybrid that delivers skin-boosting benefits with high-performance medium-to-full coverage.
Available in a 20-shade range, the dermatologist-tested, Radiant Skin Brightening Serum Concealer is infused with TULA's unique Rainbow Seabright™ Elixir. This clinically-proven serum-like formula instantly conceals dark circles and discoloration for longwearing, crease-proof results, while brightening the appearance of skin over time. Additional ingredients include TULA's S6Pro Complex® - a US patent pending super six blend of prebiotics and probiotic extracts to help soothe skin, improve skin smoothness and maintain skin balance, along with eye peptides and tea leaf caffeine to help improve the look of dark circles, skin texture, and eye bags. The Radiant Skin Brightening Serum Concealer can be paired with the brand's Radiant Skin Brightening Serum Skin Tint or Filter Primer Blurring & Moisturizing Primer to help build one's complexion wardrobe, or spot conceal for a no-makeup, makeup look.
"Expanding our complexion category to include a concealer was a natural next step for us, especially knowing the strong desire our customers have had for an eye treatment with brightening benefits." said TULA Skincare CEO, Savannah Sachs. " We are excited to have another offering for our glow getters that will surely be a staple in their skincare and beauty routines."
To mark the launch, TULA will be executing a multi-channel launch campaign across its digital platform, and organic social, paid media, and influencer channels. Efforts will include launching a custom "shade finder" on tula.com to help customers find their perfect match concealer shade, highlighting content speaking to the "no-makeup, makeup" and makeup-skincare hybrid trends across TikTok and Instagram, and partnering with a curated set of influencers and providing them with an early access link exclusively for their followers to purchase the concealer prior to launch. In addition to tula.com, the concealer will launch in Ulta Beauty stores nationwide and online and will be featured in an upcoming issue of the Ulta Beauty Magazine, with in-store complexion events planned in the coming months in multiple doors.
TULA's Radiant Skin Brightening Serum Concealer will be available for purchase on July 31 on tula.com, and will retail for $32.
About TULA Skincare
TULA is a doctor-founded skincare brand built on clinically proven formulas powered by probiotic extracts. We believe that the same types of ingredients which are good for your body are also great for your skin. We focus on being healthy, not perfect and on empowering everyone to feel confident in their skin.
Media Contact: Zoe Jeans at Bux + Bewl Communications: zoe@buxandbewl.com
View original content to download multimedia:
SOURCE TULA Skincare | https://www.wkyt.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ | 2023-07-31T11:25:16 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ |
- Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 39.5% - Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 27.9% - Net Profit Attributable to Owners of the Company for the First Half Increased 14.6% to RMB 5,313 Million
- Diluted Earnings per Share (EPS) for the First Half Increased 20.9% to RMB1.79
- Adjusted Non-IFRS Net Profit Attributable to Owners of the Company for the First Half Increased 18.5% to RMB5,095 Million
- Adjusted Non-IFRS Diluted EPS for the First Half Increased 18.5% to RMB1.73[1]
- Free Cash Flow Achieved RMB2,926 Million for the First Half, Turned Positive and Grew Strongly
SHANGHAI, July 31, 2023 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half ending June 30, 2023 ("Reporting Period").
This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the 2023 Interim Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.
All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.
The 2023 Interim Report of the Company has not been audited.
Second Quarter 2023 Financial Highlights
Revenue grew 6.7% year-over-year to RMB9,908 million, excluding COVID-19 commercial projects, revenue grew strongly by 39.5%. This is primarily attributable to the Company's continued excellent execution of our unique Contract Research, Development and Manufacturing Organization (CRDMO) business model to achieve strong synergy and continuous growth:
- WuXi Chemistry revenue grew 2.6% year-over-year to RMB7,034 million, excluding COVID-19 commercial projects, revenue grew strongly by 51.6%. Adjusted non-IFRS gross profit grew 12.9% year-over-year to RMB3,216 million, with a gross profit margin of 45.7%.
- WuXi Testing revenue grew 23.6% year-over-year to RMB1,638 million and adjusted non-IFRS gross profit grew 36.2% year-over-year to RMB640 million, with a gross profit margin of 39.1%.
- WuXi Biology revenue grew 17.5% year-over-year to RMB656 million and adjusted non-IFRS gross profit grew 21.3% year-over-year to RMB 271 million, with a gross profit margin of 41.4%.
- WuXi ATU revenue grew 22.9% year-over-year to RMB389 million and adjusted non-IFRS gross profit was RMB(16) million, with a gross profit margin of (4.2)%
- WuXi DDSU revenue declined 17.9% year-over-year to RMB176 million and adjusted non-IFRS gross profit grew year-over-year 5.2% to RMB63 million, with a gross profit margin of 35.8%. Meanwhile, we received the first royalty income from customers in the second quarter, which is a breakthrough for DDSU.
Unit: RMB million
- IFRS gross profit increased 18.1% year-over-year to RMB4,030 million. Gross profit margin was 40.7%[2]
- Adjusted non-IFRS gross profit increased 16.4% year-over-year to RM4,177 million. Adjusted non-IFRS gross margin was 42.2%.
- Net profit attributable to owners of the Company increased 5.1% year-over-year to RMB3,145 million.
- Adjusted non-IFRS net profit attributable to owners of the Company increased 22.4% year-over-year to RMB2,753 million.
First-Half 2023 Financial Highlights
Revenue grew 6.3% year-over-year to RMB18,871 million, excluding COVID-19 commercial projects, revenue grew strongly by 27.9%. This is primarily attributable to the Company's continued excellent execution of our unique Contract Research, Development and Manufacturing Organization (CRDMO) business model to achieve strong synergy and continuous growth:
- WuXi Chemistry revenue grew 3.8% year-over-year to RMB13,467 million, excluding COVID-19 commercial projects, revenue grew strongly by 36.1%. Adjusted non-IFRS gross profit grew 14.9% year-over-year to RMB6,103 million, with a gross profit margin of 45.3%.
- WuXi Testing revenue grew 18.7% year-over-year to RMB3,091 million and adjusted non-IFRS gross profit grew 26.1% year-over-year to RMB1,168 million, with a gross profit margin of 37.8%.
- WuXi Biology revenue grew 13.0% year-over-year to RMB1,233 million and adjusted non-IFRS gross profit grew 15.1% year-over-year to RMB511 million, with a gross profit margin of 41.5%.
- WuXi ATU revenue grew 16.0% year-over-year to RMB714 million and adjusted non-IFRS gross profit was RMB(40) million, with a gross profit margin of (5.7)%.
- WuXi DDSU revenue declined 24.9% year-over-year to RMB342 million and adjusted non-IFRS gross profit declined 26.2% year-over-year to RMB103 million, with a gross profit margin of 30.1%. Meanwhile, DDSU achieved a breakthrough in receiving the first royalty income from customers.
Unit: RMB million
- IFRS gross profit increased 17.6% year-over-year to RMB7,556 million. Gross profit margin was 40.0%[3].
- Adjusted non-IFRS gross profit increased 15.7% year-over-year to RMB7,855 million. Adjusted non-IFRS gross margin was 41.6%.
- Net profit attributable to owners of the Company increased 14.6% year-over-year to RMB 5,313 million.
- Adjusted non-IFRS net profit attributable to owners of the Company increased 18.5% year-over-year to RMB5,095 million.
- Diluted EPS increased 20.9% year-over-year to RMB1.79, while adjusted diluted non-IFRS EPS increased by 18.5% year-over-year to RMB1.73.
- Free cash flow achieved RMB2,926 million, turned positive and grew strongly year-over-year.
First-Half 2023 Business Operation Highlights
- As an industry innovation enabler, we grow together with our customers. In the first half of 2023, we added over 600 new customers, and in total we served more than 6,000 active customers over the past 12 months. Backlog grew 25% year-over-year excluding COVID-19 commercial projects. We continued to optimize our cross-platform synergies to better serve our customers worldwide, strengthen our unique competitive advantage as a fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) and Contract Testing, Development and Manufacturing Organization (CTDMO) platform, and provide one-stop services for our customers from discovery to development and manufacturing. The diversified revenue streams from customers across regions ensure the stability and resilience of the Company's financial performance.
- WuXi Chemistry: Integrated CRDMO Business Model Drives Steady Growth, with Continued Expansion in New Modalities (WuXi TIDES)
- In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to customers, which grew 20% year-over-year. Through our chemistry drug discovery services, we enabled our customers to accelerate their research while generating opportunities for our downstream business units. In the past 12 months, 120 molecules have transitioned from R to D&M, representing a year-on-year growth of 21%. Through our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our global customers, supporting the sustainable growth of our CRDMO business.
- We continued executing our "long-tail" strategy. Demand from "long-tail" customers in discovery services of small molecule and new modalities continued to grow, with the number of new customers growing 17% year-over-year.
- In the first half of 2023, D&M services revenue grew 2.1% year-over-year to RMB9.67 billion. Excluding COVID-19 commercial projects, D&M services revenue grew strongly by 54.5%.
- In the first half of 2023, we added 583 molecules to our D&M pipeline. To date, our D&M pipeline consists of 2,819 molecules, including 56 commercial projects, 59 in phase III, 301 in phase II and 2,403 in phase I and pre-clinical stages, among which, 8 commercial and phase III projects were added in the first half of 2023.
- In the first half of 2023, TIDES revenue grew 37.9% year-over-year to RMB1.33 billion. As of June 30, 2023, backlog of TIDES grew strongly by 188% year-over-year. We expect revenue growth from TIDES business to exceed 70% in 2023.
- The number of TIDES D&M customers increased 25% year-over-year to 121, and the number of TIDES molecules increased 46% year-over-year to 207.
- WuXi Testing: Lab Testing Services Drive Steady Growth, Clinical Business Fully Recovered
- The Company provides a full range of laboratory testing services for our customers, including drug metabolism and pharmacokinetics (DMPK), toxicology, and bioanalysis for drug development testing, as well as medical device testing. We provide customers with high-quality services, realize "one report for global submission," and enable customers to save time, reduce costs and increase efficiency.
- H1 2023 revenue from drug safety evaluation services grew 24% year-over-year. We maintained our industry leadership position in Asia Pacific for drug safety evaluation services that meet global regulatory requirements. In the first half of 2023, new lab testing facilities in Qidong and Suzhou began operations as scheduled, ensuring the business growth to accelerate in the second half of 2023.
- Moreover, we continued to enhance capabilities related to new modalities, with comprehensive coverage such as target protein degradation, nucleic acids, conjugates, and cell and gene therapies (CGT), etc.
- SMO revenue grew strongly by 53.9% in Q2 2023 and 34.3% in H1 2023, maintaining a leadership position in China. In the first half of 2023, SMO supported 25 new drug approvals for customers.
- In the first half of 2023, clinical CRO enabled our customers to obtain 8 IND approvals and submit 3 NDA filings.
- WuXi Biology: Strong Contribution from New Modalities; Early Discovery Screening Platform Continued to Generate Downstream Opportunities
- WuXi ATU: CTDMO Business Model Drives Growth
- WuXi DDSU: the First Year to Receive New Drug Application (NDA) Approval of New Drugs Developed for Customers; Breakthrough to Receive the First Royalty Income
Our Commitment to ESG
As an industry innovation enabler, a trusted partner and a contributor to the global healthcare industry, the Company is committed to environmental protection and sustainability, and to being a good global corporate citizenship.
Our outstanding ESG performance has been recognized by major global ESG rating agencies, including MSCI, S&P Global, Sustainalytics, CDP and EcoVadis. In June 2023, we received the fourth "Silver" medal recognition from EcoVadis for our Couvet site in Switzerland.
By the first half of 2023, our carbon emission intensity, energy consumption intensity and water use intensity reduced by 20.1%, 18.4%, and 31.6%, respectively, as compared to the baseline year 2020.
As we continue to advance our sustainability strategy, we embrace our shared responsibility to be good stewards of the environment.
Management Comment
Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "We continued to achieve steady growth of revenue, net profit, and free cash flow in the first half of 2023. Our revenue increased 6.3% year-over-year to RMB18.87 billion, or 27.9% if excluding COVID-19 commercial projects. Our adjusted non-IFRS net profit attributable to owners of the Company increased 18.5% year-over-year, outpacing the revenue growth rate, and our free cash flow achieved RMB2.93 billion, as a result of the Company's pursuit of operational excellence and productivity."
"The Company's performance in the first half of 2023 demonstrated that WuXi AppTec's unique CRDMO and CTDMO business models can effectively meet the growing demands from customers worldwide and continue to drive solid growth for the Company. In 2023, we aim to deliver a 5-7% revenue growth, increase adjusted non-IFRS gross profit by 13-14%, and expand free cash flow by 750-850%. We remain committed to prioritizing our customers' needs and enhancing our capacity and capabilities as we support our customers' efforts to bring groundbreaking therapies to patients around the world. Together, we can realize our vision that 'every drug can be made and every disease can be treated'."
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com
Forward-Looking Statements
This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our customers' intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Use of Non-IFRS and Adjusted Non-IFRS Financial Measures
We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses, amortization of intangible assets acquired in business combinations, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither is required by, or presented in accordance with IFRS.
We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such adjusted non-IFRS net profit attributable to owners of the Company, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.
For more information, please contact:
Ms. Ruijia Tang (for investors)
IR Director
Email: tang_ruijia@wuxiapptec.com
Mr. Davy Wu (for media)
PR Director
Email: davy_wu@wuxiapptec.com
View original content:
SOURCE WuXi AppTec | https://www.1011now.com/prnewswire/2023/07/31/wuxi-apptec-announced-strong-results-second-quarter-first-half-2023-top-an-exceptionally-strong-year-2022/ | 2023-07-31T11:25:17 | 0 | https://www.1011now.com/prnewswire/2023/07/31/wuxi-apptec-announced-strong-results-second-quarter-first-half-2023-top-an-exceptionally-strong-year-2022/ |
Launch demonstrates companies' commitment to bringing complex generic medicines to the market to help increase patient access
PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.
Viatris Head of North America Jose Cotarelo said: "We are excited to bring Breyna to the U.S. market for the many Americans living with asthma and COPD. This launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain. Being the first to bring an FDA-approved generic version of Symbicort to patients is a true example of how access is the cornerstone of our mission to empower people worldwide to live healthier at every stage of life."
The indications for Breyna include asthma in patients six years of age and older, and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD, including chronic bronchitis and/or emphysema. Breyna is not indicated for the relief of acute bronchospasm. The 160 mcg/4.5 mcg is the only strength indicated for the treatment of COPD. COPD is a term used to describe a certain kind of chronic lung disease and is characterized by breathlessness; it affects more than 16 million Americans. Asthma causes swelling of the airways resulting in difficulty breathing, and approximately 25 million Americans have the chronic condition.
Milton Boyer, CEO of Kindeva Drug Delivery, added: "The launch of Breyna represents a significant milestone as it is the first FDA-approved generic version of Symbicort in the U.S., one of the most prescribed complex drug-device combination products to treat asthma and COPD. We are pleased for Viatris as well as the many Kindeva colleagues who have worked tirelessly to leverage our complex drug-delivery expertise for this important respiratory product — supporting a persistent need to continue bringing more quality medicines for asthma and COPD to patients."
To further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply. The program offers $30/month or up to $360 per year with 12 refills annually. The program will be available in August.
About Breyna
Breyna is indicated for the treatment of asthma in patients 6 years and older not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonists (LABA). Breyna 160 mcg/4.5 mcg dosage is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and Breyna 160 mcg/4.5 mcg is also indicated to reduce exacerbations of COPD. Breyna is NOT indicated for the relief of acute bronchospasm.
Important Safety Information
Breyna is contraindicated in the primary treatment of status asthmaticus or other acute episode of asthma or COPD where intensive measures are required, and in hypersensitivity to any of the ingredients in Breyna. Use of long-acting beta2-adrenergic agonists (LABA) as monotherapy (without inhaled corticosteroids [ICS]) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinial trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA. When LABA are used in fixed dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone. Breyna is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms. Breyna should not be initiated in patients during rapidly deteriorating episodes of asthma or COPD. Patients who are receiving Breyna should not use additional formoterol or other LABA for any reason. Localized infections of the mouth and pharynx with Candida albicans has occurred in patients treated with Breyna. Patients should rinse the mouth after inhalation of Breyna. Lower respiratory tract infections, including pneumonia, have been reported following the administration of ICS. Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients. It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may occur, particularly at higher doses. Particular care is needed for patients who are transferred from systemically active corticosteroids to ICS. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available ICS. Caution should be exercised when considering administration of Breyna in patients on long-term ketoconazole and other known potent CYP3A4 inhibitors. As with other inhaled medications, paradoxical bronchospasm may occur with Breyna. Immediate hypersensitivity reactions may occur, as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm. Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. Breyna should be used with caution in patients with cardiovascular disorders especially coronary insufficiency, cardiac arrhythmias, and hypertension. Long-term use of ICS may result in a decrease in bone mineral density (BMD Assessment of BMD is recommended prior to initiating Breyna and periodically thereafter. ICS may result in a reduction in growth velocity when administered to pediatric patients. Glaucoma, increased intracolular pressure, and cataracts have been reported following the administration of ICS, including budesonide, a component of Breyna. Close monitoring for glaucoma and cataracts is warranted in patients with a change in vision or history of increased intraocular pressure. In rare cases, patients on ICS may present with systemic eosinophilic conditions. Breyna should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines. The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis. The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection. Breyna should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents. Beta-blockers may not only block the pulmonary effect of beta-agonists, such as formoterol, but may produce severe bronchospasm in patients with asthma. ECG changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. Use caution with the coadministration of Breyna.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development manufacturing organization focused on drug-device combination products. Kindeva Drug Delivery develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary & nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva Drug Delivery serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements that the launch of Breyna demonstrates the companies' commitment to bringing complex generic medicines to the market to help increase patient access; Breyna will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths; this launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain; to further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply; and, the program will be available in August. Factors that could cause or contribute to such differences include, but are not limited to: the possibility that the Company may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives; the possibility that the Company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with acquisitions, divestitures, or its global restructuring program, within the expected timeframe or at all; impairment charges or other losses related to the divestiture or sale of businesses or assets; the Company's failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by COVID-19; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, inflation and exchange rates; failure to execute stock repurchases consistent with current expectations; stock price volatility; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.
View original content to download multimedia:
SOURCE Viatris Inc. | https://www.wkyt.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ | 2023-07-31T11:25:22 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ |
GUANGZHOU, China, July 31, 2023 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG), a leading China-based beauty group, today announced that it has published its 2022 Environmental, Social and Governance ("ESG") report, outlining the Company's progress and performance in key ESG areas.
The report provides a comprehensive review of Yatsen's ESG initiatives and developments, including corporate governance, research and development, employee rights protection, human capital development, environmental sustainability and social responsibility, among others.
To view the report in full, please visit the ESG section on the Yatsen Investor Relations website. Alternatively, please click here for the English version and here for the Chinese version of the 2022 report.
About Yatsen Holding Limited
Yatsen Holding Limited (NYSE: YSG) is a leading China-based beauty group with the mission of creating an exciting new journey of beauty discovery for consumers around the world. Founded in 2016, the Company has launched and acquired numerous color cosmetics and skincare brands, including Perfect Diary, Little Ondine, Abby's Choice, Galénic, DR.WU (its mainland China business), Eve Lom, Pink Bear and EANTiM. The Company's flagship brand, Perfect Diary, is one of the leading color cosmetics brands in China in terms of retail sales value. The Company primarily reaches and engages with customers directly, both online and offline, with an expansive presence across all major e-commerce, social and content platforms in China.
For more information, please visit http://ir.yatsenglobal.com/.
For investor and media inquiries, please contact:
In China:
Yatsen Holding Limited
Investor Relations
E-mail: ir@yatsenglobal.com
The Piacente Group, Inc
Hui Fan
Tel: +86-10-6508-0677
E-mail: yatsen@thepiacentegroup.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: yatsen@thepiacentegroup.com
View original content:
SOURCE Yatsen Holding Limited | https://www.1011now.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ | 2023-07-31T11:25:24 | 0 | https://www.1011now.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ |
New nuclear unit now serving customers with clean, reliable energy 24/7
ATLANTA, July 31, 2023 /PRNewswire/ -- Georgia Power declared today that Plant Vogtle Unit 3 has entered commercial operation and is now serving customers and the State of Georgia. The new unit represents a long-term investment in the state's clean energy future and will provide reliable, emissions-free energy to customers for decades to come.
"The Plant Vogtle 3 & 4 nuclear expansion is another incredible example of how Georgia Power is building a reliable and resilient energy future for our state," said Kim Greene, chairman, president and CEO of Georgia Power. "It is important that we make these kinds of long-term investments and see them through so we can continue providing clean, safe, reliable and affordable energy to our 2.7 million customers. Today's achievement is a testament to our commitment to doing just that, and it marks the first day of the next 60 to 80 years that Vogtle Unit 3 will serve our customers with clean, reliable energy."
Vogtle Unit 3 is the first newly-constructed nuclear unit in the U.S. in over 30 years and can power an estimated 500,000 homes and businesses. Once all four units are online, the Plant Vogtle site will be the largest generator of clean energy in the nation and support continued growth in Georgia as more industries, businesses and families come to the state.
"Today is a historic day for the State of Georgia, Southern Company, and the entire energy sector, as we continue transforming the way we power the lives of millions of Americans," said Chris Womack, president and CEO of Southern Company. "With Unit 3 completed, and Unit 4 in the final stages of construction and testing, this project shows just how new nuclear can and will play a critical role in achieving a clean energy future for the United States. Bringing this unit safely into service is a credit to the hard work and dedication of our teams at Southern Company and the thousands of additional workers who have helped build that future at this site, as well as all of the partners who have helped make this day a reality."
Nuclear energy is the only zero-emission baseload energy source available today, offering high reliability, and efficient operations around the clock. Nuclear energy currently provides approximately 25% of Georgia Power's overall energy mix, including the existing units at Plant Vogtle and Georgia's other nuclear facility at Plant Hatch in Baxley, Georgia.
"The Vogtle expansion is an American energy success story and would not be possible without the support of strong public and private partners like our partners at North America's Building Trades Unions," said Tom Fanning, chairman of the Board of Directors for Southern Company. "We continue to appreciate their support and those who have stood with us at the local, state and federal levels to complete this new clean energy source to serve electric customers. Providing leadership in our industry and a commitment to safety and quality are in Southern Company's DNA. Today's milestone at the Vogtle expansion site underscores this legacy, and I couldn't be prouder of the dedication our teams have shown in seeing Unit 3 through to completion."
The final stages of construction and testing continue at Vogtle Unit 4, with the unit projected to be placed in service during the late fourth quarter 2023 or the first quarter of 2024. The unit completed hot functional testing in May, in significantly less time than Unit 3 as the team continues leveraging best practices and learnings from the earlier unit. The Vogtle site has also received nuclear fuel for Unit 4, with a total of 157 fuel assemblies necessary for the safe and reliable startup of the unit.
Also, last week, Georgia Power announced the receipt of the 103(g) finding from the Nuclear Regulatory Commission (NRC) for Vogtle Unit 4. This finding was confirmed in an official letter received by Southern Nuclear and signifies that the new unit has been constructed and will be operated in conformance with the Combined License and NRC regulations. No further NRC findings are necessary in order for Southern Nuclear to load fuel or begin the startup sequence for the new unit.
The new Vogtle units are an essential part of Georgia Power's commitment to delivering clean, safe, reliable and affordable energy to its 2.7 million customers. Southern Nuclear will operate the new units on behalf of the co-owners: Georgia Power, Oglethorpe Power, MEAG Power and Dalton Utilities.
About Georgia Power
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America's premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company's promise to 2.7 million customers in all but four of Georgia's 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), Twitter (Twitter.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).
Cautionary Note Regarding Forward-Looking Statements
Certain information contained in this release is forward-looking information based on current expectations and plans that involve risks and uncertainties. Forward-looking information includes, among other things, statements concerning the projected in-service date for Plant Vogtle Unit 4 and the future operations of Plant Vogtle Units 3 and 4. Georgia Power cautions that there are certain factors that can cause actual results to differ materially from the forward-looking information that has been provided. The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of Georgia Power; accordingly, there can be no assurance that such suggested results will be realized. The following factors, in addition to those discussed in Georgia Power's Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent securities filings, could cause actual results to differ materially from management expectations as suggested by such forward-looking information: the ability to control costs and avoid cost and schedule overruns during the development, construction, and operation of facilities or other projects, including Plant Vogtle Unit 4, which includes components based on new technology that only within the last few years began initial operation in the global nuclear industry at this scale, due to current and/or future challenges which include, but are not limited to, changes in labor costs, availability and productivity, challenges with the management of contractors or vendors, subcontractor performance, adverse weather conditions, shortages, delays, increased costs, or inconsistent quality of equipment, materials, and labor, contractor or supplier delay, the impacts of inflation, delays due to judicial or regulatory action, nonperformance under construction, operating, or other agreements, operational readiness, including specialized operator training and required site safety programs, engineering or design problems or any remediation related thereto, design and other licensing-based compliance matters, challenges with start-up activities, including major equipment failure, or system integration, and/or operational performance, continued challenges related to the COVID-19 pandemic or future pandemic health events, continued public and policymaker support for projects, environmental and geological conditions, delays or increased costs to interconnect facilities to transmission grids, and increased financing costs as a result of changes in market interest rates or as a result of project delays; the ability to overcome or mitigate the current challenges, or challenges yet to be identified, at Plant Vogtle Unit 4, that could further impact the cost and schedule for the project; legal proceedings and regulatory approvals and actions related to construction projects, such as Plant Vogtle Unit 4, including Georgia Public Service Commission approvals and U.S. Nuclear Regulatory Commission ("NRC") actions; under certain specified circumstances, a decision by holders of more than 10% of the ownership interests of Plant Vogtle Unit 3 and 4 not to proceed with construction; the notices of tender by Oglethorpe Power Corporation and the City of Dalton of a portion of their ownership interests in Plant Vogtle Units 3 and 4 to Georgia Power, including related litigation; the ability to construct facilities in accordance with the requirements of permits and licenses (including satisfaction of NRC requirements), to satisfy any environmental performance standards and the requirements of tax credits and other incentives, and to integrate facilities into the Southern Company system upon completion of construction; the inherent risks involved in operating and constructing nuclear generating facilities; the ability of counterparties of Georgia Power to make payments as and when due and to perform as required; the direct or indirect effect on Georgia Power's business resulting from cyber intrusion or physical attack and the threat of cyber and physical attacks; catastrophic events such as fires, earthquakes, explosions, floods, tornadoes, hurricanes and other storms, droughts, pandemic health events, political unrest, wars or other similar occurrences; the potential effects of the continued COVID-19 pandemic; and the direct or indirect effects on Georgia Power's business resulting from incidents affecting the U.S. electric grid or operation of generating or storage resources. Georgia Power expressly disclaim any obligation to update any forward–looking information.
View original content to download multimedia:
SOURCE Georgia Power | https://www.wkyt.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ | 2023-07-31T11:25:29 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ |
The Nation's Largest Network for Affordable Housing Protects Consumers from Unfair Fees and Costs
BOCA RATON, Fla., July 31, 2023 /PRNewswire/ -- AffordableHousing.com today announced it will join the White House and a compendium of government agencies and other private sector companies in large-scale efforts to end junk fees and ensure that Americans are provided with honest, transparent pricing. More than 100 million property searches per year are performed on AffordableHousing.com–the largest platform for affordable housing in the nation.
"For decades, families have relied on us to help them find affordable housing," says Richard Cupelli, CEO at AffordableHousing.com. "We take pride in advocating for these families, so it was a natural fit for us to join forces with the Administration and other socially responsible companies to help protect consumers in our industry."
On July 19, 2023, the White House published a Fact Sheet announcing its crack-down on junk fees in the rental market, highlighting private-sector commitments supporting this initiative made by the three major rental housing platforms: AffordableHousing.com, Zillow, and Apartments.com.
Late last year, the President called on federal agencies, Congress, and private companies to take action to address junk fees across the economy. The initiative aims to ensure Americans are provided with honest, transparent pricing. By February 2023, the Consumer Financial Protection Bureau (CFPB) announced proposed rules limiting credit card late fees. The Federal Communications Commission (FCC) finalized a rule requiring cable and internet providers to list fees up front. And the Department of Transportation (DOT) proposed a requirement for airlines and booking services show the full price of a plane ticket, including baggage and other fees.
In March, HUD Secretary Marcia Fudge released an open letter to housing providers and state and local governments, encouraging them to adopt policies promoting greater fairness and transparency of fees faced by renters. Substantial research shows such fees obstruct comparison shopping, impede competition, and lead to consumers paying more.
A long-standing resource for families seeking affordable housing, AffordableHousing.com has policies in place supporting this transparency and protecting its customers from unfair fees.
Renters can search available properties free on AffordableHousing.com, and property owners are required to be upfront about all refundable and non-refundable rental fees and costs. AffordableHousing.com also does not charge rental application fees.
"Our socially responsible technology platform has allowed us to establish the largest network of affordable housing in the nation," says Cupelli. "We understand the accountability that comes with our standing in the industry and the trust that our customers place in us."
As a hub for housing agencies across the nation, AffordableHousing.com also allows state and local governments to have their own customized website that serves their local community, enforces their specific regulatory requirements, centralizes all affordable housing, and simplifies the application and approval process.
"We are working with AffordableHousing.com to implement the Vermont Affordable Housing Hub, which will allow families to easily find and apply to all affordable housing in the state," says Kathleen Berk, Executive Director at Vermont State Housing Authority. "By utilizing AffordableHousing.com's custom housing hub to build our state-specific site, we can streamline compliance with state laws, which have strict application fee guidelines. We can also add safeguards to protect our families by providing the Clear and Fair Lease template for property owners to use. These leases will also comply with affordable housing programs, like Section 8."
AffordableHousing.com also rewards reputable property owners. Those with a history of good standing can qualify for a Trusted Owner Badge, which ensures their credibility to prospective renters on the site and increases consumer confidence. Trusted Owners also receive prominent listing status.
Earning and maintaining status as a Trusted Owner requires providing various levels of documentation to verify qualifications and authenticity, adhering to all relevant federal, state, and local laws, and complying with the site's reasonable fee guidelines.
Together with its research partner, Learning Collider (www.learningcollider.org), AffordableHousing.com is conducting research into the real cost of administrative fees, the impact of fee transparency in rental listings, and the effectiveness of platform features like the common application for rental and government programs—an endeavor that the company has been urging agencies to adopt for years.
"Our research partnership with AffordableHousing.com has allowed us to analyze the impacts of rental fees on low-income families in real-time," says Peter Bergman, Professor at UT Austin and Director of the Learning Collider research lab. "Together, we are advancing research to identify junk fees and establish transparent fee practices, easing the path to affordable rentals for families across the U.S."
The President announced in latest White House Fact Sheet, released on July 27, 2023, further plans to protect renters, naming AffordableHousing.com as an ally in the initiative and endorsing the site's plans to deploy additional consumer protection tools by the end of the year, including "Clear and Fair" digital leases, which will align with the principles outlined in the White House Blueprint for a Renter Bill of Rights. Property owners who use these "Clear and Fair" digital leases will be acknowledged on AffordableHousing.com.
About AffordableHousing.com: For more than 20 years, AffordableHousing.com has provided innovative technology and real solutions that help solve some of the most complex challenges impacting the availability of affordable housing in the United States. By simplifying access to available resources, AffordableHousing.com boosts participation in government programs, increasing the much-needed supply of affordable housing nationwide, and providing more homes to more families.
View original content to download multimedia:
SOURCE AffordableHousing.com | https://www.wkyt.com/prnewswire/2023/07/31/white-house-announces-partnership-with-affordablehousingcom-end-junk-fees/ | 2023-07-31T11:25:29 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/white-house-announces-partnership-with-affordablehousingcom-end-junk-fees/ |
The cutting-edge platform empowers B2B SaaS start-ups to reduce churn, increase upsell, and boost NRR
WILMINGTON, Del., July 31, 2023 /PRNewswire/ -- ZapScale, a new-age customer success platform, is making waves in the industry by offering an unrivalled one-day onboarding experience along with the ability to track 150 customer data points for a comprehensive 360-degree view of customer health. This ground-breaking feature sets ZapScale apart from its competitors.
The secret behind ZapScale's lightning-fast onboarding lies in its comprehensive toolkit. With a robust framework of 40 pre-built KPI-based health frameworks, 60 pre-designed playbooks to automate CS ops, and seamless native integrations with all popular tools, ZapScale empowers businesses to gain complete visibility over customer data. With deep customer health insights, ZapScale's customers have seen an improvement in retention and increase in upsell opportunities.
Manasij Ganguli, Founder and CEO of ZapScale, shares his personal motivation for creating this game-changing platform: "ZapScale was born out of my passion to empower B2B SaaS start-ups with an efficient and effective CS platform. Having faced numerous customer success challenges in my previous start-up, which I successfully sold in 2019, I realized the critical need for a solution that could streamline, optimize, and accelerate CS operations.
For small to mid-sized businesses that have limited time and resources, implementing a CS platform has historically been a daunting task, taking weeks, if not months, to set up essential elements like customer health, playbooks, and integrations. ZapScale has addressed this challenge by offering a user-friendly and efficient implementation process, eliminating waste of time and resources. Now, businesses can seamlessly focus on their customers right from day 1."
ZapScale eliminates the traditional barriers and time-consuming processes associated with implementing CS platforms using key in-built features that facilitate custom mapping, support custom fields, and require no unique key to integrate applications, ensuring a tailored yet quick integration experience.
ZapScale is swiftly gaining traction in the market, with 30+ global companies already using the customer success platform. Starting at $249 per month, with a one-month free trial, ZapScale is helping businesses significantly improve their customer success initiatives.
For more information about ZapScale and to schedule a demo, visit www.zapscale.com.
Contact:
Nikita Kalra
Marketing Head, ZapScale
nikita@zapscale.com
Logo: https://mma.prnewswire.com/media/2097823/ZS_Logo.jpg
View original content:
SOURCE ZapScale | https://www.1011now.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ | 2023-07-31T11:25:30 | 1 | https://www.1011now.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ |
- Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 39.5% - Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 27.9% - Net Profit Attributable to Owners of the Company for the First Half Increased 14.6% to RMB 5,313 Million
- Diluted Earnings per Share (EPS) for the First Half Increased 20.9% to RMB1.79
- Adjusted Non-IFRS Net Profit Attributable to Owners of the Company for the First Half Increased 18.5% to RMB5,095 Million
- Adjusted Non-IFRS Diluted EPS for the First Half Increased 18.5% to RMB1.73[1]
- Free Cash Flow Achieved RMB2,926 Million for the First Half, Turned Positive and Grew Strongly
SHANGHAI, July 31, 2023 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half ending June 30, 2023 ("Reporting Period").
This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the 2023 Interim Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.
All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.
The 2023 Interim Report of the Company has not been audited.
Second Quarter 2023 Financial Highlights
Revenue grew 6.7% year-over-year to RMB9,908 million, excluding COVID-19 commercial projects, revenue grew strongly by 39.5%. This is primarily attributable to the Company's continued excellent execution of our unique Contract Research, Development and Manufacturing Organization (CRDMO) business model to achieve strong synergy and continuous growth:
- WuXi Chemistry revenue grew 2.6% year-over-year to RMB7,034 million, excluding COVID-19 commercial projects, revenue grew strongly by 51.6%. Adjusted non-IFRS gross profit grew 12.9% year-over-year to RMB3,216 million, with a gross profit margin of 45.7%.
- WuXi Testing revenue grew 23.6% year-over-year to RMB1,638 million and adjusted non-IFRS gross profit grew 36.2% year-over-year to RMB640 million, with a gross profit margin of 39.1%.
- WuXi Biology revenue grew 17.5% year-over-year to RMB656 million and adjusted non-IFRS gross profit grew 21.3% year-over-year to RMB 271 million, with a gross profit margin of 41.4%.
- WuXi ATU revenue grew 22.9% year-over-year to RMB389 million and adjusted non-IFRS gross profit was RMB(16) million, with a gross profit margin of (4.2)%
- WuXi DDSU revenue declined 17.9% year-over-year to RMB176 million and adjusted non-IFRS gross profit grew year-over-year 5.2% to RMB63 million, with a gross profit margin of 35.8%. Meanwhile, we received the first royalty income from customers in the second quarter, which is a breakthrough for DDSU.
Unit: RMB million
- IFRS gross profit increased 18.1% year-over-year to RMB4,030 million. Gross profit margin was 40.7%[2]
- Adjusted non-IFRS gross profit increased 16.4% year-over-year to RM4,177 million. Adjusted non-IFRS gross margin was 42.2%.
- Net profit attributable to owners of the Company increased 5.1% year-over-year to RMB3,145 million.
- Adjusted non-IFRS net profit attributable to owners of the Company increased 22.4% year-over-year to RMB2,753 million.
First-Half 2023 Financial Highlights
Revenue grew 6.3% year-over-year to RMB18,871 million, excluding COVID-19 commercial projects, revenue grew strongly by 27.9%. This is primarily attributable to the Company's continued excellent execution of our unique Contract Research, Development and Manufacturing Organization (CRDMO) business model to achieve strong synergy and continuous growth:
- WuXi Chemistry revenue grew 3.8% year-over-year to RMB13,467 million, excluding COVID-19 commercial projects, revenue grew strongly by 36.1%. Adjusted non-IFRS gross profit grew 14.9% year-over-year to RMB6,103 million, with a gross profit margin of 45.3%.
- WuXi Testing revenue grew 18.7% year-over-year to RMB3,091 million and adjusted non-IFRS gross profit grew 26.1% year-over-year to RMB1,168 million, with a gross profit margin of 37.8%.
- WuXi Biology revenue grew 13.0% year-over-year to RMB1,233 million and adjusted non-IFRS gross profit grew 15.1% year-over-year to RMB511 million, with a gross profit margin of 41.5%.
- WuXi ATU revenue grew 16.0% year-over-year to RMB714 million and adjusted non-IFRS gross profit was RMB(40) million, with a gross profit margin of (5.7)%.
- WuXi DDSU revenue declined 24.9% year-over-year to RMB342 million and adjusted non-IFRS gross profit declined 26.2% year-over-year to RMB103 million, with a gross profit margin of 30.1%. Meanwhile, DDSU achieved a breakthrough in receiving the first royalty income from customers.
Unit: RMB million
- IFRS gross profit increased 17.6% year-over-year to RMB7,556 million. Gross profit margin was 40.0%[3].
- Adjusted non-IFRS gross profit increased 15.7% year-over-year to RMB7,855 million. Adjusted non-IFRS gross margin was 41.6%.
- Net profit attributable to owners of the Company increased 14.6% year-over-year to RMB 5,313 million.
- Adjusted non-IFRS net profit attributable to owners of the Company increased 18.5% year-over-year to RMB5,095 million.
- Diluted EPS increased 20.9% year-over-year to RMB1.79, while adjusted diluted non-IFRS EPS increased by 18.5% year-over-year to RMB1.73.
- Free cash flow achieved RMB2,926 million, turned positive and grew strongly year-over-year.
First-Half 2023 Business Operation Highlights
- As an industry innovation enabler, we grow together with our customers. In the first half of 2023, we added over 600 new customers, and in total we served more than 6,000 active customers over the past 12 months. Backlog grew 25% year-over-year excluding COVID-19 commercial projects. We continued to optimize our cross-platform synergies to better serve our customers worldwide, strengthen our unique competitive advantage as a fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) and Contract Testing, Development and Manufacturing Organization (CTDMO) platform, and provide one-stop services for our customers from discovery to development and manufacturing. The diversified revenue streams from customers across regions ensure the stability and resilience of the Company's financial performance.
- WuXi Chemistry: Integrated CRDMO Business Model Drives Steady Growth, with Continued Expansion in New Modalities (WuXi TIDES)
- In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to customers, which grew 20% year-over-year. Through our chemistry drug discovery services, we enabled our customers to accelerate their research while generating opportunities for our downstream business units. In the past 12 months, 120 molecules have transitioned from R to D&M, representing a year-on-year growth of 21%. Through our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our global customers, supporting the sustainable growth of our CRDMO business.
- We continued executing our "long-tail" strategy. Demand from "long-tail" customers in discovery services of small molecule and new modalities continued to grow, with the number of new customers growing 17% year-over-year.
- In the first half of 2023, D&M services revenue grew 2.1% year-over-year to RMB9.67 billion. Excluding COVID-19 commercial projects, D&M services revenue grew strongly by 54.5%.
- In the first half of 2023, we added 583 molecules to our D&M pipeline. To date, our D&M pipeline consists of 2,819 molecules, including 56 commercial projects, 59 in phase III, 301 in phase II and 2,403 in phase I and pre-clinical stages, among which, 8 commercial and phase III projects were added in the first half of 2023.
- In the first half of 2023, TIDES revenue grew 37.9% year-over-year to RMB1.33 billion. As of June 30, 2023, backlog of TIDES grew strongly by 188% year-over-year. We expect revenue growth from TIDES business to exceed 70% in 2023.
- The number of TIDES D&M customers increased 25% year-over-year to 121, and the number of TIDES molecules increased 46% year-over-year to 207.
- WuXi Testing: Lab Testing Services Drive Steady Growth, Clinical Business Fully Recovered
- The Company provides a full range of laboratory testing services for our customers, including drug metabolism and pharmacokinetics (DMPK), toxicology, and bioanalysis for drug development testing, as well as medical device testing. We provide customers with high-quality services, realize "one report for global submission," and enable customers to save time, reduce costs and increase efficiency.
- H1 2023 revenue from drug safety evaluation services grew 24% year-over-year. We maintained our industry leadership position in Asia Pacific for drug safety evaluation services that meet global regulatory requirements. In the first half of 2023, new lab testing facilities in Qidong and Suzhou began operations as scheduled, ensuring the business growth to accelerate in the second half of 2023.
- Moreover, we continued to enhance capabilities related to new modalities, with comprehensive coverage such as target protein degradation, nucleic acids, conjugates, and cell and gene therapies (CGT), etc.
- SMO revenue grew strongly by 53.9% in Q2 2023 and 34.3% in H1 2023, maintaining a leadership position in China. In the first half of 2023, SMO supported 25 new drug approvals for customers.
- In the first half of 2023, clinical CRO enabled our customers to obtain 8 IND approvals and submit 3 NDA filings.
- WuXi Biology: Strong Contribution from New Modalities; Early Discovery Screening Platform Continued to Generate Downstream Opportunities
- WuXi ATU: CTDMO Business Model Drives Growth
- WuXi DDSU: the First Year to Receive New Drug Application (NDA) Approval of New Drugs Developed for Customers; Breakthrough to Receive the First Royalty Income
Our Commitment to ESG
As an industry innovation enabler, a trusted partner and a contributor to the global healthcare industry, the Company is committed to environmental protection and sustainability, and to being a good global corporate citizenship.
Our outstanding ESG performance has been recognized by major global ESG rating agencies, including MSCI, S&P Global, Sustainalytics, CDP and EcoVadis. In June 2023, we received the fourth "Silver" medal recognition from EcoVadis for our Couvet site in Switzerland.
By the first half of 2023, our carbon emission intensity, energy consumption intensity and water use intensity reduced by 20.1%, 18.4%, and 31.6%, respectively, as compared to the baseline year 2020.
As we continue to advance our sustainability strategy, we embrace our shared responsibility to be good stewards of the environment.
Management Comment
Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "We continued to achieve steady growth of revenue, net profit, and free cash flow in the first half of 2023. Our revenue increased 6.3% year-over-year to RMB18.87 billion, or 27.9% if excluding COVID-19 commercial projects. Our adjusted non-IFRS net profit attributable to owners of the Company increased 18.5% year-over-year, outpacing the revenue growth rate, and our free cash flow achieved RMB2.93 billion, as a result of the Company's pursuit of operational excellence and productivity."
"The Company's performance in the first half of 2023 demonstrated that WuXi AppTec's unique CRDMO and CTDMO business models can effectively meet the growing demands from customers worldwide and continue to drive solid growth for the Company. In 2023, we aim to deliver a 5-7% revenue growth, increase adjusted non-IFRS gross profit by 13-14%, and expand free cash flow by 750-850%. We remain committed to prioritizing our customers' needs and enhancing our capacity and capabilities as we support our customers' efforts to bring groundbreaking therapies to patients around the world. Together, we can realize our vision that 'every drug can be made and every disease can be treated'."
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com
Forward-Looking Statements
This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our customers' intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Use of Non-IFRS and Adjusted Non-IFRS Financial Measures
We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses, amortization of intangible assets acquired in business combinations, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither is required by, or presented in accordance with IFRS.
We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such adjusted non-IFRS net profit attributable to owners of the Company, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.
For more information, please contact:
Ms. Ruijia Tang (for investors)
IR Director
Email: tang_ruijia@wuxiapptec.com
Mr. Davy Wu (for media)
PR Director
Email: davy_wu@wuxiapptec.com
View original content:
SOURCE WuXi AppTec | https://www.wkyt.com/prnewswire/2023/07/31/wuxi-apptec-announced-strong-results-second-quarter-first-half-2023-top-an-exceptionally-strong-year-2022/ | 2023-07-31T11:25:36 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/wuxi-apptec-announced-strong-results-second-quarter-first-half-2023-top-an-exceptionally-strong-year-2022/ |
GUANGZHOU, China, July 31, 2023 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG), a leading China-based beauty group, today announced that it has published its 2022 Environmental, Social and Governance ("ESG") report, outlining the Company's progress and performance in key ESG areas.
The report provides a comprehensive review of Yatsen's ESG initiatives and developments, including corporate governance, research and development, employee rights protection, human capital development, environmental sustainability and social responsibility, among others.
To view the report in full, please visit the ESG section on the Yatsen Investor Relations website. Alternatively, please click here for the English version and here for the Chinese version of the 2022 report.
About Yatsen Holding Limited
Yatsen Holding Limited (NYSE: YSG) is a leading China-based beauty group with the mission of creating an exciting new journey of beauty discovery for consumers around the world. Founded in 2016, the Company has launched and acquired numerous color cosmetics and skincare brands, including Perfect Diary, Little Ondine, Abby's Choice, Galénic, DR.WU (its mainland China business), Eve Lom, Pink Bear and EANTiM. The Company's flagship brand, Perfect Diary, is one of the leading color cosmetics brands in China in terms of retail sales value. The Company primarily reaches and engages with customers directly, both online and offline, with an expansive presence across all major e-commerce, social and content platforms in China.
For more information, please visit http://ir.yatsenglobal.com/.
For investor and media inquiries, please contact:
In China:
Yatsen Holding Limited
Investor Relations
E-mail: ir@yatsenglobal.com
The Piacente Group, Inc
Hui Fan
Tel: +86-10-6508-0677
E-mail: yatsen@thepiacentegroup.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: yatsen@thepiacentegroup.com
View original content:
SOURCE Yatsen Holding Limited | https://www.wkyt.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ | 2023-07-31T11:25:43 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ |
The cutting-edge platform empowers B2B SaaS start-ups to reduce churn, increase upsell, and boost NRR
WILMINGTON, Del., July 31, 2023 /PRNewswire/ -- ZapScale, a new-age customer success platform, is making waves in the industry by offering an unrivalled one-day onboarding experience along with the ability to track 150 customer data points for a comprehensive 360-degree view of customer health. This ground-breaking feature sets ZapScale apart from its competitors.
The secret behind ZapScale's lightning-fast onboarding lies in its comprehensive toolkit. With a robust framework of 40 pre-built KPI-based health frameworks, 60 pre-designed playbooks to automate CS ops, and seamless native integrations with all popular tools, ZapScale empowers businesses to gain complete visibility over customer data. With deep customer health insights, ZapScale's customers have seen an improvement in retention and increase in upsell opportunities.
Manasij Ganguli, Founder and CEO of ZapScale, shares his personal motivation for creating this game-changing platform: "ZapScale was born out of my passion to empower B2B SaaS start-ups with an efficient and effective CS platform. Having faced numerous customer success challenges in my previous start-up, which I successfully sold in 2019, I realized the critical need for a solution that could streamline, optimize, and accelerate CS operations.
For small to mid-sized businesses that have limited time and resources, implementing a CS platform has historically been a daunting task, taking weeks, if not months, to set up essential elements like customer health, playbooks, and integrations. ZapScale has addressed this challenge by offering a user-friendly and efficient implementation process, eliminating waste of time and resources. Now, businesses can seamlessly focus on their customers right from day 1."
ZapScale eliminates the traditional barriers and time-consuming processes associated with implementing CS platforms using key in-built features that facilitate custom mapping, support custom fields, and require no unique key to integrate applications, ensuring a tailored yet quick integration experience.
ZapScale is swiftly gaining traction in the market, with 30+ global companies already using the customer success platform. Starting at $249 per month, with a one-month free trial, ZapScale is helping businesses significantly improve their customer success initiatives.
For more information about ZapScale and to schedule a demo, visit www.zapscale.com.
Contact:
Nikita Kalra
Marketing Head, ZapScale
nikita@zapscale.com
Logo: https://mma.prnewswire.com/media/2097823/ZS_Logo.jpg
View original content:
SOURCE ZapScale | https://www.wkyt.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ | 2023-07-31T11:25:49 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ |
Elvina Kalieva 2023 Livesport Prague Open 2021 Odds
Elvina Kalieva's round of 32 match in the Livesport Prague Open 2021 will be versus Linda Noskova. Kalieva is +4000 to win this tournament at Tennis Club Sparta Praha.
Find all the latest odds for the 2023 Livesport Prague Open 2021 and place your bets with a new user bonus from BetMGM.
Kalieva at the 2023 Livesport Prague Open 2021
- Next Round: Round of 32
- Tournament Dates: July 28 - August 6
- Venue: Tennis Club Sparta Praha
- Location: Prague, Czechia
- Court Surface: Hard
Watch live sports without cable! Sign up today for a free trial to Fubo!
Kalieva's Next Match
Kalieva will meet Noskova in the round of 32 on Tuesday, August 1 at 5:00 AM ET, after getting past Tayisiya Morderger 6-2, 6-3 in the qualification final.
Kalieva is listed at +375 to win her next matchup against Noskova. Check out the latest odds for the entire field at BetMGM.
Want to bet on Kalieva? Head to BetMGM using our link for a bonus bet special offer for new players!
Kalieva Stats
- Kalieva defeated Morderger 6-2, 6-3 on Sunday in the qualifying round.
- In five tournaments over the past year, Kalieva is yet to win a title, and her overall record is 3-5.
- Kalieva has a record of 2-3 on hard courts over the last 12 months.
- In her eight matches over the past year, across all court surfaces, Kalieva has averaged 18.6 games.
- On hard courts, Kalieva has played five matches over the past 12 months, and she has totaled 20.8 games per match while winning 49.0% of games.
- Over the past year, Kalieva has been victorious in 12.5% of her return games and 28.6% of her service games.
- Kalieva has claimed 50% of her service games on hard courts and 11.1% of her return games over the past 12 months.
Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER.
© 2023 Data Skrive. All rights reserved. | https://www.wkyt.com/sports/betting/2023/07/28/elvina-kalieva-livesport-prague-open-2021-betting-odds/ | 2023-07-31T11:25:56 | 0 | https://www.wkyt.com/sports/betting/2023/07/28/elvina-kalieva-livesport-prague-open-2021-betting-odds/ |
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2023, before the U.S. market opens on Thursday, August 24, 2023.
111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 24, 2023 (7:30 PM Beijing Time on the same day).
Details for the conference call are as follows:
Conference Topic: 111, Inc. Second Quarter 2023 Earnings Conference Call
Registration Link: https://s1.c-conf.com/diamondpass/10032701-ygfhis.html
All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.
Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.
A telephone replay of the call will be available after the conclusion of the conference call until August 31, 2023
United States: +1 855 883 1031
Mainland China: 4001 209 216
Hong Kong: 800 930 639
International: +61 7 3107 6325
Conference ID: 10032701
A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/iw7ck9oc
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine Marketplace, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.
For more information on 111, please visit: http://ir.111.com.cn/.
View original content:
SOURCE 111, Inc. | https://www.kbtx.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ | 2023-07-31T11:27:05 | 1 | https://www.kbtx.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ |
DOVER, Del. (AP) — A judge has refused to dismiss a lawsuit alleging that a Delaware hospital system performed an autopsy on a 16-week-old fetus despite the parents refusing to give their consent.
Superior Court Judge Patricia Winston denied a motion this week by Christiana Care Health Services and Christiana Care Health System to dismiss a claim of intentional infliction of emotional distress filed by Maryland residents Meredith and Brandon Boas.
The couple had adequately stated a claim for intentional infliction of emotional distress, Winston said. The offense is defined as "extreme and outrageous conduct" that intentionally or recklessly causes severe emotional distress to another.
Attorneys for the hospital system argued that performing a fetal autopsy without consent and against the express wishes of the parents does not rise to the level of being "beyond all possible bounds of decency."
"Plaintiffs do not allege that the autopsy was performed in an indecent manner or that CCHS intentionally abused the fetus by dissecting and examining the fetus' internal organs," hospital lawyers wrote.
Meredith Boas began to experience fluid leakage in May 2021 when she was 16 weeks pregnant, according to the complaint. After being admitted to Christiana Care and diagnosed with preterm premature rupture of the membranes, she chose to have labor induced.
"She explicitly stated that she wanted her baby to remain whole and intact; that was why she chose to vaginally deliver him," the lawsuit states. "She delivered her baby boy, Ronan, approximately three hours later. Meredith and Brandon held Ronan and took pictures with him and said hello and goodbye for many hours."
Meredith specifically declined an autopsy when a nurse handed her autopsy consent paperwork, and the couple wanted private cremation and funeral services, the lawsuit states. The couple wanted placental pathology but "no fetal autopsy unless there are visual abnormalities," a doctor's note states. Discharge notes also indicated that the mother specifically declined an autopsy, according to the lawsuit.
"Meredith and Brandon left the hospital on May 6, 2021 believing their baby would be taken to the morgue and then the funeral home," the lawsuit states. "Instead — behind her back he was taken to pathology and was disemboweled."
The couple didn't learn what happened until more than a month later, when Meredith found the pathology report in her medical records.
"She, a grieving mother, read the words 'the fetus is eviscerated' and read how they took him apart after she had seen her son for the last time as whole and intact," according to the lawsuit.
The couple was later told that the hospital had a policy of performing autopsies on any babies who died under 20 weeks, "regardless of explicit parental directives to the contrary," the complaint states.
It is unclear whether such a policy is still in effect and whether Christiana Care officials acted contrary to staff rule documents that are publicly available online. According to those documents, which date back several years, an autopsy may be performed "only with proper consent in accordance with state law and hospital policy." The documents also state that consent for an autopsy is effective only if it is noted on a hospital form "signed by the appropriate legal representative of the patient."
An informational page on Christiana's website for parents who have experienced a miscarriage or pregnancy loss indicates that parents can "choose" to have an autopsy and that they have up to 24 hours to make that decision.
Hiran Ratnayake, a Christiana Care spokesperson, refused to say whether the policies were in effect in May 2021. He also declined to address the court ruling, saying Christiana Care does not comment on pending legal matters.
While allowing the lawsuit to proceed, the judge did dismiss a claim of negligent infliction of emotional distress. She said that claim could not remain because the parents themselves were not in a "zone of danger" in which negligent conduct causes a person to fear for his or her own safety.
"Plaintiffs claim defendants' autopsy performance on their fetus, against their express consent, caused them emotional distress, and their fright arose when they read Mrs. Boas's medical records," Winston wrote. "Hence, plaintiffs' fright arose from the peril of another, their fetus." | https://www.wdel.com/news/judge-allows-suit-alleging-that-hospital-ignored-parents-and-performed-fetal-autopsy-without-consent/article_f7ac9b22-2db7-11ee-b05b-2b39fe2db9dd.html | 2023-07-31T11:27:05 | 0 | https://www.wdel.com/news/judge-allows-suit-alleging-that-hospital-ignored-parents-and-performed-fetal-autopsy-without-consent/article_f7ac9b22-2db7-11ee-b05b-2b39fe2db9dd.html |
BEIJING, July 31, 2023 /PRNewswire/ -- 36Kr Holdings Inc. ("36Kr" or the "Company") (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced the launch of its 36Kr Media Lab in Silicon Valley, an initiative to embrace the large language models (LLM) revolution taking place in the content creation industry and optimize the application of artificial intelligence (AI) for the new economy sector.
36Kr Silicon Valley Media Lab's first project leveraging LLM, "Empty Office," will experimentally explore scenarios where AI can think and work as humans, enhancing content production efficiency and reducing costs. Through "Empty Office," 36Kr is also building innovative media solutions that will transform traditional video, graphic and text communications into avant-garde dialogues between customized AI characters and audiences. These network-based dialogues will be naturally and seamlessly driven by real-time data generation, and available anytime, anywhere.
At the same time, 36Kr Silicon Valley Media Lab continues to focus on tailoring its LLM to the new economy sector. By utilizing dedicated financial and business datasets, including enterprises' financial results, news, market dynamics and knowledge repositories, among other resources, to train its LLM to thoroughly understand and analyze business information, 36Kr has developed a model that keenly grasps the business nuances to generate accurate analysis and interpretation. 36Kr Silicon Valley Media Lab constantly maintains its database, serving as the reference foundation to ensure that its fact-based model produces rigorous and up-to-date business and financial analysis.
Furthermore, 36Kr's professionally-training, fine-tuning capability enables its LLM-empowered "Empty Office" to quickly and efficiently create informative content for the new economy sector. For instance, in the case of a business event, such as a new product launch, an AI agent can instantly extract relevant data from the database, automatically perform a comprehensive analysis, and issue reports within just seconds. This top-speed response gives 36Kr's business and financial-focused media platform an unrivaled edge.
Mr. Dagang Feng, Co-chairman and CEO of 36Kr, commented, "The launch of 36Kr Silicon Valley Media Lab is a testament to our AI technology acumen and vision as well as our commitment to extending media's boundaries. By integrating pioneering AI technology into content creation, 36Kr will constantly elevate the efficiency and quality of content production alongside the rapid advancement of the LLM, fostering a superior content ecosystem encompassing business, finance and technology, further turbocharging the evolution of the New Economy. As we adopt and develop more AI tools amid the technology's rapid advancement, we are strategically positioning the Company to break new ground and ultimately drive long-term growth for our business."
About 36Kr Holdings Inc.
36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China's New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services, and subscription services, to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by a comprehensive database and strong data analytics capabilities. Through diverse service offerings and significant brand influence, the Company is well-positioned to continuously capture the high growth potential of China's New Economy.
For more information, please visit: http://ir.36kr.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's goal and strategies; the Company's future business development, results of operations and financial condition; relevant government policies and regulations relating to our business and industry; the Company's expectations regarding the use of proceeds from this offering; the Company's expectations regarding demand for, and market acceptance of, its services; the Company's ability to maintain and enhance its brand; the Company's ability to provide high-quality content in a timely manner to attract and retain users; the Company's ability to retain and hire quality in-house writers and editors; the Company's ability to maintain cooperation with third-party professional content providers; the Company's ability to maintain relationships with third-party platforms; general economic and business conditions in China; possible disruptions in commercial activities caused by natural or human-induced disasters; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 8965-0708
E-mail: ir@36kr.com
The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: 36Kr@tpg-ir.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: 36Kr@tpg-ir.com
View original content:
SOURCE 36Kr Holdings Inc. | https://www.kbtx.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ | 2023-07-31T11:27:09 | 0 | https://www.kbtx.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ |
A 26-year-old man is dead after the dirt bike he was riding slammed into a tree Saturday night.
It happened around 8:40 p.m. in the 800 block of Sheldon Drive in Newark, New Castle County Police said.
First responders, who found the victim under the bike when they arrived, pronounced him dead at the scene, and detectives determined he'd lost control of the bike going around a curve.
Police are asking anyone with information about the incident to contact Detective Belk at (302)395.8052, by e-mail at Corey.Belk@newcastlede.gov, or by calling the New Castle County Division of Police non-emergency number at (302)573.2800. | https://www.wdel.com/news/man-killed-in-newark-dirt-bike-crash/article_21764e2c-2ee3-11ee-a604-1f8a595dfcaa.html | 2023-07-31T11:27:11 | 1 | https://www.wdel.com/news/man-killed-in-newark-dirt-bike-crash/article_21764e2c-2ee3-11ee-a604-1f8a595dfcaa.html |
Delaware State Police have identified a Dover man killed in a crash between a motorcycle and a car on Route 1 in Middletown.
47-year-old Luis Lopez was riding his motorcycle southbound, apparently at a high rate of speed, early Friday morning and traveled into another lane, colliding with the back of a car, police said.
Lopez was thrown from the motorcycle, and was hit by a southbound pick-up truck.
He died at the scene.
The other drivers were not injured.
Southbound Route One was closed near Route 299 for about four hours.
Police say Lopez was not wearing a helmet. | https://www.wdel.com/news/update-troopers-identify-victim-of-fatal-motorcycle-crash-on-route-1/article_b4d14550-2ecf-11ee-94d0-f32c4c0e28ee.html | 2023-07-31T11:27:13 | 1 | https://www.wdel.com/news/update-troopers-identify-victim-of-fatal-motorcycle-crash-on-route-1/article_b4d14550-2ecf-11ee-94d0-f32c4c0e28ee.html |
- Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023
- Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disorders
- Brain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date
- Advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications
- Orphan drug designation (ODD) granted by the European Commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)
- Type A meeting planned with FDA regarding troriluzole program in Spinocerebellar Ataxia Type 3 (SCA3) and enrollment in Phase 3 obsessive compulsive disorder (OCD) trial expected to complete at end of 2023
NEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "In less than a year since our spin-off, the Biohaven team has driven strong and consistent progress across multiple drug development platforms. We were excited to recently report positive interim data from the ongoing EEG biomarker study of our lead Kv7 activator, BHV-7000. As expected, BHV-7000 demonstrated CNS activity consistent with what has been reported in EEG studies with other Kv7 channel activators in development that are clinically effective in treating epilepsy and with other approved anti-seizure medications. Importantly, BHV-7000 demonstrates CNS target engagement but is not associated with the typical CNS adverse events associated with other ASMs, like somnolence and fatigue. We look forward to completing the higher dose groups in this EEG study and initiating Phase 2/3 studies with our once daily, extended-release oral formulation later this year."
Dr. Coric continued, "We also shared a number of equally exciting announcements across our broader pipeline this quarter. We successfully administered the first three doses in the SAD portion of our ongoing SAD/MAD study evaluating BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor. Potential therapeutic concentrations of BHV-8000 were achieved and BHV-8000 was well tolerated with only mild adverse events reported, reinforcing our plans to start a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. In addition, we have advanced IND enabling preclinical studies and remain on track to submit an IND with our IgG degrader, BHV-1300, later this year. We also anticipate submitting an IND with our IgA degrader in 2024 as we continue to advance multiple clinical degrader candidates across a wide range of indications. We also shared key updates for our taldefgrobep alfa program (an anti-myostatin) with enrollment completion in our pivotal study in SMA and a planned Phase 2 trial initiation in obesity."
"Finally, I want to reaffirm Biohaven's commitment to the SCA3 patient community in spite of the recent disappointing regulatory decision by the FDA not to review our submitted NDA. Given the seriousness of SCA3 and consistent treatment benefits observed across multiple prespecified outcome measures, including an 80% delay in disease progression over the one-year study period with substantial risk reduction in falls, we believe that full consideration of all available data is warranted for this ultra-rare disease. Biohaven has built its foundation around our patient mission and we plan to continue to work with regulatory agencies to try to advance troriluzole for individuals suffering from SCA3."
Second Quarter 2023 and Recent Business Highlights
- Announced positive interim data from EEG biomarker study with BHV-7000 - In July 2023, the Company provided a preliminary data update from the ongoing electroencephalogram (EEG) biomarker study for the Kv7 Channel Activator platform. Preliminary Phase 1 data confirmed evidence of target engagement in the central nervous system for subjects with projected therapeutic concentrations of BHV-7000 (based on the EC50 from preclinical models), measured by changes from baseline in EEG spectral power that occurred after dosing. These pharmacodynamic (PD) effects were similar to those reported in the literature for anti-seizure medicines (ASMs), including Kv7 activators in development that are clinically effective in treating epilepsy. BHV-7000's PD effects were also differentiated from those reported for other Kv7 activators including, specifically, the absence of increases in EEG spectral power in frequency bands associated with drowsiness and somnolence. Results from the low-dose group validate the preclinical hypothesis, confirm the Phase 1 SAD/MAD clinical data, and provide strong support for Biohaven's plans to initiate pivotal studies with BHV-7000 in focal epilepsy and bipolar disorder in the second half of 2023. The preliminary data highlight BHV-7000's differentiation and potentially favorable clinical profile compared to other ASMs, and the Company expects to present the complete EEG results by the end of the year. Additionally, new pharmacokinetic data from multiple clinical formulations being studied has now confirmed a once daily extended-release oral formulation that will be used in the Phase 2/3 clinical programs.
- Successfully dosed three cohorts with single ascending doses of oral, brain penetrant, dual TYK2/JAK1 agent, BHV-8000 - In July 2023, the Company announced that it successfully dosed three cohorts in the SAD portion of an ongoing SAD/MAD Phase 1 study evaluating brain penetrant TYK2/JAK1 agent, BHV-8000 in healthy volunteers. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and PD of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported. These data provide support for further development of BHV-8000, and the Company anticipates beginning a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. The Company had previously reported initiation of dosing with BHV-8000 in the Phase 1 study at Biohaven's R&D Day in May 2023.
- Reported on continued progress observed with Biohaven's first-in-class bispecific IgG degrader, BHV-1300, as compound advances to IND filing in 2H2023 - In July 2023, the Company shared an update on BHV-1300's highly competitive safety, manufacturable and PD profile. The Company is assembling a pipeline of partially de-risked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track for submission in 2023 and an IND application for Biohaven's IgA degrader on track for submission in 2024
- Type A meeting planned to comprehensively address FDA's concerns in connection with Troriluzole program in SCA3 - In July 2023, the Company announced that the FDA informed Biohaven it would not review the recently submitted New Drug Application (NDA) for troriluzole for the treatment of spinocerebellar ataxia type 3 (SCA3), an ultra-rare, genetically-defined, neurodegenerative disease associated with progressive disability, frequent falls, loss of ambulation, speech and swallowing impairment, and premature death that is the most common SCA genotype worldwide. The FDA informed Biohaven it would not review the application given that the study's primary endpoint was not met and thus, would not permit a substantive review. Biohaven is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible given no therapy is currently approved for this ultra-rare genetic disorder. Biohaven plans to request a Type A meeting to comprehensively address FDA's concerns cited in the refusal to file letter.
- EMA orphan drug designation granted for taldefgrobep alfa for the treatment of SMA: - In July 2023, the Company announced that taldefgrobep alfa received orphan drug designation (ODD) from the European Commission for taldefgrobep for the treatment of SMA. Taldefgrobep previously received Fast-Track and ODD from the FDA. At Biohaven's R&D Day, the Company announced plans to complete randomization of approximately 180 patients in global SMA trial.
Upcoming Milestones:
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company plans to reach significant pipeline milestones in the coming periods. Biohaven expects to:
- Announce Phase 1 EEG study results by year-end 2023: The Company expects to present complete results from its ongoing EEG study with BHV-7000 in healthy volunteers by the end of the year.
- Initiate Phase 2/3 studies with BHV-7000 in the second half of 2023: Biohaven expects to initiate pivotal trials in patients with focal epilepsy and bipolar disorder in the second half of 2023.
- Submit IND with BHV-1300, the Company's lead extracellular degrader: The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023 and expects to initiate Phase 2 studies in 2024.
- Submit IND with selective Gd-IgA1 degrader: The Company expects to submit an IND with a Gd-IgA1 degrader indicated for IgA nephropathy in the first half of 2024.
- Initiate Phase 2 study with BHV-8000: The Company commenced Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor for neuroinflammatory disorders, in the first half of 2023 and expects to initiate a Phase 2 study in Parkinson's disease in 2024.
- Submit IND with BHV-2100 in chronic pain: The Company expects to submit an IND with BHV-2100, a selective TRPM3 antagonist in the Company's ion channel platform, in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023: Two Phase 3 randomized, double-blind, placebo-controlled studies of troriluzole in OCD are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in at least one Phase 3 trial by year-end 2023.
- Complete enrollment in Phase 3 clinical study of taldefgrobep alfa in SMA: The Company expects to complete enrollment in the study of taldefgrobep in SMA in the second half of 2023.
- Continue advancements across multiple neuroscience and immunoscience indications: The Company's preclinical pipeline includes a platform of bispecific degraders of extracellular proteins directed against IgG, IgA and other targets, TRPM3 and Kv7 family of ion channels, and other undisclosed targets, including those with disease-modifying potential.
Capital Position:
Cash, cash equivalents and marketable securities as of June 30, 2023 was $349.0 million, including $13.9 million of restricted cash, and excluding $40.4 million of cash payable to Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 20221.
Second Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were $79.5 million for the three months ended June 30, 2023, compared to $177.1 million for the three months ended June 30, 2022. Non-cash share-based compensation expense was $2.5 million for the three months ended June 30, 2023, a decrease of $10.3 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
General and Administrative (G&A) Expenses: General and administrative expenses were $14.5 million for the three months ended June 30, 2023, compared to $20.0 million for the three months ended June 30, 2022. The decrease of $5.5 million was primarily due to decreased non-cash share-based compensation costs. Non-cash share-based compensation expense was $2.2 million for the three months ended June 30, 2023, a decrease of $5.8 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
Other Income (Expense), Net: Other income (expense), net was a net income of $5.8 million for the three months ended June 30, 2023, compared to net expense of $0.1 million for the three months ended June 30, 2022. The increase of $5.9 million was primarily due to an increase in net investment income and an increase of $1.7 million in other income related to our transition services provided to the Former Parent, which is largely non-recurring.
Net Loss: Biohaven reported a net loss for the three months ended June 30, 2023, of $90.3 million, or $1.32 per share, compared to $203.3 million, or $5.16 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended June 30, 2023 was $85.7 million, or $1.25 per share, compared to $182.5 million, or $4.63 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under "Non-GAAP Financial Measures," exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the "Spin-Off"), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022. The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods.
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:
SOURCE Biohaven Ltd. | https://www.kbtx.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ | 2023-07-31T11:27:13 | 1 | https://www.kbtx.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Today, Blitz Insurance, a specialty insurance carrier, partners with Ascend to modernize payment experiences for insurance brokers selling in specialty markets. With this partnership, Blitz Insurance will open new customer segments by offering both direct bill and premium financing into their payments workflow.
"When we looked into the market for a solution, Ascend was the right choice. Ascend meets our needs for a better payments experience for our partners while reducing everyone's operational expenses," said Brandon Murphy, Chief Distribution Officer of Blitz Insurance. "We will now have the ability to not only expand to direct bill and a premium finance option but also simplify the movement of money between us and our partners."
With Ascend, Blitz Insurance is now able to provide a direct bill in addition to their existing agency bill workflow - allowing brokers to decide what billing method works best for them. By utilizing Ascend, Blitz Insurance not only grows their footprint of appointed brokers but also gains administrative efficiency by automating what would otherwise have been a large operational undertaking.
Ascend automatically attributes incoming payments to policies in real time, speeding up the reconciliation process. By modernizing the payments experience and speeding up the reconciliation of incoming premiums, Blitz Insurance can offer a best-in-class experience to its brokers and agents.
"We find that across the insurance ecosystem - companies want to provide a seamless payment workflow for their customers and their teams," said Andrew Wynn, co-CEO of Ascend. "Ascend is built so brokers and carriers can offer this experience without shouldering the administrative resources and costs needed to support these operations."
About Ascend
Ascend is the first insurance payments platform that automates financial operations from collections and financing to carrier and commission payables. Founded by two-time insurtech entrepreneurs Andrew Wynn and Praveen Chekuri, Ascend helps insurance brokers, MGAs, and carriers improve their bottom lines by eliminating expensive and labor-intensive payment workflows. To learn more, please visit LinkedIn, Twitter or check out https://www.useascend.com/.
About Blitz Insurance
Blitz is a tech-driven insurer revolutionizing the $60B specialty market catering to SME segment. By leveraging industry knowledge and cutting-edge technology, we deliver a simpler, smarter, and faster coverage experience.
The company is led by a veteran team of insurance and technology experts and has been funded with $25M from its founder & CEO, a Forbes-listed serial entrepreneur in the real estate and insurance industries.
Contact:
Mike Nguyen
press@useascend.com
View original content to download multimedia:
SOURCE Ascend | https://www.kbtx.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ | 2023-07-31T11:27:14 | 1 | https://www.kbtx.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ |
PITTSBURGH (AP) — The Philadelphia Phillies designated Navy veteran Noah Song for assignment Saturday.
The 26-year-old right-handed pitcher was taken by the Phillies from Boston in the Rule 5 draft during the league's winter meetings in December with hopes he would play after completing his military service.
If Song clears waivers, Boston will have the option of taking him back to its organization.
Song reported to major league spring training on Feb. 23 after the Navy granted his transfer from active duty to the reserves. Song hadn't pitched in a professional game since Aug. 29, 2019, for Class A Lowell.
Song went 1-0 with a 7.36 ERA in eight games in stints with three of Philadelphia's minor league teams while on the major league injured list with a lower-back strain. Song's 30-day rehab assignment ended this week, forcing the Phillies to decide whether to add him to the active roster or expose him to waivers and offer him back to the Red Sox if he is not claimed.
The Phillies are in the thick of the NL wild-card race and opted not to use a roster spot on a pitcher who had not pitched in any baseball game before this season since 2019.
"(The major-league coaching staff) hasn't really seen him," Phillies manager Rob Thomson said of Song before his team played the Pirates on Saturday night. "We trust the people who have seen him and if they think it can work then we try to make it work. There just wasn't enough there."
The 6-foot-4, 200-pound Song was picked from the Red Sox in the draft for unprotected minor league players. Philadelphia put him on the military list while he continued active duty. The Red Sox drafted Song in the fourth round — he likely would've gone much higher, but his impending military service caused teams to back off.
Song impressed in his only pro season, making seven starts for Boston's Class A Lowell affiliate in 2019, with a 1.06 ERA and 19 strikeouts in 17 innings. With a fastball clocked in the upper 90s mph, he dominated that year as a senior at the U.S. Naval Academy, going 11-1 with a 1.44 ERA and 161 strikeouts in 94 innings.
In November 2019, Defense Secretary Mark Esper signed a memo clearing the way for athletes at military academies to delay service commitments and play pro sports after graduation. Song's request to have those rules retroactively applied to him was denied.
Song began school as a flight officer in the summer of 2020 and finished that phase last April. He started additional aviation training the next month.
—
AP MLB: https://apnews.com/hub/mlb and https://twitter.com/AP_Sports | https://www.wdel.com/sports/phillies-designate-navy-veteran-noah-song-for-assignment/article_79ee5e20-2ee6-11ee-bfe4-130ff5a8a01f.html | 2023-07-31T11:27:14 | 1 | https://www.wdel.com/sports/phillies-designate-navy-veteran-noah-song-for-assignment/article_79ee5e20-2ee6-11ee-bfe4-130ff5a8a01f.html |
PITTSBURGH (AP) — Endy Rodriguez hit a go-ahead, bases-loaded triple and drove in four runs, fellow rookie Liover Peguero had a home run among his three hits and the Pittsburgh Pirates beat the Philadelphia Phillies 7-6 on Saturday night.
Rodriguez's triple sparked a four-run fifth inning against Aaron Nola (9-7) that put the Pirates in front 7-4. Phillies center fielder Brandon Marsh was unable to make a play on the sinking liner and Rodriguez then scored on Alika Williams' single, which was his first career hit.
Rodriguez smiled when asked if he likes to hit with the bases loaded.
"That's the best part of the game because that's where you get paid," Rodriguez said with a smile through a translator.
Peguero hit a leadoff home run in the third, his second, to open the scoring.
"I feel like one thing we're trying to do is trying to help each other, pass it to the next guy," Peguero said of the Pirates' young players. "It's been showing up."
Yet another rookie, Quinn Priester (2-1), won his second straight start despite allowing five runs and six walks in five innings.
Closer David Bednar entered the game in the eighth inning with the Pirates leading 7-5 and gave up a run-scoring single to rookie Johan Rojas. However, he got J.T. Realmuto to hit into a game-ending double play with runners on first and third for his 21st save.
Rookie third baseman Jared Triolo started the around-the-horn double play.
"We've said when you have a bunch of young guys that you want them to learn and contribute," Pirates manager Derek Shelton said. "All around, they played outstanding. They're not scared. We know we're going to make mistakes, but we also know they're going to do things like tonight that really excite you."
Bryson Stott had three hits for the Phillies, who entered the night leading the NL wild-card standings by percentage points over Cincinnati.
Nola was tagged for seven runs — five earned — and nine hits in 4 2/3 innings. He had won four of his previous five decisions.
The Phillies scored four runs in the fourth inning to move in front 4-1. Marsh ripped a three-run double to the gap in right-center and scored on Jake Cave's double.
The Pirates got within a run in the bottom of the fourth as Rodriguez hit an RBI double and scored on a single by Peguero.
Kyle Schwarber drew a bases-loaded walk from Ryan Borucki in the sixth to draw the Phillies to 7-5.
Jack Suwinski, on his 25th birthday, had two hits along with Rodriguez and Ji-Man Choi for the Pirates, who have alternated wins and losses in their last nine games.
The Pirates had their first sellout since opening day with a crowd of 38,434.
PHILLIES WAIVE NAVY VET
The Phillies designated Navy veteran Noah Song for assignment before the game.
The 26-year-old right-handed pitcher was taken by the Phillies from Boston in the Rule 5 draft during the league's winter meetings in December with hopes he would play after completing his military service.
If Song clears waivers, Boston will have the option of taking him back to its organization.
Song reported to major league spring training on Feb. 23 after the Navy granted his transfer from active duty to the reserves. Song hadn't pitched in a professional game since Aug. 29, 2019, for Class A Lowell.
Song went 1-0 with a 7.36 ERA in eight games in stints with three of Philadelphia's minor league teams while on the major league injured list with a lower-back strain. Song's 30-day rehab assignment ended this week, forcing the Phillies to decide whether to add him to the active roster or expose him to waivers and offer him back to the Red Sox if he is not claimed.
TURNER DROPPED IN ORDER
Slumping Phillies shortstop Trea Turner was dropped to seventh in the batting order from his customary No. 2 spot. Turner entered the game in a 0-for-12 slump and is hitting .242 in his first season since signing an 11-year, $300-million contract as a free agent.
"I think he's disappointed but not because he's batting seventh but because he expects to produce more than he's producing," Phillies manager Rob Thomson said. "He's trying to do too much."
Turner went 1 for 3 with a walk.
Thomson said he hopes Turner hitting near the bottom of the lineup will be only temporary.
"When he gets his stroke back and looks comfortable, I'll put him back up there," Thomson said. "I've said all along that I think our best lineup is with Trea hitting second."
UP NEXT
Phillies LHP Cristopher Sanchez (0-3, 2.98 ERA) starts in Sunday's series finale against LHP Rich Hill (7-10, 4.82), who could be making his last start for the Pirates with baseball's trade deadline approaching Tuesday.
___
AP MLB: https://apnews.com/hub/mlb and https://twitter.com/AP_Sports | https://www.wdel.com/sports/rookies-rodriguez-and-peguero-lift-pirates-over-phillies/article_f28311ba-2ee5-11ee-a700-13d8cf29bdea.html | 2023-07-31T11:27:14 | 0 | https://www.wdel.com/sports/rookies-rodriguez-and-peguero-lift-pirates-over-phillies/article_f28311ba-2ee5-11ee-a700-13d8cf29bdea.html |
STAMFORD, Conn., July 31, 2023 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, recently announced the successful sale of an 11.5 MWp PV project to the Swiss-based energy company MET Group. The project was sold at the Ready-to-Build ("RTB") stage and MET Group will complete the construction and operate the power plant. This is the first project developed to RTB stage by Emeren Germany GmbH, the Berlin-based subsidiary of Emeren Group, since its entry into the market in early 2021. Capcora, a German consulting company, acted as the exclusive sell-side M&A advisor to Emeren.
The new PV power plant will be located in Kentzlin nestled in the state of Mecklenburg-Western Pomerania and the commercial operations are expected to start in the second half of 2024.
Yumin Liu, CEO of Emeren Group, commented, "This project is an important milestone for our business in Germany and represents our commitment to developing renewable energy infrastructure in the region. We look forward to continuing to work with our local partners to build a more sustainable future."
Bernd Wollwerth-Carl, Director of Emeren Germany GmbH, added, "We are delighted to have sold our first RTB project in Germany. Starting from scratch in 2021, we managed to grow quickly in a competitive German PV market, establishing partnerships and building a pipeline of medium and large-scale ground mounted PV plants. With MET, we found a reliable and competent partner and we look forward to further expanding our cooperation."
Christian Hürlimann, Renewables CEO of MET Group, commented, "The Kentzlin project fits well into MET's strategic vision to enter the highly competitive German renewables market, as well as to further expand its renewables portfolio across Europe and particularly in Western Europe. Emeren Group's expertise in renewable energy was instrumental in achieving this milestone, and we anticipate future collaboration on additional projects."
Henning Prigge, Director at Capcora, adds: "We are delighted to have played a pivotal role in Emeren's successful project sale to MET Group, a prominent integrated European energy company. Our long-standing partnership with Emeren has allowed us to witness their growth and success, and we couldn't be happier to have been a part of this milestone. This collaboration reinforces our commitment to providing top-notch support and solutions to our valued clients."
About Emeren Group Ltd
Emeren Group Ltd (NYSE: SOL) is a leading global solar project developer, owner, and operator with a pipeline of projects and IPP assets totaling over 3 GW, as well as a storage pipeline of over 6 GWh across Europe, North America, and Asia. The Company focuses on solar power project development, construction management and project financing services with local professional teams across multiple countries. For more information, go to www.emeren.com.
About MET Group
MET Group is an integrated European energy company, headquartered in Switzerland, with activities and assets in natural gas and power markets. MET is present in 14 countries through subsidiaries, 30 national gas markets, and 22 international trading hubs. MET has extensive experience in operating green (renewable) and flexible (conventional) energy assets, thus providing the widest possible support to energy transition. In 2022, MET Group's consolidated sales revenue amounted to EUR 41.5 billion, the total traded volume of natural gas was 109 BCM including futures, total traded electricity 67 TWh including futures.
About Capcora
Capcora is an independent financial advisory boutique specializing in M&A and project finance services to accelerate the energy transition in Europe. Founded in 2015, the Frankfurt-based company helps its clients succeed in the renewable energy and infrastructure sectors by advising them on sell-side and buy-side transactions, and by raising mezzanine, unitranche or senior debt.
View original content to download multimedia:
SOURCE Emeren Group Ltd | https://www.kbtx.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ | 2023-07-31T11:27:14 | 1 | https://www.kbtx.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ |
BEIJING, July 31, 2023 /PRNewswire/ -- Gravitas Education Holdings, Inc. ("GEHI" or the "Company") (NYSE: GEHI), a leading early childhood education service provider in China, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 3/F, No. 28 Building, Fangguyuan Section 1, Fangzhuang Fengtai District, Beijing 100078, People's Republic of China, at 10:00 a.m. (Beijing time) on September 11, 2023, for the purposes of considering and, if thought fit, approving the transactions contemplated in the Agreement and Plan of Merger (the "Merger Agreement"), dated April 18, 2023, by and among the Company, Bright Sunlight Limited, a Cayman Islands exempted company and a direct, wholly owned subsidiary of the Company ("Merger Sub"), Best Assistant Education Online Limited, a Cayman Islands exempted company ("Best Assistant") and a controlled subsidiary of NetDragon Websoft Holdings Limited (HKEX: 0777, "NetDragon"), a Cayman Islands exempted company, and solely for purposes of certain named sections thereof, NetDragon. It is contemplated that Best Assistant will transfer the education business of NetDragon outside of the PRC to Elmtree Inc., a Cayman Islands exempted company limited by shares ("eLMTree") and currently a wholly owned subsidiary of Best Assistant. Pursuant to the Merger Agreement, Merger Sub will merge with and into eLMTree with eLMTree continuing as the surviving company and becoming a wholly owned subsidiary of the Company (the "Merger").
Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each ordinary share of eLMTree issued and outstanding immediately prior to the Effective Time (excluding the Dissenting Shares and the Excluded Shares, each as defined in the Merger Agreement) will be cancelled in exchange for the right to receive a number of validly issued, fully paid and non-assessable ordinary shares of the Company in a transaction exempt from the registration requirements under the Securities Act of 1933.
Shareholders of the Company will also be asked to consider and vote on certain additional Merger-related proposals at the EGM, including, among others:
- that, subject to and conditional upon the Merger becoming effective, the fifth amended and restated memorandum and article of association of the Company be amended and restated by their deletion in their entirety and the substitution of in their place of the sixth amended and restated memorandum and articles of association of the Company (the "A&R MAA") effective immediately prior to the Effective Time of the Merger;
- that, subject to and conditional upon the Merger becoming effective, the name of the Company be changed from "Gravitas Education Holdings, Inc." to "Mynd.ai, Inc." effective immediately prior to the Effective Time;
- that, subject to and conditional upon the Merger becoming effective, immediately prior to the Effective Time, the authorized share capital of the Company be varied as follows: (a) the authorized share capital of the Company shall be varied to US$1,000,000 divided into 1,000,000,000 shares comprising of (i) 990,000,000 ordinary shares of a par value of US$0.001 each (each a "ListCo Ordinary Share") and (ii) 10,000,000 shares of a par value of US$0.001 each of such class or classes (however designated) as the board of directors may determine in accordance with the A&R MAA, and (b) all Class A ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class A Ordinary Shares") and all Class B ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class B Ordinary Shares") in the authorized share capital of the Company (including all issued and outstanding ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares, and all authorized but unissued ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares) shall be re-designated as ListCo Ordinary Shares.
Holders of the Company's ordinary shares whose names are on the register of members of the Company at the close of business in the Cayman Islands on August 7, 2023, are entitled to notice of, and to vote at, the EGM or any adjournment or postponement thereof in person. Holders of the Company's American depositary shares ("ADSs") at the close of business in New York City on August 7, 2023, are entitled to exercise their voting rights for the underlying ordinary shares and must act through Citibank, N.A., the depositary of the Company's ADS program.
The notice of the EGM, which contains the detailed proposals to be presented at the EGM, and the proxy statement related to the EGM, are being filed today with the U.S. Securities and Exchange Commission ("SEC") and can be obtained without charge from the SEC's website (http://www.sec.gov). These documents are also available in the "Financial Information" section of the Company's investor relations website at https://ir.geh.com.cn/. In addition, the proxy materials (including the proxy statement) will be mailed to the Company's shareholders and holders of ADSs.
SHAREHOLDERS AND ADS HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN VOTING INSTRUCTIONS AND IMPORTANT INFORMATION ABOUT THE COMPANY, ELMTREE, THE MERGER AND RELATED MATTERS.
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of eLMTree or the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Forward-Looking Statements
This press release contains certain "forward-looking statements." These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the pending transactions described herein, and the parties' perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the Merger, including the equity values, the benefits of the Merger, expected revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words "will," "expect," "believe," "estimate," "intend," "plan" and similar expressions indicate forward-looking statements.
Such forward-looking statements are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from the expectations as a result of a variety of factors. Such forward-looking statements are based upon management's current expectations and include known and unknown risks, uncertainties and other factors, many of which are hard to predict or control, that may cause the actual results, performance, or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the Merger, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iii) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of the Company or eLMTree; (iv) risks related to disruption of management time from ongoing business operations due to the Merger; (v) the risk that any announcements relating to the Merger could have adverse effects on the market price of the Company's securities; (vi) the risk that the Merger and its announcement could have an adverse effect on the ability of eLMTree to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (vii) any changes in the business or operating prospects of eLMTree or its businesses; (viii) changes in applicable laws and regulations; and (ix) risks relating to the combined company's ability to enhance its services and products, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the proxy statement that will be filed with the SEC by the Company in connection with the Merger, and other documents that the parties may file with or furnish to the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and eLMTree, the Company and their subsidiaries and affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information and Where to Find It
The Company will file with the SEC and mail to its shareholders and ADS holders a proxy statement in connection with the Merger. Investors and security holders are urged to read the proxy statement when it becomes available because it will contain voting instructions and important information regarding the proposed arrangement. You may access the proxy statement (when available) and other related documents filed by the Company with the SEC at the SEC's website at www.sec.gov. You also may obtain the proxy statement and other documents filed by the Company with the SEC relating to the proposed arrangement for free by accessing the Company's website at https://ir.geh.com.cn/ by clicking on the link for "Financial Information," and then clicking on the link for "SEC Filings."
CONTACT: Gravitas Education Holdings, Inc., Investor Relations, E-mail: ir@geh.com.cn
View original content:
SOURCE Gravitas Education Holdings Inc. | https://www.kbtx.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ | 2023-07-31T11:27:25 | 0 | https://www.kbtx.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ |
CASS COUNTY, Ind. – Severe weather spawned at least one tornado as it swept across Indiana early Saturday morning.
The National Weather Service confirmed an EF0 tornado hit Walton in Cass County at 2:19 a.m. on Saturday, July 29. It stayed on the ground for about two minutes.
The tornado packed maximum winds of 75 mph hour, NWS officials said. It was on the ground near Walton and the Cass-Miami county line.
The majority of damage involved beans and corn extending from west of S CR 900 E and north of SR 218 to near the intersection of E CR 700 S and S CR 500 W. There was also a small area of tree damage at a property on S CR 900 E. Grissom Air Reserve Base recorded a wind gust of 74 mph.
The National Weather Service said the tornado’s path was about 2.1 miles in length. Its maximum width was about 50 yards.
NWS crews also assessed storm damage in Jay County over the weekend, after receiving reports of downed trees and damaged structures. That damage appeared to be consistent with straight-line winds, but investigators were reviewing drone footage to see if a tornado could’ve been responsible.
The same storm system spawned an EF1 tornado in Defiance, Ohio, according to NWS.
It was on the ground for less than a mile and packed peak winds of 90 mph. Although it was on the ground for about a minute, NWS officials said it damaged three barns and a home. It also snapped branches and uprooted trees before dissipating. | https://cbs4indy.com/indiana-news/weekend-storm-spawned-tornado-in-cass-county-nws-says/ | 2023-07-31T11:27:30 | 0 | https://cbs4indy.com/indiana-news/weekend-storm-spawned-tornado-in-cass-county-nws-says/ |
LA ROMANA, Dominican Republic, July 31, 2023 /PRNewswire/ -- The international known company Hilton Hotels & Resorts opens its doors to its Hilton Garden Inn La Romana hotel project in the Dominican Republic, in collaboration with a group of important investors under the company Riverhome Capital S.A.S., whose main shareholder is the prominent Dominican former major league player, Edwin Encarnación; together with the vision of the lawyer Guillermo Estrella Ramia and the Minister of Tourism, David Collado.
The inauguration was led by Luis Abinader Corona, president of the Dominican Republic and who expressed that "This hotel has something very special, opening up the beach and the sector of La Caleta of La Romana, which for a long time was closed to the province and its visitors. Since private investment must always be accompanied by public infrastructure, we are working on creating them, so we are all part of this development of La Romana."
With an investment of 25 million united states dollars and the creation of more than 300 direct jobs, it is considered as a hotel option for the growing flows of tourists that the area is currently receiving. Located a short distance from other points of relevance, such as La Romana Airport 18 minutes away, Casa de Campo 12 minutes away and Central Romana just a few blocks away.
The new hotel facility has a privileged location on a 5,000 square meters property, located on the coast of the municipal district of La Caleta, La Romana province. With a capacity of 130 rooms, distributed in five of the seven floors of the building, it also counts with swimming pools, two bars, a restaurant, gym, event, meeting and multipurpose rooms, and outdoor areas, ideal for social and corporate celebrations.
The hotel responds to the interest of Edwin Encarnación to invest in the development of his province of origin, who expressed that "from the moment this project was presented to me, I knew that I had to be part and be the one to assume this. I joined the development of this hotel, with the only requirement that most of the workers came from here, from my town La Romana, and we achieved this."
View original content to download multimedia:
SOURCE Grupo De Valle | https://www.kbtx.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ | 2023-07-31T11:27:32 | 0 | https://www.kbtx.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ |
WESTFIELD, Ind. – The Indianapolis Colts will give “Kids Day” another shot.
Friday’s practice at Grand Park Sports Campus in Westfield was supposed to celebrate the special day, but a round of severe weather during the morning forced the team to move practice inside.
As a result, many of the thousands of fans expected for Friday’s session couldn’t attend practice, which moved indoors to the Events Center, a smaller venue capable of seating about 750 fans. The weather also forced the team to close Colts City for the day.
The Colts moved Kids Day to Monday, July 31. Practice is scheduled to begin at 10 a.m.; free tickets are available at the Colts’ website. The team said tickets to July 28’s practice will not be accepted; fans need to claim new ones for Monday’s session.
While tickets remain for several training camp practices, the following four dates are sold out:
- Sat. Aug. 5 – 6 p.m.
- Sun., Aug. 6 – 2 p.m. (“Give Back Sunday,” presented by Meijer)
- Wed., Aug. 16 – 6 p.m. (Joint Practice No. 1 with the Chicago Bears)
- Thurs., Aug. 17 – 6 p.m. (Joint Practice No. 2 with the Chicago Bears; Thirsty Thursday) | https://cbs4indy.com/news/indianapolis-colts-to-host-rescheduled-kids-day-at-training-camp/ | 2023-07-31T11:27:36 | 0 | https://cbs4indy.com/news/indianapolis-colts-to-host-rescheduled-kids-day-at-training-camp/ |
- CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled
- Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population
CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threatening cardiovascular (CV) events. The study enrolled more than 1,400 patients.
Eplontersen is an investigational antisense medicine designed to inhibit the production of transthyretin and slow the progression of cardiomyopathy for people living with hereditary or wild-type ATTR-CM.
"CARDIO-TTRansform is the largest and most comprehensive ATTR-CM study ever conducted. The evaluation of eplontersen in this broad, diverse patient population will enable robust and clinically meaningful analysis of the composite endpoint of CV mortality and recurrent CV events," said Eugene Schneider, M.D., executive vice president and chief clinical development officer for Ionis. "It will also allow us to gather data from important patient subsets, including patients with or without stabilizer therapy and those with or without hereditary disease within the evolving ATTR-CM landscape. We look forward to reporting results as early as the first half of 2025."
As part of a global development and commercialization agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. The U.S. Food and Drug Administration accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.
For more information on the CARDIO-TTRansform study, please visit www.clinicaltrials.gov (NCT04136171).
About the CARDIO-TTRansform Study
CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase 3 cardiovascular outcome study in more than 1,400 patients with ATTR cardiomyopathy (ATTR-CM). It is designed to compare eplontersen to placebo in patients with both wild-type ATTRwt-CM and hereditary ATTRv-CM who are either naïve to treatment or on a currently available standard of care. The primary composite endpoint is cardiovascular (CV) mortality and recurrent CV clinical events comparing the two study arms up to week 140. Secondary endpoints include the change from baseline in the 6-minute walk test (6MWT) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at week 121, as well as the rates of CV mortality, CV clinical events and all-cause mortality at week 140.
About Eplontersen
Eplontersen is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to inhibit the production of TTR protein. Eplontersen is being developed as a monthly self-administered subcutaneous injection to treat all types of ATTR. ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.
About Transthyretin-mediated Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. It is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within three to five years from disease onset. ATTR-CM includes both the genetic and wild-type form of the disease. Worldwide, there are an estimated 300,000 – 500,0001,2 patients with ATTR-CM.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of eplontersen, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
1 Mohamed-Salem L, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018 Nov 1;270:192-196. doi: 10.1016/j.ijcard.2018.06.006.
2 Cuscaden C, et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020 May 8. doi: 10.1007/s12350-020-02152-x.
View original content to download multimedia:
SOURCE Ionis Pharmaceuticals, Inc. | https://www.kbtx.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ | 2023-07-31T11:27:38 | 0 | https://www.kbtx.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ |
Miss Lane College Jada Brown crowned Miss TN Volunteer on Saturday in Jackson
In its fifth year, the Miss Tennessee Volunteer pageant drew a crowd of supporters offering women the chance to win $85,000 in scholarships and represent their state as the 2024 winner.
Miss Lane College Jada Brown won the spotlight on Saturday as she was crowned as the next Miss Tennessee Volunteer.
Crowned moment:PHOTOS: Miss Lane College crowned as new Miss Tennessee Volunteer
Brown will hold the Miss Tennessee title through 2024 and receive an $11,000 scholarship. Her performance in the talent portion of the evening entailed an American Sign Language (ASL) interpretation of the song “This Is Me.”Saturday night began with host Keli McAlister announcing the 16 finalists that were to compete for the crown. After the first phase of the night, health and fitness, 12 contestants were chosen to move on to the talent competition.
Contestants were then narrowed down to a remaining 10 that advanced to the final phase — evening gown. From there, a final five were chosen and the winner was crowned.In a special performance by former Miss Tennessee Volunteer Paige Clark and her dance partner Jed, the pair received a standing ovation for their clogging routine.
Each year, the pageant brings the city of Jackson to a buzz as women from across the state from west, to middle, to east Tennessee compete for the crown.
Lights, sparkle and rousing performances in song, dance and music defined each night from Wednesday until Saturday as 36 contestants competed in Talent, Lifestyle and Wellness and interview competitions.
"The Miss Tennessee Volunteer system continues to grow in every aspect," Emily Anne Sparks, Co-Executive Director of the pageant said. "Beginning with the Teen, Pre-teen and Little Miss pageants, leading up to the Miss pageant, almost 100 contestants cross the stage and that is a testament to the organization and the future of Miss Tennessee Volunteer."
Most of all she enjoys the character and confidence the pageant instills in the young women competing.
The crown competition promotes five components, or S.E.R.V.E: Scholarship, Education, Responsibility, Volunteerism and Empowerment.
"Seeing the past contestants grow and develop their confidence each year is just amazing," Sparks said.
On Friday, Miss Northwest Tennessee Emily Pennington won the Wellness competition, while Miss Germantown Erin Sharp won the Talent competition.
On Thursday, the following contestants won the Wellness category: Miss Nashville Volunteer Mary Humphrey, Miss Bethel University Kameshia Moxley, Miss Fall Fest Emma Martin and Miss Murfreesboro Jordynne Tucker.
Miss Delta Blues Volunteer Lydia Fisher won the Talent category on Thursday.
On Wednesday, Miss Mid-South Fair Lydia Waldrop won the Talent category, while Miss Tipton County Gracelyn Eaves won the Lifestyle and Wellness competition.
Previously Visit Jackson Executive Director Lori Nunnery explained that at least three major pageants bring tourism dollars to Jackson. Last year's Miss Volunteer America pageant raked in $4 million in revenue for the city of Jackson, while the state pageant brought in approximately $2-2.5 million in revenue.
Nunnery speaks to local businesses, who support the pageant after it's over to gauge if there was a traffic increase in their respective business. She added that Visit Jackson hopes to conduct an economic impact study from someone outside of their agency in the future.
More:Miss Tennessee Volunteer pageant kicks off at Civic Center
On Saturday, Paige Clark, Miss Tennessee Volunteer 2023, passed the crown to Brown as the new winner.
Miss Volunteer America pageant earlier this spring drew 51 contestants and their families and supporters over four days in Jackson. | https://www.jacksonsun.com/story/news/local/miss-tennessee/2023/07/29/miss-lane-college-jada-brown-crowned-miss-tn-volunteer-in-jackson/70473957007/ | 2023-07-31T11:27:38 | 1 | https://www.jacksonsun.com/story/news/local/miss-tennessee/2023/07/29/miss-lane-college-jada-brown-crowned-miss-tn-volunteer-in-jackson/70473957007/ |
Juggernaut and Mr. Highman will continue as substantial shareholders of Bobbie. The acquisition positions the combined company as the third largest fully integrated infant and toddler brand in the U.S., creating a more resilient industry for American families
WASHINGTON, July 31, 2023 /PRNewswire/ -- Juggernaut Capital Partners, a leading middle market private equity investor primarily in the consumer and healthcare sectors, is pleased to announce the sale of Nature's One, the pediatric nutrition company founded by Jay Highman which set the bar for quality and innovation in formula over decades. Joining forces with Bobbie Baby, Inc., the nation's fastest growing infant formula company, the combined business will be the first of its kind in pediatric nutrition.
"Nature's One is a true pioneer in the pediatric nutrition space. Juggernaut partnered with founder, Jay Highman, to accelerate product development and vertical integration initiatives. Over the past five years, the company completed the first FDA-approved clinical feeding study of an organic infant formula and designed and constructed the first newly built infant formula facility in the U.S. in 35 years," said John Shulman, Founder and Managing Partner at Juggernaut. "It has been a pleasure to partner with Jay and his team. We believe the combination with Bobbie cements the organization as a continued disruptor and a next-generation industry leader. We are proud to continue as a meaningful shareholder in the go-forward company."
Founded in 1997, Nature's One introduced the first organic baby formula to the U.S. market. Recognized for its dedication to purity and quality, all of the company's formulas have received the Clean Label Project's Purity Award and have tested best in class for purity and nutrition when compared to popular baby formulas sold in the U.S. Nature's One operates the only independent, FDA audited organic infant nutrition facility in the U.S.
Nature's One was advised by CG / Sawaya Partners (operating under Canaccord Genuity) and Morgan Lewis & Bockius LLP. Bobbie was advised by Perella Weinberg Partners LP and Goodwin Procter LLP.
About Juggernaut Capital Partners:
Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies, primarily in the consumer and healthcare sectors. Juggernaut is currently investing out of Juggernaut Capital Partners V, L.P. For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.
About Nature's One:
Founded in 1997, Nature's One introduced the first organic formula, Baby's Only® Organic in the United States. Nature's One has dedicated 25 years to the research, development, and sourcing of pure ingredients. Recognized as the first and highest-ranked formulas for purity and nutritional superiority by the Clean Label Project, Baby's Only Formulas are preferred by parents who want to offer their child a "Better Start…for Life™." Baby's Only Formulas are sold nationally at Whole Foods, Target, Walmart, Sam's Club, and many fine natural food retailers, as well online at www.naturesone.com.
About Bobbie:
Bobbie is the mission-driven organic pediatric nutrition company that exists to build a parenting culture of confidence, not comparison. Founded in 2018, Bobbie hit the market with its flagship European-inspired formula in 2021 as the first direct-to-consumer, subscription-based infant formula in the U.S. Today, it's proud to be the only mom-founded and led infant formula brand in the world, and the fastest-growing in the U.S. since the 1980's. Bobbie is focused on providing purposefully sourced, USDA Organic products made with simple ingredients – crafted right here in America, for American families. For more information, visit www.hibobbie.com.
View original content:
SOURCE Juggernaut Capital Partners | https://www.kbtx.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ | 2023-07-31T11:27:44 | 0 | https://www.kbtx.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ |
Dr. Noemí Cruz-Orcutt of Mint Springs Dentistry was recognized as a fellow in the Academy of General Dentistry on July 22, 2023. Cruz-Orcutt was honored with the receipt of the Academy of General Dentistry (AGD) fellowship award, according to a press release.
Only 6% of dentists have earned their AGD Fellowship. AGD offers fellowship awards to members who truly go above and beyond in their learning. To earn a fellowship award, a dentist must complete at least 500 continuing dental education hours, pass a rigorous and comprehensive exam, and maintain AGD membership for three continuous years. | https://globegazette.com/mint-springs-dentistry-doctor-recognized/article_f9c75db0-2b1a-11ee-a804-978ab8d069dd.html | 2023-07-31T11:27:44 | 0 | https://globegazette.com/mint-springs-dentistry-doctor-recognized/article_f9c75db0-2b1a-11ee-a804-978ab8d069dd.html |
BURLINGTON, N.C., July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 14, 2023, in New York City, beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET.
This event will highlight Labcorp's go-forward strategy from Labcorp Chairman & CEO Adam Schechter, followed by business overviews and a longer-term financial outlook. Presentations will be followed by a Q&A session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 1:00 p.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
View original content to download multimedia:
SOURCE Labcorp | https://www.kbtx.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ | 2023-07-31T11:27:50 | 1 | https://www.kbtx.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ |
Mason City folks should be prepared for high temperatures. It looks to reach a balmy 81 degrees. 56 degrees is today's low. It should be a fairly cloudless day. The forecast is calling for clear skies. Today's UV index is high. Be careful outside, especially during late morning through mid-afternoon. If your shadow is shorter than you, seek shade and wear protective clothing and generously apply sunscreen on exposed skin. The Mason City area should see a light breeze, with winds only reaching 7 miles per hour, coming from the North. This report is created automatically with weather data provided by TownNews.com. For more daily forecast information, visit globegazette.com.
Here is today's weather outlook for Jul. 30, 2023 in Mason City, IA
Related to this story
Most Popular
The forecast is showing a hot day in Mason City. Temperatures are projected to be a steamy day today with temperatures reaching a high of 96 t…
The Mason City area can expect a very hot day. Temperatures are projected to be a steamy day today with temperatures reaching a high of 93 tho…
Mason City folks should be prepared for high temperatures. Temperatures are projected to be a steamy day today with temperatures reaching a hi…
Hot temperatures are predicted today. The forecast calls for it to be a balmy 89 degrees. 65 degrees is today's low. We will see a mix of sun … | https://globegazette.com/weather/here-is-todays-weather-outlook-for-jul-30-2023-in-mason-city-ia/article_74a56613-2414-5bf5-a696-993a35e01929.html | 2023-07-31T11:27:51 | 1 | https://globegazette.com/weather/here-is-todays-weather-outlook-for-jul-30-2023-in-mason-city-ia/article_74a56613-2414-5bf5-a696-993a35e01929.html |
Adult Males are Slightly More Likely to Live with Parents Than Their Female Counterparts
58% of Gen Z Consumers Live with Family Members
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from the 24th edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS. The Household Finances Deep Dive Edition examines the impact of household composition on consumers' ability to manage expenses and put aside savings. The series draws on insights from a survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data.
The Paycheck-to-Paycheck Landscape
In June 2023, 61% of U.S. consumers lived paycheck to paycheck, unchanged from June 2022 — as is the share of those struggling to pay bills (at 21%) — even though more middle-income consumers cited living paycheck to paycheck in June 2023 than last year. Among consumers earning $50,000 to $100,000, 65% lived paycheck to paycheck as of June 2023, compared to 60% in June 2022. Meanwhile, the shares of high-income consumers — those earning more than $100,000 annually — and low-income consumers — those earning less than $50,000 annually — living paycheck to paycheck in June 2023 sit at 45% and 77%, respectively, relatively unchanged from June 2022.
This stability in the financial situation of U.S. households indicates that consumers continue to adapt to inflationary pressures, finding ways to manage their spending and live within their means.
Household Composition Determines Financial Lifestyle
Consumers living with only a partner or spouse are likely to face less financial hardship, while those with dependents and those living with friends or housemates are more likely to live paycheck to paycheck.
The research finds that 86% of consumers live with one or more people, and one-third of paycheck-to-paycheck consumers live in households of four or more people. Consumers not living paycheck to paycheck are most likely to reside in two-person households, at 41%. Meanwhile, 49% of millennials and 55% of bridge millennials live in households of four or more people, making them the age groups most likely to reside in the largest households.
There is also a direct correlation among household size, stage of life and financial lifestyle. As household size increases, the ratio of income earners to non-earners typically falls, attributable to households with dependent children. When looking at the share of paycheck-to-paycheck consumers who live in a two-member household, the data finds that 54% do so — 7 percentage points below the sample average. Meanwhile, at 66%, consumers with children under the age of 18 are 12% more likely to live paycheck to paycheck than those without children, at 59%. Among consumers living with friends or housemates, 77% live paycheck to paycheck — the most likely to do so. This suggests that those sharing expenses with a partner or spouse fare better, that is until they have children or even parents to support.
"As household size increases, the ratio of income earners to household members typically falls, creating a higher likelihood of financial distress," said Alia Dudum, LendingClub's Money Expert. "The relationship between household income and household composition explains why many families tend to struggle financially and why millennials and bridge millennials, many of whom are in their peak child-rearing years, tend to remain financially vulnerable."
Economic Considerations Top Reason to Stay in the Family Household
Economics are the main driver for consumers to live with family longer, with 43% wanting to save money and 30% unable to afford housing independently. Besides economic reasons, consumers remain at home to maintain family ties (24%), for transitional reasons (23%), and to provide care (22%).
At one-fifth (20%), adult males are slightly more likely to live with parents than their female counterparts (18%), a phenomenon that grows significantly among those financially struggling (26% of males compared to 18% of females). At 58%, Gen Z is the generation most likely to stay with family members, with 50% citing economic reasons. Members of Gen Z living with three or more people — often familial settings — spent 22% of their income on housing, compared to 30% of those living alone or with a partner.
That said, consumers living with family members to offset expenses are not planning extended stays. For example, one-third of those consumers expect to move out in the coming year, particularly millennials and bridge millennials.
Financial Transparency Determined by Relationship Status
Financial transparency within shared households is paramount to ensure bills are paid and expenses are covered, but the transparency level depends on who consumers live with. Couples living together share financial information 87% of the time and have a joint bank account 76% of the time. Parents are also likely to discuss finances with the children residing in their household, with 45% of parents sharing financial information with their children and 34% granting them access to a shared account. Bill splitting is the most common financial interaction for consumers living with friends or housemates, at 74%. Additionally, borrowing money from other household members is a financial option many use to make ends meet, with consumers mostly engaging in this practice with parents or siblings, at 47%, and friends and housemates, at 44%.
Families and couples maintain outstanding credit card balances that are significantly higher, on average, than those of consumers who live alone. Consumers with children under the age of 18 average 50% more credit card debt than those who live alone. Families represent the lion's share of credit card spending, holding average balances of $6,300 for consumers living with a partner and $7,200 for those living with children under 18. Living with a partner or children also significantly increases a consumer's likelihood of having an auto loan or mortgage.
"With today's inflationary pressures, sharing household finances has become not only common but crucial," continued Dudum. "The increasing complexity of modern lifestyles and the rising cost of living have necessitated a shift in the way consumers approach household finances. One person solely bearing the burden of managing all financial matters has become a minority practice. Instead, couples, families, and even roommates increasingly jointly navigate their economic realities, and it's a trend that is here to stay."
To view the full report, visit: https://www.pymnts.com/study/reality-check-paycheck-to-paycheck-inflation-household-spending-shared-expenses/
Methodology
New Reality Check: The Paycheck-to-Paycheck Report — The Household Finances Deep Dive Edition is based on a census-balanced survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data. The data in this report is not intended to be a representation of LendingClub's core member base. The Paycheck-to-Paycheck series expands on existing data published by government agencies, such as the Federal Reserve System and the Bureau of Labor Statistics, to provide a deep look into the core elements of American consumers' financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 51% of respondents identified as female, 33% were college-educated and 38% declared incomes of more than $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $85 billion in loans, our advanced credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4.7 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
Contact:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.kbtx.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ | 2023-07-31T11:27:56 | 1 | https://www.kbtx.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ |